EP4655007A1 - Conjugués anticorps-oligonucléotide - Google Patents

Conjugués anticorps-oligonucléotide

Info

Publication number
EP4655007A1
EP4655007A1 EP24709225.7A EP24709225A EP4655007A1 EP 4655007 A1 EP4655007 A1 EP 4655007A1 EP 24709225 A EP24709225 A EP 24709225A EP 4655007 A1 EP4655007 A1 EP 4655007A1
Authority
EP
European Patent Office
Prior art keywords
optionally substituted
seq
antibody
conjugate
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24709225.7A
Other languages
German (de)
English (en)
Inventor
Dale L. Ludwig
Poornima Bala Sahithi PAMARTHY
Rebaz A. AHMED
Venugopalareddy Bommireddy Venkata
Elias QUIJANO
Peter Glazer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of EP4655007A1 publication Critical patent/EP4655007A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present disclosure relates to compositions and methods for treating cancer with antibody-oligonucleotide conjugates (AOCs).
  • AOCs antibody-oligonucleotide conjugates
  • AOCs Antibody-oligonucleotide conjugates
  • Oligonucleotides are a class of precise payloads, for example, because their sequence can be used to affect a particular genomic and/or transcriptomic location through hybridization. Tn this fashion, for example, oligonucleotides can be designed to inhibit protein transcription and/or translation by targeting specific genes and/or transcripts in a sequence- dependent manner. Even though oligonucleotides, e.g., siRNA and antisense oligonucleotides (ASOs), have great promise as targeted therapeutics, several challenges with their implementation exist, such as short serum stability, low membrane permeability, and lack of tissue selectivity.
  • siRNA and antisense oligonucleotides ASOs
  • Antibodies with their longer half-life, ability to selectively deliver therapeutics inside the cells, and targeting properties, are ideal partners for the targeted delivery of oligonucleotides, particularly in the form of an antibody-oligonucleotide conjugate, with a cleavable or non- cleavable linker.
  • the 3E10 antibody is an ideal molecular delivery vehicle due to its efficiency in penetrating into living cells with specific nuclear localization, absence of toxicity, and successful delivery of therapeutic cargo proteins in vitro and in vivo. 3E10 selectively penetrates cells expressing the nucleoside transporter ENT2. To date, in vitro and in vivo studies on 3E10 have not shown any cellular toxicity in normal cells.
  • AOCs antibody-oligonucleotide conjugates
  • Polynucleotide-based cancer therapies present a promising path for cancer therapy because of their versatility to encode any polypeptide, the availability of highly reproducible manufacturing methods, the ability to make simple and precise adjustments to polynucleotide sequences, their inexpensive nature, their ability to specifically target and/or edit any genetic sequence, etc.
  • the delivery of polynucleotide therapeutics to specific tissues in vivo has posed many challenges, including the rapid degradation of foreign nucleic acids in the body and immunogenicity caused by common delivery vehicles, such as liposomes and viral vectors.
  • compositions, conjugates, and methods for polynucleotide-based cancer therapy that are not reliant upon liposomal or viral vector based nucleic acid delivery.
  • the disclosure provides a conjugate of Formula (I):
  • A is an antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of SEQ ID NO:58, CDR2 comprising the amino acid sequence of SEQ ID NO:59, CDR3 comprising SEQ ID NO:60; and a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO:61, CDR2 comprising the amino acid sequence of SEQ ID NO:62, CDR3 comprising the amino acid sequence of SEQ ID NO: 63;
  • VH heavy chain variable region
  • VL light chain variable region
  • L is a linker
  • P is an oligonucleotide moiety
  • r is an integer from 1 to 4
  • q is an integer from 1 to 16.
  • -XAA- is an amino acid sequence comprising 1 to 6 amino acid moieties.
  • each amino acid moiety of -XAA- is independently selected from alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), cysteine (Cys), glutamine (Gin), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (He), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), tryptophan (Trp), tyrosine (Tyr), valine (Vai), citrulline (Cit), and homocitrulline (HoCit).
  • the linker L comprises one or more groups selected from optionally substituted C1-C16 alkylene, -C ⁇ C-, -CR a ⁇ CR a -, optionally substituted phenylene, optionally substituted C 3 -C 6 cycloalkylene, -[CH 2 CH 2 O] 1-16 -, -[CH 2 CH 2 CH 2 O] 1-16 -, optionally substituted 5- to 6-membered heteroarylene, optionally substituted 5- to 20-membered heterocycloalkylene, -NR a -, -N ⁇ CR a -, -CR a ⁇ N-, -S-, -OP(O)OR a O-, -O-, -CR b 2-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)NR a -, -NR a C(O)-, -OC(O)O-,
  • the linker L comprises one or more groups selected from -[C(R b )2]1-16-, -C ⁇ C-, -CR a ⁇ CR a -, -[CH2CH2O]1-16-, -NR a -, -N ⁇ CR a -, -CR a ⁇ N-, -S-, -OP(O)OR a O-, -O-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)NR a -, -NR a C(O)-, -OC(O)O-, -OC(O)NR a -, , and , , , , , , O.
  • Lp is a connecting moiety through which P is covalently attached to L'.
  • the linker L comprises at least one cleavable moiety.
  • the cleavable moiety comprises an acid-labile moiety, a reducibly-labile moiety, or an enzymatically-labile moiety.
  • the cleavable moiety comprises one or more groups selected from: wherein: each R a ' is independently selected at each occurrence from hydrogen, optionally substituted alkyl, and optionally substituted heteroalkyl.
  • the cleavable moiety comprises the reducibly-labile moiety -S-S-.
  • the linker L is of Formula (L-10):
  • LA is selected from a bond, -NR a '-, and -S-;
  • Lc is selected from an acid-labile moiety, a reducibly-labile moiety, and an enzymatically- labile moiety;
  • -XAA- is an amino acid sequence comprising 1 to 4 amino acid moieties.
  • Lc is selected from: wherein: each R a is independently selected at each occurrence from hydrogen, optionally substituted alkyl, and optionally substituted heteroalkyl.
  • Lc is -S-S-.
  • the linker L is of Formula (L-l 1):
  • LA is selected from a bond, -NH-, and -S-;
  • each Ri is independently selected from hydrogen, optionally substituted alkyl, optionally substituted fluoroalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; or both Ri groups are taken together to form optionally substituted cycloalkyl; each R 2 is independently selected from hydrogen, optionally substituted alkyl, optionally substituted fluoroalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroalkyl, optionally substituted heterocyclo
  • -XAA- is an amino acid sequence comprising 2 to 4 amino acid moieties.
  • the linker L is of Formula (L-12):
  • LA is selected from a bond and -NH-;
  • L 1 ' comprises one or more groups selected from -[C(R b )2]i-io-, -[CH2CH2O] 1-10-, -NR a -, -O-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)NR a -, -NR a C(O)-, -OC(O)O-, -XAA-, -OC(O)NR a -,
  • each Ri is independently selected from hydrogen, optionally substituted Ci-Cs alkyl, optionally substituted Ci-Cs fluoroalkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted phenyl, optionally substituted benzyl, optionally substituted 5- to 10-membered heterocycloalkyl, optionally substituted 5- to 6-membered heteroaryl; or both Ri groups are taken together to form optionally substituted C3-C6 cycloalkyl; each R2 is independently selected from hydrogen, optionally substituted Ci-Cs alkyl, optionally substituted Ci-Cs fluoroalkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted phenyl, optionally substituted benzyl, optionally substituted 5- to 10-membered heterocycloalkyl, optionally substituted 5- to 6-membered heteroaryl; or both R2 groups are taken together to form optionally substituted C3-C6 cycloalkyl; each R
  • At least one R1 or R2 is other than hydrogen. In some embodiments, at least one R 1 is an optionally substituted C 1 -C 8 alkyl. In some embodiments, each R 1 is independently an optionally substituted C 1 -C 8 alkyl. In some embodiments, at least one R 2 is an optionally substituted C1-C8 alkyl. In some embodiments, each R2 is independently an optionally substituted C 1 -C 8 alkyl. [0025] In some embodiments, the linker L is selected from: . ,
  • the linker is a cleavable linker.
  • the linker L is of Formula (L-20):
  • LA is selected from a bond, -NR a -, and -S-;
  • Lp is selected from a bond, -NR a -, -S-, and -O-; each R a is independently selected at each occurrence from hydrogen, optionally substituted alkyl, optionally substituted fluoroalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R a′ is independently selected at each occurrence from hydrogen, optionally substituted alkyl, and optionally substituted heteroalkyl; and each R b is independently selected at each occurrence from hydrogen, halide, -OH, -SO3H, -OPO 3 H 2 , -PO 3 H 2 , -C(O)NR a 2 , -CO 2 R
  • the linker L is of Formula (L-21): , wherein in Formula (L-21): LA is selected from a bond and -NH-; LX comprises one or more groups selected from optionally substituted -[C(R b )2]1-16-, -C ⁇ C-, -CR a ⁇ CR a -, -[CH 2 CH 2 CH 2 O] 1-16 -, -NR a -, -O-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)S-,
  • each R a is independently selected at each occurrence from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 fluoroalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted phenyl, optionally substituted benzyl, optionally substituted 5- to 10-membered heterocycloalkyl, optionally substituted 5- to 6-membered heteroaryl; each R a′ is independently selected at each occurrence from hydrogen and optionally substituted C1-C6 alkyl; and each R b is independently selected at each occurrence from hydrogen, halide, -OH, -SO 3 H, -OPO 3 H 2 , -PO 3 H 2 , -CO 2 R a , -NR a 2 , optionally substituted C 1 -C 8 alkyl, optionally substituted C1-C8 fluoroalkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted
  • the linker L is of Formula (L-22a) or Formula (L-22b): wherein in Formulas (L-22a) and (L-22b): L A is selected from a bond and -NH-; LX comprises one or more groups selected from optionally substituted -[C(R b )2]1-10-, -C ⁇ C-, -CR a ⁇ CR a -, -[CH2CH2CH2O]1-10-, -NR a -, -C(O)-, -C(O)O-, -OC(O)-, -C(O)S-, -SC(O)-, , each R a is independently selected at each occurrence from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 fluoroalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted phenyl, optionally substituted benzyl
  • the linker is a non-cleavable linker.
  • the linker L comprises a moiety of Formula (L-100) or
  • each Rio is hydrogen; each Rn is independently selected at each occurrence from hydrogen, -CH3, -CH2CH3, and -CH(CH3)2; and k is 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, each Rio is hydrogen; each R11 is independently selected at each occurrence from hydrogen, -CH3, and -CH2CH3; and k is 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, each Rio is hydrogen; each R11 is independently selected at each occurrence from hydrogen and -CH3; and k is 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, each Rio is hydrogen; each R11 is hydrogen; and k is 3, 4, 5, 6, 7, 8, 9, or 10.
  • the linker L is selected from:
  • each amino acid moiety of -XAA- is independently selected from alanine (Ala), arginine (Arg), glycine (Gly), histidine (His), isoleucine (He), leucine (Leu), lysine (Lys), phenylalanine (Phe), tryptophan (Trp), tyrosine (Tyr), valine (Vai), citrulline (Cit), and homocitrulline (HoCit).
  • each amino acid moiety of -XAA- is independently selected from alanine (Ala), glycine (Gly), lysine (Lys), phenylalanine (Phe), valine (Vai), and citrulline (Cit).
  • the amino acid sequence -XAA- is selected from -Val-Cit-, -Cit-VaL, -Val-Ala-, -Ala-Vai-, -Phe-Lys-, -Lys-Phe-, -Ala-Ala-, -Val-Val-, -Gly-Gly-, -Ala-Ala-Ala-, -Gly-Gly-Gly-, -Gly-Gly-Phe-Gly-(SEQ ID NO: 1032) -Gly-Phe-Gly-Gly-(SEQ ID NO: 1033),
  • the amino acid sequence -XAA- is selected from -Val-Cit-, -Cit-VaL, -Val-Ala-, -Ala-Vai-, -Phe-Lys-, -Lys-Phe-, -Ala-Ala-, -Val-Val-, -Gly-Gly-, -Ala-Ala-Ala-, and -Gly-Gly-Gly-.
  • the oligonucleotide moiety P is selected from a small interfering RNA (siRNA) molecule and an antisense oligonucleotide (ASO) molecule. In some embodiments, the oligonucleotide moiety P is a small interfering RNA (siRNA) molecule. In some embodiments, the oligonucleotide moiety P is an antisense oligonucleotide (ASO) molecule. In some embodiments, the siRNA molecule targets cMyc mRNA.
  • the siRNA molecule comprises a nucleotide sequence selected from the group consisting of 5’-GCLTUUUUUGCCCUGCGUGACCAGAT-3’ (SEQ ID NO: 138), 5’-GCCACAGCAUACAUCCUGUUU-3’ (SEQ ID NO:139), and 5’- GCCACAGCAUACAUCCUGUUU-3’ (SEQ ID NO: 140), 3’-
  • the siRNA molecule comprises at least one 2' modified nucleotide comprising a 2'-O-methyl, 2'-O-methoxyethyl (2'-O-MOE), 2'-O-aminopropyl , 2'- deoxy, 2 '-deoxy -2 '-fluoro, 2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylaminoethyl (2'-O- DMAOE), 2'-O-dimethylaminopropyl (2'-O-DMAP), 2'-O-dimethylaminoethyloxyethyl (2'-O- DMAEOE), or 2′-O-N-methylacetamido (2′-O-NMA) modified nucleotide, at least one modified internucleotide linkage, or at least one inverted abasic moiety, or a combination thereof.
  • 2′-O-NMA 2′-O-N-methyl
  • the siRNA molecules comprises a nucleotide sequence selected from the group consisting of: 5’-N6-G-mC-U-U-mU-U-mU-U-G-C-mC-mC-U-mG-C- G-mU-mG-A-C-C-A-G-dA-dT-3’ (SEQ ID NO:144), 5’-N6-G-C-C- A-C-A-G-C-A-U-A-C-A- U-C-C-U-G-U-U-3’ (SEQ ID NO:145), 5’-N6*2’FG*mC*2’FC-mA-2’FC-mA-2’FG-mC- 2’FA-mU-2’FA-mC-2’FA-mU-2’FC-mC-2’FU-mG-2’FU-mU-2’FU-3’ (SEQ ID NO:146), 3’- mC-mU-mC
  • the siRNA molecule hybridizes to at least 8 contiguous bases of the c-Myc mRNA. In some embodiments, the siRNA molecule is from 8 to 50 nucleotides in length or from 10 to 30 nucleotides in length. In some embodiments, the siRNA molecule comprises a nucleotide sequence selected from: Strand Sequence SEQ ID NO
  • the ASO molecule targets a c-Myc gene. In some embodiments, the ASO molecule targets exon 2 of the c-Myc gene. In some embodiments, the ASO molecule comprises a sequence of UUCACCATCTCUC (SEQ ID NO: 150). In some embodiments, the ASO molecule comprises a sequence of mU*mU*mC*A*C*C*A*T*C*T*C*mU*mC (SEQ ID NO: 151), wherein m denotes 2'-O- methyl-modified ribose nucleotides and * denotes phosphorothioate linkage.
  • the VL CDR1 comprises the amino acid sequence of SEQ ID NO:9
  • CDR2 comprises the amino acid sequence of SEQ ID NO: 10
  • CDR3 comprises SEQ ID NO: 11
  • the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 15
  • CDR2 comprises the amino acid sequence of SEQ ID NO:4
  • CDR3 comprises the amino acid sequence of SEQ ID NO:5.
  • the VL CDR1 comprises the amino acid sequence of SEQ ID NO:29
  • CDR2 comprises the amino acid sequence of SEQ ID NO: 10
  • CDR3 comprises SEQ ID NO: 11
  • the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 15
  • CDR2 comprises the amino acid sequence of SEQ ID NO:26
  • CDR3 comprises the amino acid sequence of SEQ ID NO:5.
  • the antibody or antigen-binding fragment thereof comprises a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO:21 and a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 14.
  • VL light chain variable region
  • VH heavy chain variable region
  • the antibody or antigen-binding fragment thereof comprises a full length light chain (LC) comprising an amino acid sequence of SEQ ID NO:20 and a full length heavy chain (HC) comprising an amino acid sequence of SEQ ID NO:13.
  • LC full length light chain
  • HC full length heavy chain
  • the antibody or antigen-binding fragment thereof comprises: a light chain variable domain (VL) comprising an amino acid sequence that is at least 95% identical to an amino acid sequence selected from the group consisting of 3E10-VL-H1 (SEQ ID NO:85), 3E10-VL-H2 (SEQ ID NO:86), 3E10-VL-H3 (SEQ ID NO:87), 3E10-VL-H4 (SEQ ID NO:88), 3E10-VL-H5 (SEQ ID NO:89), and 3E10-VL-H6 (SEQ ID NOVO); and a heavy chain variable domain (VH) comprising an amino acid sequence that is at least 95% identical to an amino acid sequence selected from the group consisting of 3E10-VH-H1 (SEQ ID NO:64), 3E10-VH-H2 (SEQ ID NO:65), 3E1O-VH-H3 (SEQ ID NO:66), 3E10-VH-H4
  • the antibody or antigen-binding fragment thereof comprises: a light chain variable domain (VL) comprising an amino acid sequence selected from the group consisting of 3E10-VL-H1 (SEQ ID NO:85), 3E10-VL-H2 (SEQ ID NO:86), 3E10-VL-H3 (SEQ ID NO:87), 3E10-VL-H4 (SEQ ID NO:88), 3E10-VL-H5 (SEQ ID NO:89), and 3E10-VL-H6 (SEQ ID NOVO); and a heavy chain variable domain (VH) comprising an amino acid sequence selected from the group consisting of 3E10-VH-H1 (SEQ ID NO:64), 3E10-VH-H2 (SEQ ID NO:65), 3E10-VH-H3 (SEQ ID NO:66), 3E10-VH-H4 (SEQ ID NO:67), 3E10-VH-H5 (SEQ ID NO:68),
  • VL light chain variable domain
  • the antibody or antigen-binding fragment thereof comprises a VL / VH pair selected from the group consisting of (a) VL1 (SEQ ID NO:85) and VH1 (SEQ ID NO:64), (b) VL1 (SEQ ID NO:85) and VH2 (SEQ ID NO:65), (c) VL1 (SEQ ID NO:85) and VH3 (SEQ ID NO:66), (d) VL1 (SEQ ID NO:85) and VH4 (SEQ ID NO:67), (e) VL2 (SEQ ID NO:86) and VH1 (SEQ ID NO:64), (f) VL2 (SEQ ID NO:86) and VH2 (SEQ ID NO:65), (g) VL2 (SEQ ID NO:86) and VH3 (SEQ ID NO:66), (h) VL2 (SEQ ID NO:86) and VH4 (SEQ ID NO:67), (i) VL3 (SEQ ID NO:
  • the antibody or antigen-binding fragment thereof comprises: a light chain variable domain (VL) comprising 3E10-VL-H6 (SEQ ID NOVO) and a heavy chain variable domain (VH) comprising 3E10-VH-H6 (SEQ ID NO:69).
  • VL light chain variable domain
  • VH heavy chain variable domain
  • the antibody or antigen-binding fragment thereof comprises: a light chain variable domain (VL) comprising the amino acid sequence (DIQMTQSPSSLSASLGDRATITCRASKTVSTSSYSYMHWYQQKPGQPPKLLIKYASYLE SGVPSRFSGSGSGTDFTLTISSLQPEDAATYYCQHSREFPWTFGGGTKVEIK) (SEQ ID NO: 117) and a heavy chain variable domain (VH) comprising the amino acid sequence (EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVSYISSGSSTI YYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRGLLLDYWGQGTTVTVS S) (SEQ ID NO: 105).
  • VL light chain variable domain
  • the present disclosure provides a method for treating a subject in need thereof, the method comprising administering a therapeutically effective amount of a conjugate of the disclosure to
  • Figure 1 illustrates amino acid sequences for the parent 3E10 monoclonal antibody.
  • Figures 2A SEQ ID NOs: 13-25
  • 2B SEQ ID NOs:26-30
  • 2C SEQ ID NOs:31-33
  • Figures 2A illustrate amino acid sequences for the D3 IN variant ( Figure 2A), other CDR variants ( Figure 2B), and additionally contemplated CDR variants (Figure 2C) of the 3E10 monoclonal antibody, in accordance with some embodiments of the present disclosure.
  • Figure 3 illustrates example charge-conserved CDR variants of the 3E10 monoclonal antibody, in accordance with various embodiments of the present disclosure.
  • Figure 4 (SEQ ID NOs: 58-63) illustrates example CDR variants containing a combination of amino acid substitutions, charged-conserved amino acid substitutions, and rationally-designed amino acid substitutions of the 3E10 monoclonal antibody, in accordance with various embodiments of the present disclosure.
  • Figure 5 (SEQ ID NOs:64-70)illustrates amino acid sequences of humanized 3E10 variable heavy (3E10-VH) domains, in accordance with various embodiments of the present disclosure.
  • Figure 6 illustrates amino acid sequences of mature humanized 3E10 heavy chains (3E10-HC), lacking a signal peptide, in accordance with various embodiments of the present disclosure.
  • Figure 7 illustrates amino acid sequences of humanized 3E10 heavy chains (3E10-HC), in accordance with various embodiments of the present disclosure.
  • Figure 8 (SEQ IDNOs:85-90) illustrates amino acid sequences of humanized 3E10 variable light (3E10-VL) domains, in accordance with various embodiments of the present disclosure.
  • Figure 9 (SEQ ID NOs:91-96) illustrates amino acid sequences of mature humanized 3E10 light chains (3E10-LC), lacking a signal peptide, in accordance with various embodiments of the present disclosure.
  • Figure 10 illustrates amino acid sequences of humanized 3E10 light chains (3E10-LC), in accordance with various embodiments of the present disclosure.
  • Figure 11 shows the schematic representations of the evaluated antibody- oligonucleotide conjugates (AOCs) 3E10-SATA-SPP-cMyc, 3E10-Az/DBCO-PEG8-cMyc, 3E10-DSP-cMyc, and 3E10-C6-cMyc.
  • AOCs antibody- oligonucleotide conjugates
  • Figure 12 shows the results of Myc luciferase activity in HCT1 116 cells treated with the antibody-oligonucleotide conjugates 3E10-SATA-SPP-cMyc, 3E10-Az/DBCO-PEG8- cMyc, 3E10-DSP-cMyc, and 3E10-C6-cMyc.
  • Figure 13 shows the results of Myc luciferase activity in HCT1116 cells treated with a 3E10-cMyc siRNA conjugate with a cleavable linker (i.e., 3E10-SATA-SPP-cMyc).
  • Figure 14 shows micrographs of HCT1116 cells treated with PBS (Vehicle), 2.5 pM 3E10 (V66), 0.625 pM 3E10 (V66)-cMyc siRNA conjugate, 1.25 pM 3E10 (V66)-cMyc siRNA conjugate, 2.5 pM 3E10 (V66)-cMyc siRNA conjugate.
  • Figure 15 shows dose response curves measuring in vitro Myc luciferase activity in a HCT116 cell line treated with 3E10-Myc-siRNA.
  • Figures 16 shows the results of a Cell Titer Gio assay in OVCAr8 cells treated with a humanized 3E10 antibody (V66), a 3E10-cMyc siRNA conjugate with a cleavable linker.
  • Figure 17 shows micrographs of OVCAr8 cells treated with PBS (Vehicle), 2.5 pM 3E10 (V66), 0.625 pM 3E10 (V66)-cMyc siRNA conjugate, 1.25 pM 3E10 (V66)-cMyc siRNA conjugate, 2.5 pM 3E10 (V66)-cMyc siRNA conjugate.
  • Figure 18 SEQ ID NOs:103-l 12) illustrates a sequence alignment of examples of humanized 3E10 heavy chain variable regions, with CDRs underlined as indicated.
  • Figure 19 illustrates a sequence alignment of examples of humanized 3E10 light chain variable regions, with CDRs and putative nuclear localization signals (NLS) underlined as indicated.
  • Figures 20A, 20B, 20C, 20D, and 20E collectively illustrate a sequence alignment of example of humanized di-scFv constructs of the 3E10 monoclonal antibody.
  • Figures 21A, 21B, 21C, and 21D collectively show the effect of 3E10-D31N antibody (V66) therapy as a single agent, in a non-covalent complex with a c-Myc antisense oligonucleotide (ASO), and in combination with the chemotherapeutic, carboplatin, on a xenograft OVCAR-8 ovarian tumor model.
  • V66 3E10-D31N antibody
  • ASO c-Myc antisense oligonucleotide
  • Figure 22A shows the Lys-azide conjugation intermediates of 3E10-D31N monoclonal antibody (V66) after proteolysis.
  • Figure 22B shows the mass spectroscopy results of mapped Lys-azide conjugation intermediates of 3E10-D31N monoclonal antibody (V66) after proteolysis.
  • Figure 22C shows the sequence of humanized 3E10-D31N monoclonal antibody (V66) and 3E10-D31N.
  • FIGS 23A and 23B collectively illustrate improved cellular internalization of 3E10-D31N monoclonal antibody (V66) oligonucleotide conjugates in A427 cells utilizing trasglutaminase-mediated enzymatic conjugation.
  • V66 monoclonal antibody
  • Figure 24A shows improved exon skipping utilizing transglutaminase-mediated enzymatic conjugation.
  • Figure 24B shows varying the length of the PEG linkers (e.g., PEG4, PEG8, and PEG12) did not significantly impact exon skipping.
  • Figure 24C shows enhanced exon- skipping of cleavable linkers, protease Cathepsin-B and SPDMV (disulfide) compared to non- cleavable linkers with transglutaminase-mediated enzymatic conjugation.
  • PEG linkers e.g., PEG4, PEG8, and PEG12
  • SPDMV disulfide
  • Figure 25A show a di-methyl-hindered disulfide cleavable linker and protease cleavable linker have greater stability over a single methyl-hindered disulfide linker in mouse serum.
  • Figure 25B show a data table indicating the panel of antibody-oligonucleotide conjugates (AOCs) tested and their oligonucleotide to antibody ratios (OAR).
  • AOCs antibody-oligonucleotide conjugates
  • OAR oligonucleotide to antibody ratios
  • Figure 26 shows a summary table of the in vitro performance of several antibody- oligonucleotides conjugates utilizing lysine and transglutaminase-mediated conjugation.
  • the methods and compositions find particular use for the treatment of cancers. For instance, compositions comprising a conjugate of (i) a 3E10 antibody or antigen-binding fragment thereof, and (ii) a therapeutic oligonucleotides, as well as methods for using such compositions for the treatment of cancers, are described.
  • Examples 1 and 2 demonstrate that a 3E10-cMyc siRNA conjugate with a cleavable linker was able to effectively knock down c-Myc expression in a human colon cancer cell line.
  • Example 3 demonstrates that a 3E10-cMyc siRNA conjugate with a cleavable linker significantly inhibited cell viability of the human ovarian cancer cell line, OVCAR8, in a dose dependent manner.
  • Example 4 demonstrates that a combination of a 3E10-cMyc siRNA conjugate with carboplatin significantly reduced tumor volumes in a xenograft OVCAR-8 ovarian tumor model.
  • antibody refers to an immunoglobulin molecule that recognizes and specifically binds to a target, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or combinations of the foregoing through at least one antigen recognition site within the variable region of the immunoglobulin molecule.
  • antibody is used in the broadest sense and encompasses monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising an antigen determination portion of an antibody, and antibody fragments (such as Fab, Fab’, F(ab’)2, Fv fragments, scFv molecules), and any other modified immunoglobulin molecule comprising an antigen recognition site, so long as they exhibit one or more of the desired biological activities.
  • “desired biological activity” of an antibody refers to the ability of the antibody to bind to its target antigen, e.g., a nucleic acid, e.g., DNA.
  • “desired biological activity” can further include antibody binding to its target antigen and resulting in a measurable biological response which can be measured in vitro or in vivo. Such activity can be antagonistic or agonistic.
  • “desired biological activity” of an antibody refers to the ability of the antibody to bind to a target, e.g., nucleic acid molecules.
  • “desired biological activity” of an antibody refers to the ability of the antibody to bind to a cellular receptor, e.g., ENT2.
  • “desired biological activity” of an antibody refers to the ability of the antibody to be internalized by a target cell.
  • Target antigen refers to the molecule that is bound specifically by the antigen-binding domain comprising the variable regions of a given antibody.
  • the term “specifically binds” refers to the binding of an antibody to its cognate antigen (e.g., a nucleic acid, e.g., DNA) while not significantly binding to other antigens.
  • antibodies can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these can be further divided into subclasses or isotypes, e.g., IgGi, IgG2, IgG.% IgG4, IgAi, and IgA?. “Isotype,” as used herein, refers to any of the subclasses of immunoglobulins defined by the chemical and antigenic characteristics of their constant regions.
  • the heavy chain constant domains that correspond to the different classes of immunoglobulins are called a, y, s, y, and p, respectively.
  • the subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known and described generally in, for example, Abbas et al. Cellular and Mol. Immunology, 4 th ed. (W.B. Saunders, Co., 2000). It should be understood that antibodies disclosed herein can also comprise hybrids of isotypes and/or subclasses.
  • Antibodies of the present disclosure are generally isolated or recombinant. “Isolated,” when used to describe the various polypeptides disclosed herein, refers to a polypeptide that has been identified and separated and/or recovered from a cell or cell culture from which it was expressed. Ordinarily, an isolated polypeptide will be prepared by at least one purification step. An “isolated antibody,” refers to an antibody which is substantially free of other antibodies having different antigenic specificities. As used herein, “recombinant antibody” refers to an antibody that is generated using recombinant nucleic acid techniques in exogenous host cells, and recombinant antibodies can be isolated as well.
  • “Native antibodies” are usually heterotetrameric glycoproteins of about 150,000 Daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies among the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (VH) followed by a number of constant domains.
  • VH variable domain
  • Each light chain has a variable domain at one end (VL) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light chain and heavy chain variable domains.
  • constant domain refers to the portion of an immunoglobulin molecule having a more conserved amino acid sequence relative to the other portion of the immunoglobulin, the variable domain, which contains the antigen-binding site.
  • the constant domain contains the CHI, CH2 and CH3 domains (collectively, CH) of the heavy chain and the CHL (or CL) domain of the light chain.
  • variable region refers to the amino-terminal domains of the heavy or light chain of the antibody.
  • the variable domain of the heavy chain may be referred to as “VH.”
  • variable domain of the light chain may be referred to as “VL.” These domains are generally the most variable parts of an antibody and contain the antigen-binding sites.
  • variable refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies.
  • variable domains hypervariable regions
  • CDRs complementary determining regions
  • a “variable heavy domain” pairs with a “variable light domain” to form an antigen-binding domain (ABD) that specifically binds a target antigen.
  • ABS antigen-binding domain
  • the more highly conserved portions of variable domains are called the framework regions (FR).
  • the variable domains of native heavy and light chains each comprise four FR regions, largely adopting a beta-sheet configuration, connected by three CDRs/HVRs, which form loops connecting, and in some cases forming part of, the beta-sheet structure.
  • the CDRs/HVRs in each chain are held together in close proximity by the FR regions and, with the CDRs/HVRs from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al Sequences of Proteins of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md. (1991)).
  • the constant domains are not involved directly in the binding of an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.
  • hypervariable region refers to the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally defined loops.
  • antibodies comprise six HVRs or CDRs; three in the VH (Hl, H2, H3; or VH CDR1, VH CDR2, VH CDR3), and three in the VL (LI, L2, L3; or VL CDR1, VL CDR2, VL CDR3).
  • the “light chains” of antibodies (immunoglobulins) from any mammalian species can be assigned to one of two clearly distinct types, called kappa (“K”) and lambda (“X”), based on the amino acid sequences of their constant domains.
  • the CDRs of the VH and VL domains form an Fv region.
  • a VH and a VL domain comprise the six CDRs of the ABD.
  • the variable heavy domain (VH; containing VH CDR1, VH CDR2, and VH CDR3) and the variable light domain (VL or VL; containing the VL CDR1, VL CDR2 and VL CDR3) comprise the set of 6 CDRs, with the C-terminus of the VH domain being attached to the N-terminus of the CHI domain of the heavy chain and the C-terminus of the VL domain being attached to the N-terminus of the constant light domain (and thus forming the light chain).
  • the VH and VL domains are covalently attached, generally through the use of a linker (e.g., an “scFv linker”), into a single polypeptide sequence, which can have the N- to C-terminus arrangement of VH-linker-VL or VL- linker-VH.
  • a linker e.g., an “scFv linker”
  • the C-terminus of the scFv domain is attached to the N-terminus of the hinge in the second monomer.
  • Fab or “Fab region,” as used herein, refers to a polypeptide that comprises VH, CHI, VL, and CL immunoglobulin domains, generally on two different polypeptide chains (e.g., VH- CH1 on one chain and VL-CL on the other). Fab can refer to this region in isolation, or this region in the context of an antibody of the disclosure. In embodiments, a Fab comprises an Fv region in addition to CHI CL domains. [0097] Another part of the heavy chain is the hinge region. As used herein, “hinge,” “hinge region,” “antibody hinge region,” or “hinge domain” refers to the flexible polypeptide comprising the amino acids between the first and second constant domains of an antibody.
  • the IgG CHI domain ends at EU position 215, and the IgG CH2 domain begins at residue EU position 231.
  • the antibody hinge is herein defined to include positions 216 (E216 in IgGl) to 230 (p230 in IgGl), wherein the numbering is according to the EU index as in Kabat.
  • a “hinge fragment” is used, which contains fewer amino acids at either or both of the N- and C-termini of the hinge domain.
  • Heavy chain constant region refers to the CHl-hinge-CH2-CH3 portion of an antibody or fragment thereof, excluding the variable heavy domain.
  • the heavy chain constant region comprises amino acids 118-447 of human IgGl, in EU numbering.
  • “heavy chain constant region fragment” refers to a heavy chain constant region that contains fewer amino acids from either or both of the N- and C-termini but still retains the ability to form a dimer with another heavy chain constant region.
  • Fv refers to a polypeptide that comprises VL and VH domains of an antibody binding domain. Fv regions can be formatted as both Fabs and scFvs, where the VL and VH domains are combined (e.g., by way of a linker, as discussed herein) to form an scFv.
  • Fc Fc region, or Fc domain, as used herein, refers to a polypeptide comprising
  • CH2-CH3 domains of an IgG molecule and, in some cases, inclusive of the hinge.
  • the CH2-CH3 domain comprises amino acids 231 to 447, and the hinge is 216 to 230.
  • the definition of “Fc domain” includes both amino acids 231-447 (CH2- CH3) and 216-447 (hinge-CH2-CH3) of IgGl, or fragments thereof.
  • an “Fc fragment” in this context can contain fewer amino acids from either or both of the N- and C-termini but still retains the ability to form a dimer with another Fc domain or Fc fragment as can be detected using standard methods, generally based on size (e.g., non-denaturing chromatography, size exclusion chromatography, etc.).
  • the disclosed AOCs comprise human Fc domains.
  • the disclosed AOCs comprise Fc domains from human IgGl, IgG2, or IgG4.
  • variant Fc domain contains amino acid modifications as compared to a parental Fc domain.
  • a “variant human IgGl Fc domain” is one that contains amino acid modifications (generally amino acid substitutions, although in the case of ablation variants, amino acid deletions are included) as compared to the human IgGl Fc domain.
  • variant Fc domains have at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, or at least about 99% identity to the corresponding parental human IgG Fc domain.
  • the percent identity is calculated using the identity algorithms discussed below.
  • variant Fc domains have from 1 to about 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) amino acid modifications as compared to the parental Fc domain.
  • variant Fc domains retain the ability to form a dimer with Ir Fc domain as measured using known techniques as described herein, such as non-denaturing gel electrophoresis.
  • EU index or EU index as in Kabat or EU numbering scheme refers to the numbering of the EU antibody.
  • Kabat et al. collected numerous primary sequences of the variable regions of heavy chains and light chains. Based on the degree of conservation of the sequences, they classified individual primary sequences into the CDR and the framework and made a list thereof. See, SEQUENCES OF IMMUNOLOGICAL INTEREST, 5 th edition, NIH publication, No. 91-3242, E.A.
  • amino acid position numbering is according to the IMGT system.
  • full length antibody “intact antibody” and “whole antibody” are used herein interchangeably to refer to an antibody in its substantially intact form, not antibody fragments as defined below.
  • the terms particularly refer to an antibody with heavy chains that contain an Fc region.
  • an “antibody fragment” comprises a portion of an intact antibody, preferably comprising the antigen-binding region thereof.
  • antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
  • a “naked antibody” for the purposes herein is an antibody that is not conjugated to a payload, e.g., an oligonucleotide, cytotoxic moiety, or radiolabel.
  • the term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, e.g., the individual antibodies comprising the population are identical except for possible mutations, e.g., naturally occurring mutations, that can be present in minor amounts. Thus, the modifier “monoclonal” indicates the character of the antibody as not being a mixture of discrete antibodies.
  • such a monoclonal antibody typically includes an antibody comprising a polypeptide sequence that binds a target, wherein the target-binding polypeptide sequence was obtained by a process that includes the selection of a single target binding polypeptide sequence from a plurality of polypeptide sequences.
  • the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, or recombinant DNA clones.
  • a selected target binding sequence can be further altered, for example, to improve affinity for the target, to humanize the target binding sequence, to improve its production in cell culture, to reduce its immunogenicity in vivo, to create a multispecific antibody, etc., and that an antibody comprising the altered target binding sequence is also a monoclonal antibody of this disclosure.
  • each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen.
  • monoclonal antibody preparations are advantageous in that they are typically uncontaminated by other immunoglobulins.
  • Antibodies herein specifically include “chimeric” antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit one or more of the desired biological activities (see, e.g., U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984)).
  • variable region of both light and heavy chains corresponds to the variable region of antibodies derived from one species of mammals (e.g., mouse, rat, rabbit, etc.) with the desired specificity, affinity, and/or capability, while the constant regions are homologous to the sequences of antibodies derived from another species of mammals (e.g., human) to avoid eliciting an immune response In that species.
  • Chimeric antibodies include PRIMATTZED® antibodies wherein the antigen-binding region of the antibody is derived from an antibody produced by, e.g., immunizing macaque monkeys with the antigen of interest.
  • “Humanized” forms of non-human (e.g., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin.
  • a humanized antibody is a human immunoglobulin (recipient antibody) in which residues from a CDR/HVR of the recipient are replaced by residues from a CDR/HVR of a non-human species (donor antibody) such as mouse, rat, rabbit, or nonhuman primate having the desired specificity, affinity, and/or capacity.
  • donor antibody such as mouse, rat, rabbit, or nonhuman primate having the desired specificity, affinity, and/or capacity.
  • FR residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • humanized antibodies can comprise residues that are not found in the recipient antibody or in the donor antibody.
  • a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin, and all or substantially all of the FRs are those of a human immunoglobulin sequence.
  • the humanized antibody optionally will also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. See, e.g., Jones et al., Nature 321 :522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol.
  • human antibody refers to an antibody which possesses an amino acid sequence which corresponds to that of an antibody produced by a human and/or has been made using any technique known in the art.
  • This definition of a human antibody includes intact or full-length antibodies, fragments thereof, and/or antibodies comprising at least one human heavy and/or light chain polypeptide.
  • This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.
  • Human antibodies can be produced using various techniques known in the art, including phage-display libraries. Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991).
  • Human antibodies can be prepared by administering the antigen to a transgenic animal that has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled, e.g., immunized xenomice (see, e.g., U.S. Pat. Nos.
  • a “species-dependent antibody” is one which has a stronger binding affinity for an antigen from a first mammalian species than it has for a homologue of that antigen from a second mammalian species.
  • the species-dependent antibody “binds specifically” to a human antigen (e.g., has a binding affinity (Kd) value of no more than about 1 X 10 -7 M, preferably no more than about U I0 x M and preferably no more than about 1 x 10 9 M) but has a binding affinity for a homologue of the antigen from a second nonhuman mammalian species which is at least about 50 fold, or at least about 500 fold, or at least about 1000 fold, weaker than its binding affinity for the human antigen.
  • the species-dependent antibody can be any of the various types of antibodies as defined above, but preferably is a humanized or human antibody.
  • linear antibodies refers to the antibodies described in Zapata et al. (1995 Protein Eng, 8(10): 1057-1062). Briefly, these antibodies comprise a pair of tandem Fd segments (VH-CH1-VH-CH1) which, together with complementary light chain polypeptides, form a pair of antigen-binding regions. Linear antibodies can be bispecific or monospecific.
  • Modification refers to an amino acid substitution, insertion, deletion, and/or any other mutation in a polypeptide sequence.
  • Variant protein refers to a protein that differs from that of a parent protein by virtue of at least one amino acid modification.
  • the protein variant has at least one amino acid modification compared to the parent protein, yet not so many that the variant protein will not align with the parental protein using an alignment program such as that described below.
  • variant proteins are generally at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.5% identical to the parent polypeptide, using any alignment program known in the art, such as BLAST.
  • Sequence identity between two similar sequences can be measured by algorithms such as that of Smith, T.F. & Waterman, M.S. (1981) “Comparison Of Biosequences,” Adv. Appl. Math. 2:482 [local homology algorithm]; Needleman, S.B. & Wunsch, CD. (1970) “A General Method Applicable To The Search For Similarities In The Amino Acid Sequence Of Two Proteins,” J. Mol. Biol.48:443 [homology alignment algorithm], Pearson, W.R. & Lipman, D.J. (1988) “Improved Tools For Biological Sequence Comparison,” Proc. Natl. Acad. Sci.
  • a parent polypeptide for example an Fc parent polypeptide, is a human wild type sequence, such as the heavy constant domain or Fc region from IgGl, IgG2, IgG3 or IgG4, although human sequences with variants can also serve as “parent polypeptides.”
  • antibody sequences described herein have at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.5% sequence identity with a parent polypeptid
  • antibody variant refers to an antibody that differs from a parent antibody by virtue of at least one amino acid modification
  • IgG variant or variant IgG refers to an IgG that differs from a parent IgG (e.g., from a human IgG sequence) by virtue of at least one amino acid modification
  • immunoglobulin variant or variant immunoglobulin refers to an immunoglobulin sequence that differs from that of a parent immunoglobulin sequence by virtue of at least one amino acid modification
  • Fc variant or “variant Fc” as used herein refers to an Fc that differs from a parent Fc, e.g., an Fc domain of human IgGl, IgG2, IgG3, or IgG4, by virtue of at least one amino acid modification.
  • IgG subclass modification or “isotype modification,” as used herein, refers to amino acid modifications that convert one amino acid of one IgG isotype to the corresponding amino acid in a different, aligned IgG isotype. For example, because IgGl comprises a tyrosine and IgG2 a phenylalanine at EU position 296, a F296Y substitution in IgG2 is considered an IgG subclass modification.
  • Non-naturally occurring modification as used herein is meant an amino acid modification that is not isotypic.
  • the substitution 434S in IgGl, IgG2, IgG3, or IgG4 (or hybrids thereof) is considered a non-naturally occurring modification.
  • oligonucleotide or “polynucleotide,” used interchangeably, refers to a linear polymer of natural or modified nucleoside monomers linked by phosphodiester bonds or analogs thereof.
  • the term “oligonucleotide” usually refers to a shorter polymer, e.g., comprising from about 3 to about 100 monomers, and the term “polynucleotide” usually refers to longer polymers, e.g., comprising from about 100 monomers to many thousands of monomers, e.g., 10,000 monomers, or more. Oligonucleotides and polynucleotides can be natural or synthetic.
  • Oligonucleotides and polynucleotides can include deoxyribonucleosides, ribonucleosides, and/or non-natural analogs thereof.
  • oligonucleotides or polynucleotides are capable of specifically binding to a target genome by way of a regular pattern of monomer-to-monomer interactions, such as Watson-Crick type of base pairing, base stacking, Hoogsteen or reverse Hoogsteen types of base pairing, or the like.
  • “functional nucleic acid” refers to a nucleic acid having biological functions in vivo or in cells, such as enzymatic functions, catalytic functions, or biologically inhibiting or enhancing functions (e.g., inhibition or enhancement of transcription or translation).
  • examples of functional nucleic acids include, but are not limited to, siRNA, ASO, shRNA, miRNA (including pri-miRNA and pre-miRNA), nucleic acid aptamers (including RNA aptamers and DNA aptamers), ribozymes (including deoxyribozymes), riboswitches, U1 adaptors, molecular beacons, and transcriptional factor- binding regions.
  • a “3E10 antibody” refers to an antibody with a set of heavy chain CDRs (VH CDR1, VH CDR2, and VH CDR3), identified according to the Kabat system, comprising amino acid sequences that vary from SEQ ID NOS: 58, 59, and 60 by no more than two amino acids each, respectively, a set of light chain CDRs (VL CDR1, VL CDR2, and VL CRD3) comprising amino acid sequences that vary from SEQ ID NOS: 61, 62, and 63 by no more than two amino acids each, respectively, that binds nucleic acids and is cell-penetrating at least when bound to a nucleic acid, as well as antigen-binding fragments thereof.
  • the 3E10 antigen is a polynucleotide.
  • the term “cell-penetrating” refers to an antibody or antigen binding fragment thereof that can penetrate a cell, e.g., a mammalian cell, without the aid of an exogeneous transport vehicle, such as a liposome, or a conjugated cell-penetrating peptide.
  • a cell e.g., a mammalian cell
  • an exogeneous transport vehicle such as a liposome
  • the cell-penetrating antibody or antigen binding fragment thereof can penetrate a cell expressing an ENT2 receptor on its cell surface in the presence of nucleic acids, e.g., non-covalently bound and/or conjugated to the 3E10 antibody or antigen binding fragment thereof, resulting in internalization of the 3E10 antibodies and antigen binding fragments thereof.
  • the cell-penetrating 3E10 antibody or antigen binding fragment thereof is conjugated to a functional molecule, e.g., a chemical agent, polynucleotide, or polypeptide.
  • a functional molecule e.g., a chemical agent, polynucleotide, or polypeptide.
  • the cell-penetrating molecules are generally referred to herein as “cell-penetrating antibodies,” it will be appreciated that fragments, including antigen-binding fragments, variants, binding proteins and fusion proteins such as scFv, di- scFv, tri-scFv, and other single chain variable fragments, and other cell-penetrating molecules disclosed herein are also expressly provided foruse in compositions, conjugates, and methods disclosed herein.
  • cell -penetrating antibodies e.g., cell-penetrating anti-DNA antibodies
  • SLE systemic lupus erythematosus
  • antibody-oligonucleotide conjugate refers to an antibody or antigen-binding fragment thereof that is covalently linked or conjugated to a biologically active molecule, for example an oligonucleotide or anti-tumor oligonucleotide, for example, an siRNA molecule, an antisense oligonucleotide.
  • a “linker” is any chemical moiety that is capable of linking or connecting a molecule, including an oligonucleotide, to a cell-binding agent such as an antibody, such as a 3E10 antibody or a fragment thereof, in a stable, covalent manner.
  • a “linker” is any chemical moiety that is capable of linking or connecting a compound such as an oligonucleotide, a polynucleotide, a DNA damage-inducing agent, a DNA repair inhibitor, an immune modulatory molecule, an alkylating agent, a microtubule inhibitor, an immune checkpoint inhibitor, an angiogenesis inhibitor, an adoptive cell therapy, or a topoisomerase inhibitor, to a cell-binding agent such as a 3E10 antibody or a fragment thereof, in a stable, covalent manner.
  • Linkers can be susceptible to or be substantially resistant to acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and/or disulfide bond cleavage, at conditions under which the compound and/or the antibody remains active.
  • Suitable linkers are well known in the art and include, for example, disulfide groups, thioether groups, acid labile groups, photolabile groups, peptidase labile groups and esterase labile groups.
  • Linkers also include charged linkers, and hydrophilic forms thereof as described herein and know in the art.
  • the term “subject” means any individual who is the target of administration.
  • the subject can be any animal (e.g., a mammal. Thus), including, but not limited to, humans, and non-human animals (including, but not limited to, non-human primates, dogs, cats, rodents, horses, cows, pigs, mice, rats, hamsters, rabbits, and the like (e.g., which is to be the recipient of a particular treatment).
  • the subject is a human.
  • methods of the disclosure are useful in treatment a human subject.
  • the human may be referred to as a patient.
  • the human is a female.
  • the human is a male.
  • the human has an age in a range of from about 1 to about 18 months old, from about 18 to about 36 months old, from about 1 to about 5 years old, from about 5 to about 10 years old, from about 10 to about 15 years old, from about 15 to about 20 years old, from about 20 to about 25 years old, from about 25 to about 30 years old, from about 30 to about 35 years old, from about 35 to about 40 years old, from about 40 to about 45 years old, from about 45 to about 50 years old, from about 50 to about 55 years old, from about 55 to about 60 years old, from about 60 to about 65 years old, from about 65 to about 70 years old, from about 70 to about 75 years old, from about 75 to about 80 years old, from about 80 to about 85 years old, from about 85 to about 90 years old, from about 90 to about 95 years old or from about 95 to about 100 years old.
  • cancer refers to or describe the physiological condition in mammals in which a population of cells are characterized by unregulated cell growth.
  • examples of cancer include, but are not limited to, colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord tumor, endocrine cancer, esophageal cancer,
  • DIPG diffuse intrinsic pontine glio
  • Tumor and “neoplasm” refer to any mass of tissue that results from excessive cell growth or proliferation, either benign (noncancerous) or malignant (cancerous), including pre- cancerous lesions.
  • cancer cell refers to the total population of cells derived from a tumor or a pre-cancerous lesion, including both non- tumorigenic cells, which comprise the bulk of the tumor cell population, and tumorigenic stem cells (cancer stem cells).
  • pharmaceutically effective amount means that the amount of the composition used is of sufficient quantity to ameliorate one or more causes or symptoms of a disease or disorder. Such amelioration only requires a reduction or alteration, not necessarily elimination. The precise dosage will vary according to a variety of factors such as subject-dependent variables (e.g., age, immune system health, etc.), the disease or disorder being treated, as well as the route of administration and the pharmacokinetics of the agent being administered.
  • carrier or “excipient” refers to an organic or inorganic ingredient, natural or synthetic inactive ingredient in a formulation, with which one or more active ingredients are combined.
  • the carrier or excipient is selected to minimize degradation of the active ingredient or to minimize adverse side effects in the subject, as would be well known to one of skill in the art.
  • the term “treat” refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder.
  • This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder.
  • this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.
  • antibody-oligonucleotide conjugate refers to an antibody or antigen-binding fragment thereof that is conjugated via a linker to a therapeutic oligonucleotide, for example, an oligonucleotide, an siRNA, or an antisense oligonucleotide (ASO), which may be delivered to specific cells or tissues otherwise not targetable by oligonucleotide delivery.
  • ASO antisense oligonucleotide
  • the conjugation of an oligonucleotide with an antibody or antigen- binding fragment thereof may also improve the pharmacokinetic properties of therapeutic oligonucleotides, expanding application of this therapeutic modality.
  • a “pharmacologically effective amount,” “pharmacologically effective dose,” “therapeutically effective amount,” or “effective amount” refers to an amount sufficient to produce the desired physiological effect or amount capable of achieving the desired result, particularly for treating or preventing the disorder or disease.
  • An effective amount as used herein would include an amount sufficient to, for example, delay the development of a symptom of the disorder or disease, alter the course of a symptom of the disorder or disease (e.g., slow the progression of a symptom of the disease), reduce or eliminate one or more symptoms or manifestations of the disorder or disease, and reverse a symptom of a disorder or disease.
  • Therapeutic benefit also includes halting or slowing the progression of the underlying disease or disorder, regardless of whether improvement is realized.
  • Effective amounts, toxicity, and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell cultures, tissue samples, tissue homogenates or experimental animals, e.g., for determining the LD50 (the dose lethal to about 50% of the population) and the ED50 (the dose therapeutically effective in about 50% of the population) or the maximum tolerated dose.
  • the dosage can vary depending upon the dosage form employed and the route of administration utilized.
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio LD50/ED50.
  • compositions, conjugates, and methods that exhibit large therapeutic indices are preferred.
  • a therapeutically effective dose can be estimated initially from in vitro assays, including, for example, cell culture assays or measurements.
  • a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 as determined in cell culture, or in an appropriate animal model.
  • Levels of the described compositions in plasma can be measured, for example, by high performance liquid chromatography.
  • the effects of any particular dosage can be monitored by a suitable bioassay. The dosage can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment.
  • the effect will result in a quantifiable change of at least about 10%, at least about 20%, at least about 30%, at least about 50%, at least about 70%, or at least about 90%. In embodiments, the effect will result in a quantifiable change of about 10%, about 20%, about 30%, about 50%, about 70%, or even about 90% or more.
  • Therapeutic benefit also includes halting or slowing the progression of the underlying disease or disorder, regardless of whether improvement is realized.
  • AOCs Antibody-Oligonucleotide Conjugates
  • AOCs antibody-oligonucleotide conjugates
  • a cell-penetrating antibody e.g., a 3E10 antibody or antigen-binding fragment thereof
  • conjugated via a linker to an oligonucleotide, e.g., a therapeutic oligonucleotide.
  • an AOC described herein has the formula A-(L-P r )q, wherein: A is a 3E10 antibody or antigen-binding fragment thereof, L is a linker, and P is an oligonucleotide moiety as described herein.
  • the present disclosure relates to the use of 3E10 antibodies, and derivatives thereof, for delivering therapeutic agents to a subject.
  • 3E10 or “3E10 antibodies”
  • fragments, variants, and binding proteins including antigen-binding fragments and fusion proteins, such as scFv, di-scFv, tr-scFv, and other single chain variable fragments, and other cell -penetrating, nucleic acid transporting molecules disclosed herein, are encompassed by the phrase and are also expressly provided for use in compositions, conjugates, and methods disclosed herein.
  • the antibodies and other binding proteins are also referred to herein as cell-penetrating.
  • the antibody is conjugated to the biologically active molecule via a linker.
  • the antibody is a 3E10 antibody or antigen-binding fragment thereof, as described herein.
  • the antibody is a humanized 3E10 antibody or antigen-binding fragment thereof, as described herein. Any variety of agents can be transported via conjugation to the 3E10 antibody or antigen-binding fragment thereof, or humanized 3E10 antibody or antigen- binding fragment thereof, herein, such as inorganic and organic molecules, pharmaceutical agents, drugs, peptides, proteins, genetic material, and the like.
  • the antibody- oligonucleotide conjugate (AOC) comprises an oligonucleotide.
  • ABSs Antigen-Binding Domains
  • an ABD refers to a domain comprising a three-dimensional structure capable of immunospecifically binding to an epitope of an antigen.
  • an ABD comprises a hypervariable region, optionally a VH and/or VL domain of an antibody, optionally at least a VH domain.
  • an ABD comprises at least one complementarity determining region (CDR) of an antibody.
  • CDR complementarity determining region
  • an ABD comprises at least two CDRs of an antibody.
  • an ABD comprises at least three CDRs of an antibody.
  • an ABD comprises at least four CDRs of an antibody.
  • an ABD comprises at least five CDRs of an antibody.
  • an ABD comprises six CDRs of an antibody.
  • the present disclosure relates to the use of 3E10 antibodies and antigen binding fragments thereof, e.g., for delivering therapeutic agents (e.g., oligonucleotides) into a cell within a subject.
  • therapeutic agents e.g., oligonucleotides
  • 3E10 3E10 antibodies
  • disclosure herein referring to such antibodies also encompass antigen-binding fragments thereof, e.g., scFv, di-scFv, tr-scFv, regardless of whether it is specifically recited in each instance.
  • a 3E10 antibody comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60. In embodiments, a 3E10 antibody comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 3, 4, and 5. In embodiments, a 3E10 antibody comprises VL CDRs of SEQ ID NOs: 22, 23, and 24 and VH CDRs of SEQ ID NOs: 15, 17, and 18. In embodiments, a 3E10 antibody comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 16, 4, and 5. Other examples of 3E10 VL and VH CDR sequences are shown in Figures 1-4.
  • 3E10 is known to interact with the ENT2 nucleoside transporter expressed on various cell types, including muscle cells and cancer cells. In fact, ENT2 is overexpressed in most, if not all cancers. Accordingly, an AOC provided herein can widely target cancers based on cell surface expression of ENT2 on cancer cells.
  • an AOC described herein can target ENT2 and extracellular DNA simultaneously.
  • 3E10 has been shown to preferentially localize into tumor cell nuclei in vivo, likely due to increased DNA in the local environment released from ischemic and necrotic regions of tumor. Targeting of the 3E10 antibody to extracellular DNA is described in, for example in Weisbart, Sci Reports, 2015, which is herein incorporated by reference.
  • an 3E10 AOC described herein presents a platform to target a variety of cancers and deliver therapeutic oligonucleotides to target and kill cancer cells.
  • the antibody or antigen-binding fragment thereof is a murine, chimeric, humanized, or human antibody or antigen-binding fragment thereof.
  • an AOC of the present disclosure penetrates into cells and nuclei in an ENT2-dependent manner.
  • a second polynucleotide is non-covalently bound to an AOC of the present disclosure, to help facilitate cellular internalization of the AOC. That is, in some embodiments, polynucleotides conjugated to the antibody (cargo polynucleotides) do not interact with the nucleic acid-binding paratope of the antibody, and a second polynucleotide (e.g., carrier nucleic acid) is non-covalently complexed with the paratope to help facilitate internalization. In embodiments, the second polynucleotide is precomplexed with the AOC prior to administering the AOC to a subject.
  • the second polynucleotide is an extracellular polynucleotide that is bound by the AOC at a site of interest in vivo, for example, at a site of tumor ischemia and/or necrosis.
  • the second polynucleotide is DNA.
  • the second polynucleotide is RNA.
  • an AOC disclosed herein comprises a VH and VL domain of a 3E10 antibody.
  • the AOC comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and/or VL CDR3 of a 3E10 antibody.
  • the present disclosure provides an antibody-oligonucleotide conjugate having the formula A-(L-P r ) q , wherein: A is a 3E10 antibody or antigen-binding fragment thereof, L is a linker, and P is an oligonucleotide as described herein, wherein the linker L links A to P.
  • L is a cleavable linker and P is an siRNA molecule that targets cMyc mRNA.
  • the amino acid residue corresponding with D31 of the heavy chain CDR1 of the 3E10 antibody or antigen-binding fragment thereof is substituted with N.
  • 3E10 antibody variants include mutation of aspartic acid at residue 31 of VH CDR1 to arginine (3E10-D31R), which modeling indicates expands cationic charge, or lysine (3E10-D31K) which modeling indicates changes charge orientation.
  • the 3E10 antibody or antigen-binding fragment thereof includes a D31R or D3 IK substitution.
  • additional 3E10 antibody variants include R96N, and/or S30D, alone or in combination with D31N, D31R, or D31K. All of the sequences disclosed herein having the residue corresponding to 3E10 D31 or N31, are expressly disclosed with a D31R or D3 IK or N31R or N3 IK substitution.
  • the present disclosure provides an antibody-oligonucleotide conjugate (AOC) having the formula A-(L-P r ) q , wherein: A is a 3E10 antibody or antigen-binding fragment thereof, L is a linker, P is an oligonucleotide as described herein, r is an integer from 1 to 4, and q is an integer from 1 to 16, wherein the linker L links A to (P); wherein the 3E10 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of XI YGMX2, where XI is D, E, N, Q, R, or K and X2 is K, R, or H (SEQ ID NO:58).
  • AOC antibody-oligonucleotide conjugate
  • the antibody or antigen-binding fragment thereof comprises (a) a light chain variable region (VL) complementarity determining region (CDR) 1 comprising the amino acid sequence of X1ASX2X3VSTSSYSYX4X5, where XI is K, R, or H, X2 is K, R, or H, X3 is T or S, X4 is M or L, and X5 is K, R, H, or A (SEQ ID NO:61), (b) a VL CDR2 comprising the amino acid sequence of YASYLX1S, where XI is D, E, N, or Q (SEQ ID NO:62), and (c) a VL CDR3 comprising the amino acid sequence of QX1SX2X3FPWT, where XI is K, R, or H, X2 is K, R, or H, and X3 is D or E (SEQ ID NO:63), and (d) a heavy chain variable region (VH) CDR1
  • the present disclosure provides an antibody-oligonucleotide conjugate (AOC) having the formula A-(L-P r ) q , wherein: A is a 3E10 antibody or antigen-binding fragment thereof, L is a linker, P is a payload as described herein, r is an integer from 1 to 4, and q is an integer from 1 to 16, wherein the linker L links A to P; wherein the 3E10 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of NYGMH (SEQ ID NO: 15).
  • AOC antibody-oligonucleotide conjugate
  • the antibody or antigen- binding fragment thereof comprises (a) a light chain variable region (VL) complementarity determining region (CDR) 1 comprising the amino acid sequence of RASKSVSTSSYSYMH (SEQ ID NO:9), (b) a VL CDR2 comprising the amino acid sequence of YASYLES (SEQ ID NO: 10), and (c) a VL CDR3 comprising the amino acid sequence of QHSREFPWT (SEQ ID NO: 11), and (d) a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of NYGMH (SEQ ID NO: 15), (e) a VH CDR2 comprising the amino acid sequence of YISSGSSTIYYADTVKG (SEQ ID NO: 4), and (f) a VH CDR3 comprising the amino acid sequence of RGLLLDY (SEQ ID NO: 5).
  • VL light chain variable region
  • CDR complementarity determining region
  • the antibody or antigen-binding fragment thereof comprises a light chain variable region (VL) comprising an amino acid sequence that is identical to SEQ ID NO:21.
  • the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) comprising an amino acid sequence that is identical to SEQ ID NO: 14.
  • the antibody or antigen-binding fragment thereof comprises a full length light chain (LC) comprising an amino acid sequence that is identical to SEQ ID NO:20.
  • the antibody or antigen-binding fragment thereof comprises a full length heavy chain (HC) comprising an amino acid sequence that is identical to SEQ ID NO: 13.
  • the antibody or antigen-binding fragment thereof comprises a light chain variable region (VL) comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO:21.
  • the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 14.
  • the antibody or antigen-binding fragment thereof comprises a full length light chain (LC) comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO:20.
  • the antibody or antigen-binding fragment thereof comprises a full length heavy chain (HC) comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to SEQ ID NO: 13.
  • the 3E10 antibody or antigen-binding fragment thereof can be transported into the cytoplasm and/or nucleus of the cells without the aid of a carrier or conjugate.
  • a monoclonal 3E10 antibody and active fragments thereof that are transported in vivo to the nucleus of mammalian cells without cytotoxic effect are disclosed in U.S. Patent Nos. 4,812,397 and 7,189,396 to Richard Weisbart, the disclosures of which are incorporated by reference herein, in their entireties.
  • a murine version of the 3E10 antibody is described in Zack, et al., Immunology and Cell Biology, 72:513-520 (1994), the disclosure of which is incorporated by reference herein, in its entirety.
  • Amino acid variants of the 3E10 antibody are also known in the art, for example, as described in Zack, et al., J. Immunol., 157(5):2082-8 (1996).
  • amino acid position 31, in CDR1 of the heavy chain variable region of 3E10 influences nucleic acid binding and the antibody’s ability to penetrate nuclei.
  • Substitution of the ‘wild-type’ (e.g., relative to the original murine antibody) aspartic acid by asparagine (the ‘D3 IN’ mutation) improves nucleic acid binding and nuclei penetration of the antibody, relative to the ‘wild type’ murine antibody.
  • 3E10 antibodies and antigen-binding fragments or variants thereof, with the D3 IN substitution are disclosed herein.
  • the 3E10 antibodies and antigen- binding fragments thereof disclosed herein include the D31N substitution.
  • other amino acids are substituted at position 31 in the 3E10 antibodies and antigen-binding fragments thereof disclosed herein.
  • D31R, D31K, or D31R substitutions are incorporated in some aspects of the present disclosure.
  • Other 3E10 light chain sequences are known in the art. See, for example, Zack, et al., J.
  • GenBank L16981.1 - Mouse Ig rearranged L-chain gene, partial cds
  • GenBank AAA65681.1 - immunoglobulin light chain, partial [Mus musculus]).
  • an antibody disclosed herein is an IgA, IgD, IgE, IgG, or IgM antibody, including any subtype or isotype thereof. In embodiments, an antibody disclosed herein is based on the IgG class.
  • an antibody disclosed herein is based on one of the subclasses of IgG, including, but not limited to IgGl, IgG2, IgG3, and IgG4.
  • IgGl, IgG2 and IgG4 are used more frequently than IgG3.
  • IgGl has different allotypes with polymorphisms at 356 (D or E) and 358 (L or M), and in embodiments, antibodies disclosed herein are based on IgGl having D or E at position 356 and/or L or M at position 358.
  • the light chain generally comprises two domains, the variable light domain (containing the light chain CDRs and together with the variable heavy domains forming the Fv region), and a constant light chain region (often referred to as CL or CK).
  • the heavy chain comprises a variable heavy domain and a constant domain, which includes a CHI -optional hinge- Fc domain comprising a CH2-CH3.
  • the hypervariable region of an antibody generally encompasses amino acid residues from about amino acid residues 24-34 (LCDR1; “L” denotes light chain), 50-56 (LCDR2) and 89-97 (LCDR3) in the light chain variable region and around about 31-35B (HCDR1; “H” denotes heavy chain), 50-65 (HCDR2), and 95-102 (HCDR3) in the heavy chain variable region; Kabat et al., SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md.
  • variable heavy and/or variable light sequence includes the disclosure of the associated (inherent) CDRs. Accordingly, the disclosure of each variable heavy region is a disclosure of the VH CDRs (e.g., VH CDR1, VH CDR2 and VH CDR3) and the disclosure of each variable light region is a disclosure of the VL CDRs (e.g., VL CDR1, VL CDR2 and VL CDR3).
  • VH CDRs e.g., VH CDR1, VH CDR2 and VH CDR3
  • VL CDRs e.g., VL CDR1, VL CDR2 and VL CDR3
  • the Kabat numbering system is generally used when referring to a residue in the variable domain (approximately, residues 1-107 of the light chain variable region and residues 1-113 of the heavy chain variable region) and the EU numbering system for Fc regions (e.g., Kabat et al., supra (1991)).
  • the present specification uses the IMGT system to define the complementarity determining regions (CDRs) provided herein.
  • a “full CDR set” comprises the three variable light CDRs, e.g., a VL CDR1, VL CDR2, and VL CDR3, and the three variable heavy CDRs, e.g. VH CDR1, VH CDR2, and VH CDR3. These can be part of a larger variable light or variable heavy domain, respectfully.
  • the variable heavy and variable light domains can be on separate polypeptide chains, when a heavy and light chain is used (for example when Fabs are used), or on a single polypeptide chain in the case of scFv sequences.
  • the present disclosure refers to different antibody domains of a 3E10 antibody or antigen-binding fragment thereof.
  • These domains include, but are not limited to, the Fc domain, the CHI domain, the CH2 domain, the CH3 domain, the hinge domain, the heavy constant domain (CHl-hinge-Fc domain or CHl-hinge-CH2-CH3), the variable heavy (VH) domain, the variable light (VL) domain, the light constant domain, Fab domains and scFv domains.
  • the antibodies of the disclosure comprise a heavy chain variable region from a particular germline heavy chain immunoglobulin gene and/or a light chain variable region from a particular germline light chain immunoglobulin gene.
  • such antibodies can comprise or consist of murine, chimeric, humanized, or human antibodies or antigen-binding fragments thereof comprising heavy or light chain variable regions that are “the product of’ or “derived from” a particular germline sequence, e g., that of the 3E10 antibody.
  • a human antibody that is “the product of’ or “derived from” a human germline immunoglobulin sequence can be identified as such by comparing the amino acid sequence of the human antibody to the amino acid sequences of human germline immunoglobulins and selecting the human germline immunoglobulin sequence that is closest in sequence (i.e., greatest % identity) to the sequence of the human antibody (using the methods outlined herein).
  • a human antibody that is “the product of’ or “derived from” a particular human germline immunoglobulin sequence can contain amino acid differences as compared to the germline sequence, due to, for example, naturally-occurring somatic mutations or intentional introduction of site-directed mutation.
  • a humanized antibody typically is at least 90% identical in amino acids sequence to an amino acid sequence encoded by a human germline immunoglobulin gene and contains amino acid residues that identify the antibody as being derived from human sequences when compared to the germline immunoglobulin amino acid sequences of other species (e.g., murine germline sequences).
  • a humanized antibody can be at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical in amino acid sequence to the amino acid sequence encoded by the germline immunoglobulin gene.
  • a humanized antibody derived from a particular human germline sequence will display no more than 10-20 amino acid differences from the amino acid sequence encoded by the human germline immunoglobulin gene.
  • the humanized antibody can display no more than 5, or even no more than 4, 3, 2, or 1 amino acid difference from the amino acid sequence encoded by the germline immunoglobulin gene.
  • the parent antibody has been affinity matured, as is known in the art.
  • Structure-based methods can be employed for humanization and affinity maturation, for example, as U.S. Patent Publication No. 2006/0008883, which is incorporated herein by reference.
  • Selection based methods can be employed to humanize and/or affinity mature antibody variable regions, including but not limited to methods described in Wu et al., 1999, J. Mol. Biol. 294: 151-162; Baca et al., 1997, J. Biol. Chem. 272(16): 10678-10684; Rosok et al., 1996, J. Biol. Chem. 271(37): 22611-22618; Rader et al., 1998, Proc.
  • one or more amino acid modifications can be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant.
  • the Fc region variant can comprise a human Fc region sequence (e.g., a human IgGl, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e g. a substitution) at one or more amino acid positions.
  • an Fc region variant possesses some but not all effector functions, which make it a desirable candidate for applications in which the half-life of the antibody in vivo is important yet certain effector functions (such as complement and ADCC) are unnecessary or deleterious.
  • In vitro and/or in vivo cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities.
  • Fc receptor (FcR) binding assays known in the art can be conducted to ensure that the antibody lacks FcyR binding (hence likely lacking ADCC activity), but retains FcRn binding ability.
  • a CDC assay can be performed (see, for example, Gazzano- Santoro et al., J. Immunol. Methods 202: 163 (1996); Cragg, M.S. et al., Blood 101 :1045-1052 (2003); and Cragg, M. S. and M. J. Glennie, Blood 103:2738-2743 (2004)).
  • FcRn binding and in vivo clearance/half life determinations can also be performed using methods known in the art (see, e.g., Petkova, S.B. et al., Int’l. Immunol. 18(12): 1759-1769 (2006)).
  • an antibody provided herein can have reduced effector function and thus can comprise a substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Pat. No. 6,737,056).
  • Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called “DANA” Fc mutant with substitution of residues 265 and 297 to alanine (U.S. Pat. No. 7,332,581).
  • an Fc region variant provided herein can have improved or diminished binding to FcRs. See, e.g., U.S. Pat. No. 6,737,056; WO 2004/056312, and Shields et al., J. Biol. Chem. 9(2): 6591-6604 (2001), the disclosure of which are incorporated herein by reference, in their entireties.
  • an Fc region variant provided herein comprises an Fc region with one or more amino acid substitutions which improve ADCC, e.g., substitutions at positions 298, 333, and/or 334 of the Fc region (EU numbering of residues).
  • an Fc region variant provided herein comprises alterations that result in altered (i.e., either improved or diminished) Clq binding and/or Complement Dependent Cytotoxicity (CDC), e.g., as described in U.S. Pat. No. 6,194,551, WO 99/51642, and Idusogie et al. J. Immunol. 164: 4178-4184 (2000).
  • CDC Complement Dependent Cytotoxicity
  • an Fc region variant provided herein comprises alterations that result in increased half-lives and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)), e.g., as described in US2005/0014934A1 (Hinton et al.). Those antibodies comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn.
  • FcRn neonatal Fc receptor
  • Such Fc variants include those with substitutions at one or more ofFc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (U.S. Pat. No. 7,371,826).
  • an Fc region variant provided herein comprises “knob-in-hole” or “skew” variants, which refer to amino acid engineering that creates stearic influences to favor heterodimeric formation and disfavor homodimeric formation, as described in USSN 61/596,846, Ridgway et al, Protein Engineering 9(7):617 (1996); Atwell et al, J. Mol. Biol. 1997 270:26; US Patent No. 8,216,805, all of which are hereby incorporated by reference in their entirety.
  • an Fc region variant provided herein comprises alterations described in Duncan & Winter, Nature 322:738-40 (1988); U.S. Pat. No. 5,648,260; U.S. Pat. No. 5,624,821; and WO 94/29351.
  • the antibody portion of an AOC described herein comprises an antigen-binding fragment of a 3E10 antibody.
  • the antigen-binding fragment retains the desired biological activity of a 3E10 antibody.
  • the antigen-binding fragment retains at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95% of the desired biological activity of a 3E10 antibody.
  • the antigen-binding fragment retains the ability of the antibody to bind to its target antigen, e.g., a nucleic acid, e.g., DNA. In embodiments, the antigen-binding fragment retains the ability of the antibody to bind to a cellular receptor, e.g., ENT2. In embodiments, the antigen- binding fragment retains the ability of the antibody to be internalized by a target cell.
  • the 3E10 antibody or antigen binding fragment thereof comprises a single-chain fragment variable (scFv), a tandem double scFv, an (scFv)2, a minibody, a VHH, an scFv-Fc, a CrossMab, a dual variable domain immunoglobulin (DVD-Ig), a single-chain tandem fragment variable (scTaFv), a diabody, a tandem diabody (TandAb), a Fabsc, a modular IgG-scFv, a Fab, or an F(ab’)2.
  • scFv single-chain fragment variable
  • scFv tandem double scFv
  • an (scFv)2 a minibody
  • VHH an scFv-Fc
  • CrossMab a dual variable domain immunoglobulin
  • DVD-Ig dual variable domain immunoglobulin
  • scTaFv single-chain tandem fragment variable
  • diabody
  • an antigen-binding fragment of a 3E10 antibody or antigen- binding fragment thereof comprises a CrossMab.
  • CrossMab complementary mutations are introduced in the heavy chain constant region of each arm to generate so-called “holes and knobs,” resulting in preferred association between different arms, forming a heterodimer, rather than a homodimer of two of the same arms.
  • the exact residues that are mutated in the heavy chain constant region of a CrossMab bispecific antibody to form “holes” and “knobs” can vary depending on the specific design and optimization goals of the antibody.
  • CrossMab antibodies see, for example, Huang, J., et al., Journal of Biological Chemistry, 294(50): 19001-10 (2019), the disclosure of which is incorporated herein by reference in its entirety.
  • an antigen-binding fragment of a 3E10 antibody or antigen- binding fragment thereof comprises a divalent, dual-variable domain immunoglobulin (DVD-Ig) of a 3E10 antibody or antigen binding fragment thereof.
  • DVD-Ig divalent, dual-variable domain immunoglobulin
  • each arm of the antibody contains two VH/VL pairs.
  • one of the VH/VL pairs comprises 3E10 VH and VL CDRs.
  • an antigen-binding fragment of a 3E10 antibody or antigen- binding fragment thereof comprises a single-chain variable fragment (scFv).
  • Single chain Fv or “scFv,” as used herein, refers to a VH domain covalently attached to a VL domain through a linker, e.g., a scFv linker as discussed herein, to form a continuous protein chain.
  • a scFv domain can be in either arrangement from N- to C-terminus (i.e., VH-linker-VL or VL-linker-VH).
  • H.X L.Y means the N- to C-terminus arrangement is VH- linker-VL
  • L.Y H.X means the N- to C-terminus arrangement is VL-linker-VH.
  • an antigen-binding fragment of a 3E10 antibody or antigen- binding fragment thereof comprises a tandem double scFv.
  • a tandem double scFv has two scFv domains linked in a linear fashion.
  • each scFv domain is derived from a different antibody and provides independent antigen-binding specificity.
  • one of the scFv domains comprises 3E10 VH and VL CDRs.
  • an antigen-binding fragment of a 3E10 antibody or antigen- binding fragment thereof comprises a dimeric scFv antibody (scFv)2.
  • a dimeric scFv antibody has two scFv domains linked in a dimeric arrangement.
  • each scFv domain is derived from a different antibody and provides independent antigen-binding specificity.
  • one of the scFv domains comprises 3E10 VH and VL CDRs.
  • an antigen-binding fragment of a 3E10 antibody or antigen- binding fragment thereof comprises a scFv-Fc.
  • An “scFv-Fc,” as meant herein, is a polypeptide that consists of a heavy and a light chain variable region of an antibody joined by a linker, which is followed by an Fc polypeptide chain of an antibody, optionally the Fc region of a human IgG antibody, such as an IgGl, IgG2, IgG3, or IgG4 antibody.
  • an antigen-binding fragment of a 3E10 antibody or antigen- binding fragment thereof comprises a single-chain tandem fragment variable (scTaFv) antibody.
  • a single-chain tandem fragment variable (scTaFv) antibody is a type of bispecific antibody that consists of two variable fragment (VH and VL) domains linked in a tandem arrangement.
  • one of the variable fragment domains comprises 3E10 VH and VL CDRs.
  • an antigen-binding fragment of a 3E10 antibody or antigen- binding fragment thereof comprises a VHH, also referred to as a nanobody.
  • VHH refers to a variable domain of heavy chain of heavy-chain antibody.
  • a VHH is a molecule that can recognize an antigen through a single domain and is the smallest unit among antibody molecules that have been found to date.
  • a VHH can include one or more variable domains of heavy chain derived from a heavy-chain antibody, and the number of the variable domains of heavy chain included in the VHH is not limited.
  • an antigen-binding fragment of a 3E10 antibody or antigen- binding fragment thereof comprises a diabody.
  • diabody refers to a divalent antibody comprising two polypeptide chains, wherein each polypeptide chain is too short for a pair to form between two domains on the same chain such that each domain is paired with a complementary domain on another polypeptide chain (see, e.g., Holliger et al., 1993, Proc. Natl. Acad. Sci. USA 90: 6444-48 and Poljak et al., 1994, Structure 2: 1121-23).
  • one of the antigen binding domains of the diabody comprises 3E10 VH and VL CDRs.
  • Polypeptide chains of different sequences can be used to prepare diabodies with two different antigen-binding sites.
  • triabodies and tetrabodies refer to antibodies that contain three and four polypeptide chains, respectively, and form three and four antigen-binding sites (which can be the same or different), respectively.
  • an antigen-binding fragment of a 3E10 antibody or antigen- binding fragment thereof comprises a tandem diabody (TandAb).
  • a tandem diabody has wo antigen-binding domains (VH and VL) linked in a tandem arrangement by a flexible peptide linker.
  • one of the antigen binding domains comprises 3E10 VH and VL CDRs.
  • an antigen-binding fragment of a 3E10 antibody or antigen- binding fragment thereof comprises a Fabsc.
  • a “Fabsc” format antibody molecule typically refers to a bispecific antibody molecule having a Fab fragment, which generally includes a hinge region, which is at the C-terminus of the Fab fragment linked to the N- terminus of a CH2 domain, of which the C-terminus is in turn linked to the N-terminus of a scFv fragment.
  • an antigen-binding fragment of a 3E10 antibody or antigen- binding fragment thereof comprises a scFab.
  • a scFab also known as a single-chain fragment antigen binding (Fab) is a type of antibody fragment that combines the variable heavy chain (VH) and variable light chain (VL) domains into a single polypeptide chain, linked by a peptide linker.
  • the domain structure of a Fabsc includes the variable domains of both the heavy chain and light chain (VH and VL), and a peptide linker that connects the two domains.
  • a Fabsc also includes the constant domains of the light chain (CL) and the hinge region of the heavy chain.
  • one of the antigen binding domains comprises 3E10 VH and VL CDRs.
  • Fabscs see, for example, Kettner, C., et al., Frontiers in Immunology, 8(8):453 (2017), the disclosure of which is incorporated herein by reference in its entirety.
  • an antigen-binding fragment of a 3E10 antibody or antigen- binding fragment thereof comprises an IgG-scFv.
  • An IgG-scFv is an antibody in which a scFv is fused to the light chain or heavy chain of an IgG.
  • the scFv comprises 3E10 VH and VL CDRs.
  • the IgG comprises 3E10 VH and V LCDRs.
  • the antibody is an F(ab’)2. 5.
  • 3E10 antibodies and antigen-binding fragments thereof can be modified to improve their therapeutic potential.
  • the cell-penetrating anti-DNA antibody is conjugated to another antibody specific for a second therapeutic target in the cytoplasm and/or nucleus of a target cell.
  • the cell-penetrating 3E10 antibody is a bispecific antibody having a first heavy chain and a first light chain from 3E10 and a second heavy chain and a second light chain from a monoclonal antibody that specifically binds a second therapeutic target.
  • Bispecific antibodies and other binding proteins having a first heavy chain and a first light chain from 3E10 and a second heavy chain and a second light chain from a monoclonal antibody that specifically binds a second target are discussed in Weisbart, et al., Mol. Cancer Ther., 11(10):2169-73 (2012), and Weisbart, et al., Int. J. Oncology, 25:1113-8 (2004), and U.S. Patent Application No. 2013/0266570, which are specifically incorporated by reference in their entireties.
  • the second target is specific for a target cell-type, tissue, organ, etc.
  • the second heavy chain and second light chain can serve as a targeting moiety that targets the complex to the target cell-type, tissue, organ.
  • the second heavy chain and second light chain target, hematopoietic stem cells, CD34 + cells, T cells or any another cell type of interest, e.g., by targeting a receptor or ligand expressed on the cell type of interest.
  • the second heavy chain and second light chain target the thymus, spleen, or cancer cells.
  • Bispecific antibodies can be used to direct cytotoxic agents or drugs to cells which express a particular antigen. These antibodies possess two binding sites directed at two different antigens or two different epitopes on the same antigen.
  • thebispecific can comprise one arm for ENT2 engagement and another arm for a second target.
  • Bispecific antibody design can include a variety of antibody designs with multiple binding arms. Techniques for making bispecific antibodies are common in the art (Millstein et al., 1983, Nature 305:537- 539; Brennan et al., 1985, Science 229:81; Suresh et al, 1986, Methods in Enzymol. 121 : 120; Traunecker et al., 1991, EMBO J.
  • Antibodies with more than two valencies are also contemplated.
  • trispecific antibodies can be prepared (Tutt et al., J. Immunol. 147:60 (1991)).
  • the contemplated bispecific antibody disclosed herein can be conjugated as a bispecific AOC.
  • Heteroconjugate antibodies are also within the scope of the present disclosure.
  • Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune cells to unwanted cells (U.S. Pat. No. 4,676,980).
  • the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents.
  • immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4- mercaptobutyrimidate.
  • the contemplated herteoconjugate antibody disclosed herein can be conjugated as a heteroconjugate AOC.
  • a 3E10 antibody or antigen-binding fragment thereof described herein includes CDR sequences corresponding to the parent 3E10 antibody.
  • a 3E10 antibody or antigen-binding fragment thereof comprises (a) a light chain variable region (VL) complementarity determining region (CDR) 1 comprising the amino acid sequence of X1ASX2X3VSTSSYSYX4X5, where XI is K, R, or H, X2 is K, R, or H, X3 is T or S, X4 is M or L, and X5 is K, R, H, or A (SEQ ID NO:61), (b) a VL CDR2 comprising the amino acid sequence of YASYLX1S, where XI is D, E, N, or Q (SEQ ID NO:62), and (c) a VL CDR3 comprising the amino acid sequence of QX1 SX2X3FPWT, where XI is K, R, or H, X2 is K, R, or H, and X3 is D or E (SEQ ID NO:63), and (d) a VL CDR1 comprising the amino acid
  • a 3E10 antibody or antigen-binding fragment thereof includes a light chain variable region (VL) complementarity determining region (CDR) 1 comprising the amino acid sequence of 3E10-VL-CDR1 (SEQ ID NOV), a VL CDR2 comprising the amino acid sequence of 3E10-VL-CDR2 (SEQ ID NO: 10), a VL CDR3 comprising the amino acid sequence of 3E10-VL-CDR3 (SEQ ID NO: 11), a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of 3E10-VH-CDR1 (SEQ ID NON), a VH CDR2 comprising the amino acid sequence of 3E10-VH-CDR2 (SEQ ID NON), and a VH CDR3 comprising the amino acid sequence of 3E10-VH-CDR3 (SEQ ID NO: 5).
  • VL light chain variable region
  • CDR complementarity determining region
  • a 3E10 antibody or antigen-binding fragment thereof described herein includes CDR sequences from a variant 3E10 antibody that includes a D31N amino acid substitution in the VH CDR1.
  • the a 3E10 antibody or antigen- binding fragment thereof includes a light chain variable region (VL) complementarity determining region (CDR) 1 comprising the amino acid sequence of 3E10-VL-CDR1 D31N (SEQ ID NO:22), a VL CDR2 comprising the amino acid sequence of 3E10-VL-CDR2 D31N (SEQ ID NO:23), a VL CDR3 comprising the amino acid sequence of 3E10-VL-CDR3 D31N (SEQ ID NO:24), a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of 3E10-VH- CDR1 D31N (SEQ ID NO: 15), a VH CDR2 comprising the amino acid sequence of 3E10-
  • a 3E10 antibody or antigen-binding fragment thereof described herein refers to CDR sequences corresponding to the parent 3E10 antibody, optionally including a D31N amino acid substitution in the VH CDR1 .
  • a 3E10 antibody or antigen-binding fragment thereof includes a light chain variable region (VL) complementarity determining region (CDR) 1 comprising the amino acid sequence of 3E10-VL-CDR1 (SEQ ID NO:9), a VL CDR2 comprising the amino acid sequence of 3E10-VL-CDR2 (SEQ ID NO: 10), a VL CDR3 comprising the amino acid sequence of 3E10-VL-CDR3 (SEQ ID NO: 11), a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of 3E10-VH-CDRla (SEQ ID NO: 16), a VH CDR2 comprising the amino acid sequence of 3E10-VH-CDR
  • a 3E10 antibody or antigen-binding fragment thereof described herein includes CDR sequences corresponding to the parent 3E10 antibody, with a known amino acid substitution in one or more CDR. Accordingly, in embodiments, a 3E10 antibody or antigen- binding fragment thereof described herein includes one or more amino acid substitution, relative to the CDR sequences of the parent 3E10 or 3E10-D31N variant, selected from a G to S substitution at position 5 of VH CDR2, a T to S substitution at position 14 of VH CDR2, an S to T substitution at position 5 of VL CDR1, an M to L substitution at position 14 of VL CDR1, an H to A substitution at position 15 of VL CDR1, and an E to Q substitution at position 6 of VL CDR2.
  • a 3E10 antibody or antigen-binding fragment thereof includes VH CDR2 comprising the amino acid sequence of 3E10-VH-CDR2 1 (SEQ ID NO:26) or 3E10-VH-CDR2.2 (SEQ ID NO:27).
  • the 3E10 antibody or antigen- binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 1 and 3 according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 1 and 3 according to the 3E10- D31N variant.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 1 and 3 having one or more amino acid substitutions relative to the CDRs of the parent 3E10 antibody or relative to the 3E10- D3 IN variant.
  • a 3E10 antibody or antigen-binding fragment thereof includes VL CDR1 comprising the amino acid sequence of 3E10-VL-CDR1.1 (SEQ ID NO:28) or 3E10-VL- CDR1.2 (SEQ ID NO:29).
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 2 and 3, and VH CDRs 1-3 according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 2 and 3, and VH CDRs 1-3 according to the 3E10- D31N variant.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 2 and 3, and VH CDRs 1-3 having one or more amino acid substitutions relative to the CDRs of the parent 3E10 antibody or relative to the 3E10- D3 IN variant.
  • a 3E10 antibody or antigen-binding fragment thereof includes VL CDR2 comprising the amino acid sequence of 3E10-VL-CDR2.1 (SEQ ID NO:30).
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 3, and VH CDRs 1-3 according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 3, and VH CDRs 1-3 according to the 3E10- D31N variant.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 3, and VH CDRs 1-3 having one or more amino acid substitutions relative to the CDRs of the parent 3E10 antibody or relative to the 3E10- D3 IN variant.
  • a 3E10 antibody or antigen-binding fragment thereof includes VH
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 1 and 3 according to the parent 3E10 antibody. In embodiments, the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 1 and 3 according to the 3E10- D31N variant.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 1 and 3 having one or more amino acid substitutions relative to the CDRs of the parent 3E10 antibody or relative to the 3E10- D3 IN variant, e.g., as described herein.
  • a 3E10 antibody or antigen-binding fragment thereof includes VL CDR1 comprising the amino acid sequence of 3E10-VL-CDR1.3 (SEQ ID NO:32).
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 2 and 3, and VH CDRs 1-3 according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 2 and 3, and VH CDRs 1-3 according to the 3E10- D31N variant.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 2 and 3, and VH CDRs 1-3 having one or more amino acid substitutions relative to the CDRs of the parent 3E10 antibody or relative to the 3E10- D3 IN variant, e.g., as described herein.
  • a 3E10 antibody or antigen-binding fragment thereof includes VL CDR2 comprising the amino acid sequence of 3E10-VL-CDR2.2 (SEQ ID NO:33).
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 3, and VH CDRs 1-3 according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 3, and VH CDRs 1-3 according to the 3E10- D31N variant.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 3, and VH CDRs 1-3 having one or more amino acid substitutions relative to the CDRs of the parent 3E10 antibody or relative to the 3E10- D3 IN variant, e.g., as described herein.
  • a 3E10 antibody or antigen-binding fragment thereof includes VH CDR1 comprising the amino acid sequence of 3E10-VH-CDR1.C1 (SEQ ID NO:34), 3E10-VH- CDRl.c2 (SEQ ID NO:35), 3E10-VH-CDRl.c3 (SEQ ID NO:36), 3E10-VH-CDRl.c4 (SEQ ID NO:37), or 3E10-VH-CDRl.c5 (SEQ ID NO:38).
  • the 3E10 antibody or antigen- binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 2 and 3 according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 2 and 3 having one or more amino acid substitutions relative to the CDRs of the parent 3E10 antibody, e.g., as described herein.
  • a 3E10 antibody or antigen-binding fragment thereof includes VH CDR2 comprising the amino acid sequence of 3E10-VH-CDR2.cl (SEQ ID NO:39), 3E10-VH- CDR2.c2 (SEQ ID NO:40), or 3E10-VH-CDR2.c3 (SEQ ID NO:41).
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 1 and 3 according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 1 and 3 according to the 3E10- D31N variant.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 1 and 3 having one or more amino acid substitutions relative to the CDRs of the parent 3E10 antibody, e.g., as described herein.
  • a 3E10 antibody or antigen-binding fragment thereof includes VH CDR3 comprising the amino acid sequence of 3E10-VH-CDR3.cl (SEQ ID NO:42), 3E10-VH- CDR3.c2 (SEQ ID NO:43), or 3E10-VH-CDR3.c3 (SEQ ID NO:44).
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 1 and 2 according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 1 and 2 according to the 3E10- D31N variant.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 -3, and VH CDRs 1 and 2 having one or more amino acid substitutions relative to the CDRs of the parent 3E10 antibody, e.g., as described herein.
  • a 3E10 antibody or antigen-binding fragment thereof includes VL CDR1 comprising the amino acid sequence of 3E10-VL-CDR1.C1 (SEQ ID NO:45), 3E10-VL- CDR1.C2 (SEQ ID NO:46), 3E10-VL-CDRl.c3 (SEQ ID NO:47), 3E10-VL-CDRl.c4 (SEQ ID NO:48), 3E10-VL-CDR1.C5 (SEQ ID NO:49), or 3E10-VL-CDRl.c6 (SEQ ID NO:50).
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 2 and 3, and VH CDRs 1-
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 2 and 3, and VH CDRs 1-3 having one or more amino acid substitutions relative to the CDRs of the parent 3E10 antibody, e.g., as described herein.
  • a 3E10 antibody or antigen-binding fragment thereof includes VL CDR2 comprising the amino acid sequence of 3E10-VL-CDR2.cl (SEQ ID NO:51).
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 3, and VH CDRs 1-3 according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 3, and VH CDRs 1- 3 according to the 3E10- D31N variant.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 3, and VH CDRs 1 -3 having one or more amino acid substitutions relative to the CDRs of the parent 3E10 antibody, e.g., as described herein.
  • a 3E10 antibody or antigen-binding fragment thereof includes VL CDR3 comprising the amino acid sequence of 3E10-VL-CDR3.cl (SEQ ID NO:52), 3E10-VL- CDR3.c2 (SEQ ID NO:53), 3E10-VL-CDR3.c3 (SEQ ID NO:54), 3E10-VL-CDR3.c4 (SEQ ID NO:55), 3E10-VL-CDR3.c5 (SEQ ID NO:56), or 3E10-VL-CDR3.c6 (SEQ ID NO:57).
  • VL CDR3 comprising the amino acid sequence of 3E10-VL-CDR3.cl (SEQ ID NO:52), 3E10-VL- CDR3.c2 (SEQ ID NO:53), 3E10-VL-CDR3.c3 (SEQ ID NO:54), 3E10-VL-CDR3.c4 (SEQ ID NO:55), 3E10-VL-CDR3.c5
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 2, and VH CDRs 1-3 according to the parent 3E10 antibody. In embodiments, the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 2, and VH CDRs 1- 3 according to the 3E10- D31N variant. In embodiments, the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 2, and VH CDRs 1-3 having one or more amino acid substitutions relative to the CDRs of the parent 3E10 antibody, e.g., as described herein. [0212] It is also contemplated that a 3E10 antibody or antigen-binding fragment thereof, as described herein, includes any combination of the 3E10 CDR amino acid substitutions described above.
  • a 3E10 antibody or antigen-binding fragment thereof includes VH CDR1 comprising the amino acid sequence of 3E10-VH-CDRlm (SEQ ID NO:58).
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 2 and 3 according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs
  • a 3E10 antibody or antigen-binding fragment thereof includes VH CDR2 comprising the amino acid sequence of 3E10-VH-CDR2m (SEQ ID NO:59).
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 1 and 3 according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 1 and
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 1 and 3 having one or more amino acid substitutions relative to the CDRs of the parent 3E10 antibody, e g., as described herein.
  • a 3E10 antibody or antigen-binding fragment thereof includes VH CDR3 comprising the amino acid sequence of 3E10-VH-CDR3m (SEQ ID NO:60).
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 1 and 2 according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 1 and 2 according to the 3E10-D31N variant.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3, and VH CDRs 1 and 2 having one or more amino acid substitutions relative to the CDRs of the parent 3E10 antibody, e.g., as described herein.
  • a 3E10 antibody or antigen-binding fragment thereof includes VL CDR1 comprising the amino acid sequence of 3E10-VL-CDRlm (SEQ ID NO:61).
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 2 and 3, and VH CDRs 1-3 according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 2 and 3, and VH CDRs 1 - 3 according to the 3E10-D31N variant.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 2 and 3, and VH CDRs 1-3 having one or more amino acid substitutions relative to the CDRs of the parent 3E10 antibody, e.g., as described herein.
  • a 3E10 antibody or antigen-binding fragment thereof includes VL CDR2 comprising the amino acid sequence of 3E10-VL-CDR2m (SEQ ID NO:62).
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 3, and VH CDRs 1-3 according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 3, and VH CDRs 1- 3 according to the 3E10-D31N variant.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 3, and VH CDRs 1-3 having one or more amino acid substitutions relative to the CDRs of the parent 3E10 antibody, e.g., as described herein.
  • a 3E10 antibody or antigen-binding fragment thereof includes VL CDR3 comprising the amino acid sequence of 3E10-VL-CDR3m (SEQ ID NO:63).
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 2, and VH CDRs 1-3 according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 2, and VH CDRs 1- 3 according to the 3E10-D31N variant.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 2, and VH CDRs 1 -3 having one or more amino acid substitutions relative to the CDRs of the parent 3E10 antibody, e.g., as described herein.
  • a 3E10 antibody or antigen-binding fragment thereof described herein includes a VL CDR 1 comprising the amino acid sequence of 3E10-VL-CDRlm (SEQ ID NO:61), a VL CDR2 comprising the amino acid sequence of 3E10-VL-CDR2m (SEQ ID NO:62), a VL CDR3 comprising the amino acid sequence of 3E10-VL-CDR3m (SEQ ID NO: 63), a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of 3E10-VH-CDRlm (SEQ ID NO: 58), a VH CDR2 comprising the amino acid sequence of 3E10-VH-CDR2m (SEQ ID NO:59), and a VH CDR3 comprising the amino acid sequence of 3E10-VH-CDR3m (SEQ ID NO:60).
  • VL CDR 1 comprising the amino acid sequence of 3E10-VL-CDRlm (SEQ ID
  • a 3E10 antibody or antigen-binding fragment thereof described herein refers to CDR sequences having no more than one amino acid substitution relative to the parent 3E10 antibody optionally including a D31N amino acid substitution in the VH CDR1.
  • a 3E10 antibody or antigen-binding fragment thereof includes a VL CDR 1 comprising an amino acid sequence having no more than one amino acid substitution relative to 3E10-VL-CDR1 (SEQ ID NO:9), a VL CDR2 comprising an amino acid sequence having no more than one amino acid substitution relative to 3E10-VL-CDR2 (SEQ ID NO: 10), a VL CDR3 comprising an amino acid sequence having no more than one amino acid substitution relative to 3E10-VL-CDR3 (SEQ ID NO: 11), a heavy chain variable region (VH) CDR1 comprising an amino acid sequence having no more than one amino acid substitution relative to 3E10-VH-CDRla (SEQ ID NO: 16), a VH CDR2 comprising an amino acid sequence having no more than one amino acid substitution relative to 3E10-VH-CDR2 (SEQ ID NO:4), and a VH CDR3 comprising an amino acid sequence having no more than one amino acid substitution
  • a 3E10 antibody or antigen-binding fragment thereof described herein refers to CDR sequences having no more than two amino acid substitution relative to the parent 3E10 antibody optionally including a D31N amino acid substitution in the VH CDR1.
  • a 3E10 antibody or antigen-binding fragment thereof includes a VL CDR 1 comprising an amino acid sequence having no more than two amino acid substitutions relative to 3E10-VL-CDR1 (SEQ ID NO:9), a VL CDR2 comprising an amino acid sequence having no more than two amino acid substitutions relative to 3E10-VL-CDR2 (SEQ ID NO: 10), a VL CDR3 comprising an amino acid sequence having no more than two amino acid substitutions relative to 3E10-VL-CDR3 (SEQ ID NO: 11), a heavy chain variable region (VH) CDR1 comprising an amino acid sequence having no more than two amino acid substitutions relative to 3E10-VH-CDRla (SEQ ID NO: 16), a VH CDR2 comprising an amino acid sequence having no more than two amino acid substitutions relative to 3E10-VH-CDR2 (SEQ ID NO:4), and a VH CDR3 comprising an amino acid sequence having no more
  • 3E10 antibody or antigen-binding fragment thereof are also known in the art, as disclosed for example, in Zack, et al., J. Immunol., 157(5):2082-8 (1996).
  • amino acid position 31 of the heavy chain variable region of 3E10 has been determined to be influential in the ability of the antibody and fragments thereof to penetrate nuclei and bind to DNA.
  • a D31N mutation in CDR1 penetrates nuclei and binds DNA with much greater efficiency than the original antibody (Zack, et al., Immunology and Cell Biology, 72:513-520 (1994), Weisbart, et al., J. Autoimmun., 11, 539-546 (1998); Weisbart, Int. J. Oncol., 25, 1867-1873 (2004)).
  • the antibody or antigen-binding fragment described herein has the D3 IN substitution.
  • AOCs described herein can be prepared with any 3E10 antibodies or antigen- fragments thereof, or any humanized 3E10 antibodies or antigen-fragments thereof, disclosed in the prior art. See, for example WO 2015/106290, 2016/033324, WO 2019/018426, and WO 2019/018428 (each of which is specifically incorporated by reference herein, in its entirety).
  • an AOC comprises a humanized 3E10 antibody.
  • a humanized antibody has one or more amino acid residues introduced into it from a source that is non-human. These non-human amino acid residues are often referred to as “import” residues, which are typically taken from an “import” variable domain.
  • Antibody humanization techniques generally involve the use of recombinant DNA technology to manipulate the DNA sequence encoding one or more polypeptide chains of an antibody molecule.
  • the disclosure provides humanized antibodies, or antigen-binding fragments thereof, that incorporate any combination of the humanized VL and VH sequences disclosed here, as well as VL and VH sequences having sequence identity thereto, e.g., having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to a VH or VL sequence described herein.
  • an AOC provided herein comprises a 3E10 antibody or antigen- binding fragment thereof comprising one, two, or three CDRs of a heavy chain having the sequence of any one of SEQ ID NOs: l, 13, or 71-84.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a heavy chain having the sequence of SEQ ID NO: 1.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a heavy chain having the sequence of SEQ ID NO: 13.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a heavy chain having the sequence of SEQ ID NO:71. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a heavy chain having the sequence of SEQ ID NO:72. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a heavy chain having the sequence of SEQ ID NO:73.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a heavy chain having the sequence of SEQ ID NO:74. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a heavy chain having the sequence of SEQ ID NO:75. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a heavy chain having the sequence of SEQ ID NO:76.
  • an AOC provided herein comprises a 3E10 antibody or antigen- binding fragment thereof comprising one, two, or three CDRs of a heavy chain having the sequence of SEQ ID NO:77. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a heavy chain having the sequence of SEQ ID NO:78. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a heavy chain having the sequence of SEQ ID NO:79.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a heavy chain having the sequence of SEQ ID NO: 80. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a heavy chain having the sequence of SEQ IDN0:81. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a heavy chain having the sequence of SEQ ID NO:82.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a heavy chain having the sequence of SEQ ID NO: 83. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a heavy chain having the sequence of SEQ ID NO:84.
  • an AOC provided herein comprises a 3E10 antibody or antigen- binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of any one of SEQ ID NOs:2, 14, 64-70, 103-112. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO:2. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO: 14.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO: 64. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO:65. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO:66.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO:67. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO:68. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO:69.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO:70. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO: 103. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO: 104.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO: 105. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO: 106. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO: 107.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO: 108. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO: 109. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO: 110.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO: 111. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VH having the sequence of SEQ ID NO: 112.
  • an AOC provided herein comprises a 3E10 antibody or antigen- binding fragment thereof comprising one, two, or three CDRs of a light chain having the sequence of any one of SEQ ID NOs:7, 20, or 91-102.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a light chain having the sequence of SEQ ID NO:7.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a light chain having the sequence of SEQ ID NO:20.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a light chain having the sequence of SEQ ID NO:91. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a light chain having the sequence of SEQ ID NO:92. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a light chain having the sequence of SEQ ID NO:93.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a light chain having the sequence of SEQ ID NO:94. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a light chain having the sequence of SEQ ID NO:95. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a light chain having the sequence of SEQ ID NO:96.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a light chain having the sequence of SEQ ID NO:97. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a light chain having the sequence of SEQ IDNO:98. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a light chain having the sequence of SEQ ID NO:99.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a light chain having the sequence of SEQ ID NO: 100. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a light chain having the sequence of SEQ ID NO:101. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen- binding fragment thereof comprising one, two, or three CDRs of a light chain having the sequence of SEQ ID NO: 102.
  • an AOC provided herein comprises a 3E10 antibody or antigen- binding fragment thereof comprising one, two, or three CDRs of a VL having the sequence of any one of SEQ TD NOs:8, 21, 85-90, or 113-121 .
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VL having the sequence of SEQ ID NO:8.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VL having the sequence of SEQ ID NO:21.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VL having the sequence of SEQ ID NO:85. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VL having the sequence of SEQ ID NO:86. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VL having the sequence of SEQ ID NO:87.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VL having the sequence of SEQ ID NO:88. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VL having the sequence of SEQ ID NO:89. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VL having the sequence of SEQ ID NO:90.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VL having the sequence of SEQ ID NO: 113. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VL having the sequence of SEQ ID NO: 114. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VL having the sequence of SEQ ID NO: 1 15.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VL having the sequence of SEQ ID NO: 116. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VL having the sequence of SEQ ID NO: 117. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VL having the sequence of SEQ ID NO: 118.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VL having the sequence of SEQ ID NO: 119. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VL having the sequence of SEQ ID NO: 120. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, or three CDRs of a VL having the sequence of SEQ ID NO : 121.
  • an AOC provided herein comprises a 3E10 antibody or antigen- binding fragment thereof comprising one, two, three, four, five, or six CDRs of an scFv having the sequence of any one of SEQ ID NOs: 122-137.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, three, four, five, or six CDRs of an scFv having the sequence of SEQ ID NO: 122.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, three, four, five, or six CDRs of an scFv having the sequence of SEQ ID NO: 123.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, three, four, five, or six CDRs of an scFv having the sequence of SEQ ID NO: 124. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen- binding fragment thereof comprising one, two, three, four, five, or six CDRs of an scFv having the sequence of SEQ ID NO: 125. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, three, four, five, or six CDRs of an scFv having the sequence of SEQ ID NO: 126.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, three, four, five, or six CDRs of an scFv having the sequence of SEQ ID NO: 127. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, three, four, five, or six CDRs of an scFv having the sequence of SEQ ID NO: 128. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, three, four, five, or six CDRs of an scFv having the sequence of SEQ ID NO: 129.
  • an AOC provided herein comprises a 3E10 antibody or antigen- binding fragment thereof comprising one, two, three, four, five, or six CDRs of an scFv having the sequence of SEQ ID NO: 130. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, three, four, five, or six CDRs of an scFv having the sequence of SEQ ID NO: 131. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, three, four, five, or six CDRs of an scFv having the sequence of SEQ ID NO: 132.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, three, four, five, or six CDRs of an scFv having the sequence of SEQ ID NO: 133. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, three, four, five, or six CDRs of an scFv having the sequence of SEQ ID NO: 134. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen- binding fragment thereof comprising one, two, three, four, five, or six CDRs of an scFv having the sequence of SEQ ID NO: 135.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, three, four, five, or six CDRs of an scFv having the sequence of SEQ ID NO: 136. In embodiments, an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof comprising one, two, three, four, five, or six CDRs of an scFv having the sequence of SEQ ID NO: 137.
  • an AOC provided herein comprises a 3E10 antibody or antigen- binding fragment thereof having a heavy chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to any one of SEQ ID NOs:l, 13, or 71-84.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a heavy chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 1.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a heavy chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:13
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a heavy chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:71.
  • an AOC provided herein comprises a 3E10 antibody or antigen- binding fragment thereof having a heavy chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:72.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a heavy chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 73.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a heavy chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:74.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a heavy chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 75.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a heavy chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:76.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a heavy chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:77.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a heavy chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:78.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a heavy chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:79.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a heavy chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:80.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a heavy chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:81.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a heavy chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:82.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a heavy chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 83.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a heavy chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 84.
  • an AOC provided herein comprises a 3E10 antibody or antigen- binding fragment thereof having a light chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to any one of SEQ ID NOs:7, 20, or 91-102.
  • an AOC provided herein comprises a 3E10 antibody or antigen- binding fragment thereof having a light chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:7.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a light chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:20.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a light chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:91.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a light chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:92.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a light chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 93.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a light chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:94.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a light chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:95.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a light chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 96.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a light chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:97.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a light chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:98.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a light chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 101.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a light chain sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 102.
  • an AOC provided herein comprises a 3E10 antibody or antigen- binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to any one of SEQ ID NOs: 2, 14, 64-70, or 103-112.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:2.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:14.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:64.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:65.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:66.
  • an AOC provided herein comprises a 3E10 antibody or antigen- binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 67.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:68.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:69.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:70.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 103.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 104.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 105.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 106.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 107.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 108.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 109.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 110.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 111.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VH sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 112.
  • an AOC provided herein comprises a 3E10 antibody or antigen- binding fragment thereof having a VL sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to any one of SEQ ID NOs: 8, 21, 85-90, or 113-121.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VL sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 8.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VL sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:21.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VL sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:85.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VL sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:86.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VL sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:87.
  • an AOC provided herein comprises a 3E10 antibody or antigen- binding fragment thereof having a VL sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:88.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VL sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:89.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VL sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO:90.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VL sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 113.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VL sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 114.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VL sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 115.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VL sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 116.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VL sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 117.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VL sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 118.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VL sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 119.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VL sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 120.
  • an AOC provided herein comprises a 3E10 antibody or antigen-binding fragment thereof having a VL sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identity to SEQ ID NO: 121.
  • an AOC provided herein comprises a humanized 3E10 antibody, or antigen-binding fragment thereof, comprising a light chain variable domain (3E10-VL) comprising an amino acid sequence that is at least about 97% identical to an amino acid sequence selected from the group consisting of 3E10-VL-hl (SEQ ID NO:85), 3E10-VL-h2 (SEQ ID NO:86), 3E10-VL-h3 (SEQ ID NO:87), 3E10-VL-h4 (SEQ ID NO:88), 3E10-VL-h5 (SEQ ID NO:89), and 3E10-VL-h6 (SEQ ID NO:90) and a heavy chain variable domain (3E10-VH) comprising an amino acid sequence that is at least about 95% identical to an amino acid sequence selected from the group consisting of 3E10-VH-hl (SEQ ID NO:64), 3E10-VH-h2 (SEQ ID NO:65), 3E10-
  • the sequence of the 3E10-VL is at least about 97% identical to 3E10-VL-hl (SEQ ID NO:85). In embodiments, the sequence of the 3E10-VL is at least about 98% identical to 3E10-VL-hl (SEQ ID NO:85). In embodiments, the sequence of the 3E10-VL is at least about 99% identical to 3E10-VL-hl (SEQ ID NO:85). In embodiments, the sequence of the 3E10-VL is 3E10-VL-hl (SEQ ID NO:85).
  • the sequence of the 3E10-VL is at least about 97% identical to 3E10-VL-h2 (SEQ ID NO:86). In embodiments, the sequence of the 3E10-VL is at least about 98% identical to 3E10-VL-h2 (SEQ ID NO:86). In embodiments, the sequence of the 3E10-VL is at least about 99% identical to 3E10-VL-h2 (SEQ ID NO:86). In embodiments, the sequence of the 3E10-VL is 3E10-VL-h2 (SEQ ID NO:86).
  • the sequence of the 3E10-VL is at least about 97% identical to 3E10-VL-h3 (SEQ ID NO:87). In embodiments, the sequence of the 3E10-VL is at least about 98% identical to 3E10-VL-h3 (SEQ ID NO:87). In embodiments, the sequence of the 3E10-VL is at least about 99% identical to 3E10-VL-h3 (SEQ ID NO:87). In embodiments, the sequence of the 3E10-VL is 3E10-VL-h3 (SEQ ID NO:87).
  • the sequence of the 3E10-VL is at least about 97% identical to 3E10-VL-h4 (SEQ ID NO:88). In embodiments, the sequence of the 3E10-VL is at least about 98% identical to 3E10-VL-h4 (SEQ ID NO:88). In embodiments, the sequence of the 3E10-VL is at least about 99% identical to 3E10-VL-h4 (SEQ ID NO:88). In embodiments, the sequence of the 3E10-VL is 3E10-VL-h4 (SEQ ID NO:88).
  • the sequence of the 3E10-VL is at least about 97% identical to 3E10-VL-h5 (SEQ ID NO:89). In embodiments, the sequence of the 3E10-VL is at least about 98% identical to 3E10-VL-h5 (SEQ ID NO:89). In embodiments, the sequence of the 3E10-VL is at least about 99% identical to 3E10-VL-h5 (SEQ ID NO:89). In embodiments, the sequence of the 3E10-VL is 3E10-VL-h5 (SEQ ID NO:89).
  • the sequence of the 3E10-VL is at least about 97% identical to 3E10-VL-h6 (SEQ ID NO:90). In embodiments, the sequence of the 3E10-VL is at least about 98% identical to 3E10-VL-h6 (SEQ ID NO:90). In embodiments, the sequence of the 3E10-VL is at least about 99% identical to 3E10-VL-h6 (SEQ ID NO:90). In embodiments, the sequence of the 3E10-VL is 3E10-VL-h6 (SEQ ID NO:90).
  • the sequence of the 3E10-VEI is at least about 95% identical to 3E10-VH-hl (SEQ ID NO:64). In embodiments, the sequence of the 3E10-VH is at least about 96% identical to 3E10-VH-hl (SEQ ID NO:64). In embodiments, the sequence of the 3E10-VH is at least about 97% identical to 3E10-VH-hl (SEQ ID NO:64). In embodiments, the sequence of the 3E10-VH is at least about 98% identical to 3E10-VH-hl (SEQ ID NO:64).
  • sequence of the 3E10-VH is at least about 99% identical to 3E10-VH-hl (SEQ ID NO:64). In embodiments, the sequence of the 3E10-VH is 3E10-VH-hl (SEQ ID NO:64).
  • the sequence of the 3E10-VH is at least about 95% identical to 3E10-VH-h2 (SEQ ID NO:65). In embodiments, the sequence of the 3E10-VH is at least about 96% identical to 3E10-VH-h2 (SEQ ID NO:65). In embodiments, the sequence of the 3E10-VH is at least about 97% identical to 3E10-VH-h2 (SEQ ID NO:65). In embodiments, the sequence of the 3E10-VH is at least about 98% identical to 3E10-VH-h2 (SEQ ID NO:65).
  • sequence of the 3E10-VH is at least about 99% identical to 3E10-VH-h2 (SEQ ID NO:65). In embodiments, the sequence of the 3E10-VH is 3E10-VH-h2 (SEQ ID NO:65).
  • the sequence of the 3E10-VH is at least about 95% identical to 3E10-VH-h3 (SEQ ID NO:66). In embodiments, the sequence of the 3E10-VH is at least about 96% identical to 3E10-VH-h3 (SEQ ID NO:66). In embodiments, the sequence of the 3E10-VH is at least about 97% identical to 3E10-VH-h3 (SEQ ID NO:66). In embodiments, the sequence of the 3E10-VH is at least about 98% identical to 3E10-VH-113 (SEQ ID NO:66).
  • sequence of the 3E10-VH is at least about 99% identical to 3E10-VH-h3 (SEQ ID NO:66). In embodiments, the sequence of the 3E10-VH is 3E10-VH-h3 (SEQ ID NO:66).
  • the sequence of the 3E10-VH is at least about 95% identical to 3E10-VH-h4 (SEQ ID NO:67). In embodiments, the sequence of the 3E10-VH is at least about 96% identical to 3E10-VH-h4 (SEQ ID NO:67). In embodiments, the sequence of the 3E10-VH is at least about 97% identical to 3E10-VH-h4 (SEQ ID NO:67). In embodiments, the sequence of the 3E10-VH is at least about 98% identical to 3E10-VH-h4 (SEQ ID NO:67).
  • sequence of the 3E10-VH is at least about 99% identical to 3E10-VH-h4 (SEQ ID NO:67). In embodiments, the sequence of the 3E10-VH is 3E10-VH-h4 (SEQ ID NO:67).
  • the sequence of the 3E10-VH is at least about 95% identical to 3E10-VH-h5 (SEQ ID NO:68). In embodiments, the sequence of the 3E10-VH is at least about 96% identical to 3E10-VH-h5 (SEQ ID NO:68). In embodiments, the sequence of the 3E10-VH is at least about 97% identical to 3E10-VH-h5 (SEQ ID NO:68). In embodiments, the sequence of the 3E10-VH is at least about 98% identical to 3E10-VH-h5 (SEQ ID NO:68).
  • sequence of the 3E10-VH is at least about 99% identical to 3E10-VH-h5 (SEQ ID NO:68). In embodiments, the sequence of the 3E10-VH is 3E10-VH-h5 (SEQ ID NO:68).
  • the sequence of the 3E10-VH is at least about 95% identical to 3E10-VH-h6 (SEQ ID NO:69). In embodiments, the sequence of the 3E10-VH is at least about 96% identical to 3E10-VH-h6 (SEQ ID NO:69). In embodiments, the sequence of the 3E10-VH is at least about 97% identical to 3E10-VH-h6 (SEQ ID NO:69). In embodiments, the sequence of the 3E10-VH is at least about 98% identical to 3E10-VH-h6 (SEQ ID NO:69).
  • sequence of the 3E10-VH is at least about 99% identical to 3E10-VH-h6 (SEQ ID NO:69). In embodiments, the sequence of the 3E10-VH is 3E10-VH-h6 (SEQ ID NO:69).
  • the sequence of the 3E10-VH is at least about 95% identical to 3E10-VH-h7 (SEQ ID NO:70). In embodiments, the sequence of the 3E10-VH is at least about 96% identical to 3E10-VH-h7 (SEQ ID NO:70). In embodiments, the sequence of the 3E10-VH is at least about 97% identical to 3E10-VH-h7 (SEQ ID NO:70). In embodiments, the sequence of the 3E10-VH is at least about 98% identical to 3E10-VH-h7 (SEQ ID NO:70).
  • sequence of the 3E10-VH is at least about 99% identical to 3E10-VH-h7 (SEQ ID NO:70). In embodiments, the sequence of the 3E10-VH is 3E10-VH-h7 (SEQ ID NO:70).
  • an AOC comprising a humanized 3E10 antibody, or antigen- binding fragment thereof, described herein includes a light chain (3E10-LC) comprising an amino acid sequence that is at least about 95% identical to an amino acid sequence selected from the group consisting of 3E10-LC-hlm (SEQ ID NO:91), 3E10-LC-h2m (SEQ ID NO:92), 3E10-LC- h3m (SEQ ID NO:93), 3E10-LC-h4m (SEQ ID NO:94), 3E10-LC-h5m (SEQ ID NO:95), and 3E10-LC-h6m (SEQ ID NO:96) and a heavy chain (3E10-HC) comprising an amino acid sequence that is at least about 95% identical to an amino acid sequence selected from the group consisting of 3E10-HC-hlm (SEQ ID NO:71), 3E10-HC-h2m (SEQ ID NO:72), 3E10-HC-h3m (
  • the sequence of the 3E10-LC is at least about 95% identical to 3E10-LC-hlm (SEQ ID NO:91). In embodiments, the sequence of the 3E10-LC is at least about 96% identical to 3E10-LC-hlm (SEQ ID NO:91). In embodiments, the sequence of the 3E10-LC is at least about 97% identical to 3E10-LC-hlm (SEQ ID NO:91). In embodiments, the sequence of the 3E10-LC is at least about 98% identical to 3E10-LC-hlm (SEQ IDN0:91).
  • sequence of the 3E10-LC is at least about 99% identical to 3E10-LC-hlm (SEQ ID NO:91). In embodiments, the sequence of the 3E10-LC is 3E10-LC-hlm (SEQ ID NO:91).
  • the sequence of the 3E10-LC is at least about 95% identical to 3E10-LC-h2m (SEQ ID NO:92). In embodiments, the sequence of the 3E10-LC is at least about 96% identical to 3E10-LC-h2m (SEQ ID NO:92). In embodiments, the sequence of the 3E10-LC is at least about 97% identical to 3E10-LC-h2m (SEQ ID NO:92). In embodiments, the sequence of the 3E10-LC is at least about 98% identical to 3E10-LC-h2m (SEQ ID NO:92).
  • sequence of the 3E10-LC is at least about 99% identical to 3E10-LC-h2m (SEQ ID NO:92). In embodiments, the sequence of the 3E10-LC is 3E10-LC-h2m (SEQ ID NO:92).
  • the sequence of the 3E10-LC is at least about 95% identical to 3E10-LC-h3m (SEQ ID NO:93). In embodiments, the sequence of the 3E10-LC is at least about 96% identical to 3E10-LC-h3m (SEQ ID NO:93). In embodiments, the sequence of the 3E10-LC is at least about 97% identical to 3E10-LC-h3m (SEQ ID NO:93). In embodiments, the sequence of the 3E10-LC is at least about 98% identical to 3E10-LC-h3m (SEQ IDNO:93).
  • sequence of the 3E10-LC is at least about 99% identical to 3E10-LC-h3m (SEQ ID NO:93). In embodiments, the sequence of the 3E10-LC is 3E10-LC-h3m (SEQ ID NO:93).
  • the sequence of the 3E10-LC is at least about 95% identical to 3E10-LC-h4m (SEQ ID NO:94). In embodiments, the sequence of the 3E10-LC is at least about 96% identical to 3E10-LC-h4m (SEQ ID NO:94). In embodiments, the sequence of the 3E10-LC is at least about 97% identical to 3E10-LC-h4m (SEQ ID NO:94). In embodiments, the sequence of the 3E10-LC is at least about 98% identical to 3E10-LC-h4m (SEQ IDNO:94).
  • sequence of the 3E10-LC is at least about 99% identical to 3E10-LC-h4m (SEQ ID NO:94). In embodiments, the sequence of the 3E10-LC is 3E10-LC-h4m (SEQ ID NO:94).
  • the sequence of the 3E10-LC is at least about 95% identical to 3E10-LC-h5m (SEQ ID NO:95). In embodiments, the sequence of the 3E10-LC is at least about 96% identical to 3E10-LC-h5m (SEQ ID NO:95). In embodiments, the sequence of the 3E10-LC is at least about 97% identical to 3E10-LC-h5m (SEQ ID NO:95). In embodiments, the sequence of the 3E10-LC is at least about 98% identical to 3E10-LC-h5m (SEQ ID NO:95).
  • sequence of the 3E10-LC is at least about 99% identical to 3E10-LC-h5m (SEQ ID NO:95). In embodiments, the sequence of the 3E10-LC is 3E10-LC-h5m (SEQ ID NO:95).
  • the sequence of the 3E10-LC is at least about 95% identical to 3E10-LC-h6m (SEQ ID NO:96). In embodiments, the sequence of the 3E10-LC is at least about 96% identical to 3E10-LC-h6m (SEQ ID NO:96). In embodiments, the sequence of the 3E10-LC is at least about 97% identical to 3E10-LC-h6m (SEQ ID NO:96). In embodiments, the sequence of the 3E10-LC is at least about 98% identical to 3E10-LC-h6m (SEQ IDNO:96).
  • sequence of the 3E10-LC is at least about 99% identical to 3E10-LC-h6m (SEQ ID NO:96). In embodiments, the sequence of the 3E10-LC is 3E10-LC-h6m (SEQ ID NO:96).
  • sequence of the 3E10-HC is at least about 95% identical to 3E10-HC-hlm (SEQ ID NO:71). In embodiments, the sequence of the 3E10-HC is at least about 96% identical to 3E10-HC-hlm (SEQ ID NO:71). In embodiments, the sequence of the 3E10-HC is at least about 97% identical to 3E10-HC-hlm (SEQ ID NO:71). In embodiments, the sequence of the 3E10-HC is at least about 98% identical to 3E10-HC-hlm (SEQ ID NO:71).
  • sequence of the 3E10-HC is at least about 99% identical to 3E10-HC-hlm (SEQ ID NO:71). In embodiments, the sequence of the 3E10-HC is 3E10-HC-hlm (SEQ ID NO:71).
  • the sequence of the 3E10-HC is at least about 95% identical to 3E10-HC-h2m (SEQ ID NO:72). In embodiments, the sequence of the 3E10-HC is at least about 96% identical to 3E10-HC-h2m (SEQ ID NO:72). In embodiments, the sequence of the 3E10-HC is at least about 97% identical to 3E10-HC-h2m (SEQ ID NO:72). In embodiments, the sequence of the 3E10-HC is at least about 98% identical to 3E10-HC-h2m (SEQ ID NO:72).
  • sequence of the 3E10-HC is at least about 99% identical to 3E10-HC-h2m (SEQ ID NO:72). In embodiments, the sequence of the 3E10-HC is 3E10-HC-h2m (SEQ ID NO:72).
  • the sequence of the 3E10-HC is at least about 95% identical to 3E10-HC-h3m (SEQ ID NO:73). In embodiments, the sequence of the 3E10-HC is at least about 96% identical to 3E10-HC-h3m (SEQ ID NO:73). In embodiments, the sequence of the 3E10-HC is at least about 97% identical to 3E10-HC-h3m (SEQ ID NO:73). In embodiments, the sequence of the 3E10-HC is at least about 98% identical to 3E10-HC-h3m (SEQ ID NO:73).
  • sequence of the 3E10-HC is at least about 99% identical to 3E10-HC-h3m (SEQ ID NO:73). In embodiments, the sequence of the 3E10-HC is 3E10-HC-h3m (SEQ ID NO:73).
  • sequence of the 3E10-HC is at least about 95% identical to 3E10-HC-h4m (SEQ ID NO:74). In embodiments, the sequence of the 3E10-HC is at least about 96% identical to 3E10-HC-h4m (SEQ ID NO:74). In embodiments, the sequence of the 3E10-HC is at least about 97% identical to 3E10-HC-h4m (SEQ ID NO:74). In embodiments, the sequence of the 3E10-HC is at least about 98% identical to 3E10-HC-h4m (SEQ ID NO:74).
  • sequence of the 3E10-HC is at least about 99% identical to 3E10-HC-h4m (SEQ ID NO:74). In embodiments, the sequence of the 3E10-HC is 3E10-HC-h4m (SEQ ID NO:74).
  • the sequence of the 3E10-HC is at least about 95% identical to 3E10-HC-h5m (SEQ ID NO:75). In embodiments, the sequence of the 3E10-HC is at least about 96% identical to 3E10-HC-h5m (SEQ ID NO:75). In embodiments, the sequence of the 3E10-HC is at least about 97% identical to 3E10-HC-h5m (SEQ ID NO:75). In embodiments, the sequence of the 3E10-HC is at least about 98% identical to 3E10-HC-h5m (SEQ ID NO:75).
  • the sequence of the 3E10-HC is at least about 99% identical to 3E10-HC-h5m (SEQ ID NO:75). In embodiments, the sequence of the 3E10-HC is 3E10-HC-h5m (SEQ ID NO:75). [0261] In embodiments, the sequence of the 3E10-HC is at least about 95% identical to 3E10-HC-h6m (SEQ ID NO:76). In embodiments, the sequence of the 3E10-HC is at least about 96% identical to 3E10-HC-h6m (SEQ ID NO:76). In embodiments, the sequence of the 3E10-HC is at least about 97% identical to 3E10-HC-h6m (SEQ ID NO:76).
  • sequence of the 3E10-HC is at least about 98% identical to 3E10-HC-h6m (SEQ ID NO:76). In embodiments, the sequence of the 3E10-HC is at least about 99% identical to 3E10-HC-h6m (SEQ ID NO:76). In embodiments, the sequence of the 3E10-HC is 3E10-HC-h6m (SEQ ID NO:76).
  • the sequence of the 3E10-HC is at least about 95% identical to 3E10-HC-h7m (SEQ ID NO:77). In embodiments, the sequence of the 3E10-HC is at least about 96% identical to 3E10-HC-h7m (SEQ ID NO:77). In embodiments, the sequence of the 3E10-HC is at least about 97% identical to 3E10-HC-h7m (SEQ ID NO:77). In embodiments, the sequence of the 3E10-HC is at least about 98% identical to 3E10-HC-h7m (SEQ ID NO:77).
  • sequence of the 3E10-HC is at least about 99% identical to 3E10-HC-h7m (SEQ ID NO:77). In embodiments, the sequence of the 3E10-HC is 3E10-HC-h7m (SEQ ID NO:77).
  • an AOC provided herein comprises a humanized 3E10 antibody, or antigen-binding fragment thereof, comprising a light chain (3E10-LC) comprising an amino acid sequence that is at least about 95% identical to an amino acid sequence selected from the group consisting of 3E10-LC-hl (SEQ ID NO:97), 3E10-LC-h2 (SEQ ID NO:98), 3E10-LC-h3 (SEQ ID NO:99), 3E10-LC-h4 (SEQ ID NO: 100), 3E10-LC-h5 (SEQ ID NO: 101), and 3E10-LC- h6 (SEQ ID NO: 102) and a heavy chain (3E10-HC) comprising an amino acid sequence that is at least about 95% identical to an amino acid sequence selected from the group consisting of 3E10- HC-hl (SEQ ID NO:78), 3E10-HC-h2 (SEQ ID NO:79), 3E10-HC-h3 (SEQ ID NO:80),
  • the sequence of the 3E10-LC is at least about 95% identical to 3E10-LC-hl (SEQ ID NO:97. In embodiments, the sequence of the 3E10-LC is at least about 96% identical to 3E10-LC-hl (SEQ ID NO:97). In embodiments, the sequence of the 3E10-LC is at least about 97% identical to 3E10-LC-hl (SEQ ID NO:97). In embodiments, the sequence of the 3E10-LC is at least about 98% identical to 3E10-LC-hl (SEQ ID NO:97). In embodiments, the
  • I l l sequence of the 3E10-LC is at least about 99% identical to 3E10-LC-hl (SEQ ID NO:97).
  • the sequence of the 3E10-LC is 3E10-LC-hl (SEQ ID NO:97).
  • the sequence of the 3E10-LC is at least about 95% identical to 3E10-LC-h2 (SEQ ID NO:98). In embodiments, the sequence of the 3E10-LC is at least about 96% identical to 3E10-LC-h2 (SEQ ID NO:98). In embodiments, the sequence of the 3E10-LC is at least about 97% identical to 3E10-LC-h2 (SEQ ID NO:98). In embodiments, the sequence of the 3E10-LC is at least about 98% identical to 3E10-LC-112 (SEQ ID NO:98). In embodiments, the sequence of the 3E10-LC is at least about 99% identical to 3E10-LC-h2 (SEQ ID NO:98). In embodiments, the sequence of the 3E10-LC is 3E10-LC-h2 (SEQ ID NO:98).
  • the sequence of the 3E10-LC is at least about 95% identical to 3E10-LC-h3 (SEQ ID NO:99). In embodiments, the sequence of the 3E10-LC is at least about 96% identical to 3E10-LC-h3 (SEQ ID NO:99). In embodiments, the sequence of the 3E10-LC is at least about 97% identical to 3E10-LC-h3 (SEQ ID NO:99). In embodiments, the sequence of the 3E10-LC is at least about 98% identical to 3E10-LC-h3 (SEQ ID NO:99). In embodiments, the sequence of the 3E10-LC is at least about 99% identical to 3E10-LC-h3 (SEQ ID NO:99). In embodiments, the sequence of the 3E10-LC is 3E10-LC-h3 (SEQ ID NO:99).
  • the sequence of the 3E10-LC is at least about 95% identical to 3E10-LC-h4 (SEQ ID NO: 100). In embodiments, the sequence of the 3E10-LC is at least about 96% identical to 3E10-LC-h4 (SEQ ID NO: 100). In embodiments, the sequence of the 3E10-LC is at least about 97% identical to 3E10-LC-h4 (SEQ ID NO: 100). In embodiments, the sequence of the 3E10-LC is at least about 98% identical to 3E10-LC-h4 (SEQ ID NO:100). In embodiments, the sequence of the 3E10-LC is at least about 99% identical to 3E10-LC-h4 (SEQ ID NO: 100). In embodiments, the sequence of the 3E10-LC is 3E10-LC-h4 (SEQ ID NO: 100).
  • the sequence of the 3E10-LC is at least about 95% identical to 3E10-LC-h5 (SEQ ID NO: 101). In embodiments, the sequence of the 3E10-LC is at least about 96% identical to 3E10-LC-h5 (SEQ ID NO: 101). In embodiments, the sequence of the 3E10-LC is at least about 97% identical to 3E10-LC-h5 (SEQ ID NO: 101). In embodiments, the sequence of the 3E10-LC is at least about 98% identical to 3E10-LC-h5 (SEQ ID NO: 101). In embodiments, the sequence of the 3E10-LC is at least about 99% identical to 3E10-LC-h5 (SEQ ID NO: 101).
  • the sequence of the 3E10-LC is 3E10-LC-h5 (SEQ ID NO: 101). [0269] In embodiments, the sequence of the 3E10-LC is at least about 95% identical to 3E10-LC-h6 (SEQ ID NO: 102). In embodiments, the sequence of the 3E10-LC is at least about 96% identical to 3E10-LC-h6 (SEQ ID NO: 102). In embodiments, the sequence of the 3E10-LC is at least about 97% identical to 3E10-LC-h6 (SEQ ID NO: 102). In embodiments, the sequence of the 3E10-LC is at least about 98% identical to 3E10-LC-h6 (SEQ ID NO: 102).
  • sequence of the 3E10-LC is at least about 99% identical to 3E10-LC-h6 (SEQ ID NO: 102). In embodiments, the sequence of the 3E10-LC is 3E10-LC-h6 (SEQ ID NO: 102).
  • the sequence of the 3E10-HC is at least about 95% identical to 3E10-HC-hl (SEQ ID NO:78). In embodiments, the sequence of the 3E10-HC is at least about 96% identical to 3E10-HC-hl (SEQ ID NO:78). In embodiments, the sequence of the 3E10-HC is at least about 97% identical to 3E10-HC-hl (SEQ ID NO:78). In embodiments, the sequence of the 3E10-HC is at least about 98% identical to 3E10-HC-111 (SEQ ID NO:78). In embodiments, the sequence of the 3E10-HC is at least about 99% identical to 3E10-HC-hl (SEQ ID NO:78). In embodiments, the sequence of the 3E10-HC is 3E10-HC-hl (SEQ ID NO:78).
  • the sequence of the 3E10-HC is at least about 95% identical to 3E10-HC-h2 (SEQ ID NO:79). In embodiments, the sequence of the 3E10-HC is at least about 96% identical to 3E10-HC-h2 (SEQ ID NO:79). In embodiments, the sequence of the 3E10-HC is at least about 97% identical to 3E10-HC-h2 (SEQ ID NO:79). In embodiments, the sequence of the 3E10-HC is at least about 98% identical to 3E10-HC-h2 (SEQ ID NO:79). In embodiments, the sequence of the 3E10-HC is at least about 99% identical to 3E10-HC-h2 (SEQ ID NO:79). In embodiments, the sequence of the 3E10-HC is 3E10-HC-h2 (SEQ ID NO:79).
  • the sequence of the 3E10-HC is at least about 95% identical to 3E10-HC-h3 (SEQ ID NO:80). In embodiments, the sequence of the 3E10-HC is at least about 96% identical to 3E10-HC-h3 (SEQ ID NO:80). In embodiments, the sequence of the 3E10-HC is at least about 97% identical to 3E10-HC-113 (SEQ ID NO:80). In embodiments, the sequence of the 3E10-HC is at least about 98% identical to 3E10-HC-h3 (SEQ ID NO:80). In embodiments, the sequence of the 3E10-HC is at least about 99% identical to 3E10-HC-h3 (SEQ ID NO:80). In embodiments, the sequence of the 3E10-HC is 3E10-HC-h3 (SEQ ID NO:80).
  • the sequence of the 3E10-HC is at least about 95% identical to 3E10-HC-h4 (SEQ ID NO:81). In embodiments, the sequence of the 3E10-HC is at least about 96% identical to 3E10-HC-h4 (SEQ ID NO:81). In embodiments, the sequence of the 3E10-HC is at least about 97% identical to 3E10-HC-h4 (SEQ ID NO:81). In embodiments, the sequence of the 3E10-HC is at least about 98% identical to 3E10-HC-h4 (SEQ ID NO:81). In embodiments, the sequence of the 3E10-HC is at least about 99% identical to 3E10-HC-h4 (SEQ ID NO:81). In embodiments, the sequence of the 3E10-HC is 3E10-HC-h4 (SEQ ID NO:81).
  • the sequence of the 3E10-HC is at least about 95% identical to 3E10-HC-h5 (SEQ ID NO:82). In embodiments, the sequence of the 3E10-HC is at least about 96% identical to 3E10-HC-h5 (SEQ ID NO:82). In embodiments, the sequence of the 3E10-HC is at least about 97% identical to 3E10-HC-h5 (SEQ ID NO:82). In embodiments, the sequence of the 3E10-HC is at least about 98% identical to 3E10-HC-h5 (SEQ ID NO:82). In embodiments, the sequence of the 3E10-HC is at least about 99% identical to 3E10-HC-h5 (SEQ ID NO:82). In embodiments, the sequence of the 3E10-HC is 3E10-HC-h5 (SEQ ID NO:82).
  • the sequence of the 3E10-HC is at least about 95% identical to 3E10-HC-h6 (SEQ ID NO:83). In embodiments, the sequence of the 3E10-HC is at least about 96% identical to 3E10-HC-h6 (SEQ ID NO:83). In embodiments, the sequence of the 3E10-HC is at least about 97% identical to 3E10-HC-116 (SEQ ID NO:83). In embodiments, the sequence of the 3E10-HC is at least about 98% identical to 3E10-HC-h6 (SEQ ID NO:83). In embodiments, the sequence of the 3E10-HC is at least about 99% identical to 3E10-HC-h6 (SEQ ID NO:83). In some aspects, the sequence of the 3E10-HC is 3E10-HC-h6 (SEQ ID NO:83).
  • the sequence of the 3E10-HC is at least about 95% identical to 3E10-HC-h7 (SEQ ID NO:84). In embodiments, the sequence of the 3E10-HC is at least about 96% identical to 3E10-HC-h7 (SEQ ID NO:84). In embodiments, the sequence of the 3E10-HC is at least about 97% identical to 3E10-HC-h7 (SEQ ID NO: 84). In embodiments, the sequence of the 3E10-HC is at least about 98% identical to 3E10-HC-h7 (SEQ ID NO:84). In embodiments, the sequence of the 3E10-HC is at least about 99% identical to 3E10-HC-h7 (SEQ ID NO:84). In embodiments, the sequence of the 3E10-HC is 3E10-HC-h7 (SEQ ID NO:84).
  • an AOC comprising a humanized 3E10 antibody or antigen- binding fragment thereof described herein has CDR sequences corresponding to those in the parent 3E10 antibody, optionally including a D31N amino acid substitution in the VH CDR1.
  • a humanized 3E10 antibody or antigen-binding fragment thereof includes a light chain variable domain (VL) complementarity determining region (CDR) 1 comprising the amino acid sequence of 3E10-VL-CDR1 (SEQ ID NO: 9), a VL CDR2 comprising the amino acid sequence of 3E10-VL-CDR2 (SEQ ID NO: 10), a VL CDR3 comprising the amino acid sequence of 3E10-VL-CDR3 (SEQ ID NO: 11), a heavy chain variable domain (VH) CDR1 comprising the amino acid sequence of 3E10-VH-CDRla (SEQ ID NO: 16), a VH CDR2 comprising the amino acid sequence of 3E10-VH-CDR2 (SEQ ID NO: 4), and a VH CDR3 comprising the amino acid sequence of 3E10-VH-CDR3 (SEQ ID NO: 5).
  • VL light chain variable domain
  • CDR complementarity determining region
  • an AOC comprising a humanized 3E10 antibody or antigen- binding fragment thereof described herein includes CDR sequences from a variant humanized 3E10 antibody that includes a D31N amino acid substitution in the VH CDR1 (SEQ ID NO: 15).
  • an AOC comprising a humanized 3E10 antibody or antigen- binding fragment thereof described herein includes a set of complementarity determining regions (CDRs) collectively having no more than seven amino acid substitutions, relative to the set of CDRs having the amino acid sequences of 3E10-VL-CDR1 (SEQ ID NO:9), 3E10-VL-CDR2 (SEQ ID NO:10), 3E10-VL-CDR3 (SEQ ID NO:11), 3E10-VH-CDR1 D31N (SEQ ID NO:15), 3E10-VH-CDR2 (SEQ ID NO:4), and 3E10-VH-CDR3 (SEQ ID NO:5).
  • CDRs complementarity determining regions
  • an AOC comprising a humanized 3E10 antibody or antigen- binding fragment thereof described herein includes a set of complementarity determining regions (CDRs) collectively having no more than ten amino acid substitutions, relative to the set of CDRs having the amino acid sequences of 3E10-VL-CDR1 (SEQ ID NO:9), 3E10-VL-CDR2 (SEQ ID NO: 10), 3E10-VL-CDR3 (SEQ ID NO: 11), 3E1O-VH-CDR1 D31N (SEQ ID NO: 15), 3E10-VH- CDR2 (SEQ ID NO:4), and 3E10-VH-CDR3 (SEQ ID NO:5).
  • CDRs complementarity determining regions
  • an AOC comprising a humanized 3E10 antibody or antigen- binding fragment thereof described herein includes a set of complementarity determining regions (CDRs) collectively having no more than nine amino acid substitutions, relative to the set of CDRs having the amino acid sequences of 3E10-VL-CDR1 (SEQ ID NO:9), 3E10-VL-CDR2 (SEQ ID NO: 10), 3E10-VL-CDR3 (SEQ ID NO: 11), 3E1O-VH-CDR1 D31N (SEQ ID NO: 15), 3E10-VH- CDR2 (SEQ ID NO:4), and 3E10-VH-CDR3 (SEQ ID NO:5).
  • CDRs complementarity determining regions
  • an AOC comprising a humanized 3E10 antibody or antigen- binding fragment thereof described herein includes a set of complementarity determining regions (CDRs) collectively having no more than eight amino acid substitutions, relative to the set of CDRs having the amino acid sequences of 3E10-VL-CDR1 (SEQ ID NO:9), 3E10-VL-CDR2 (SEQ ID NO: 10), 3E10-VL-CDR3 (SEQ ID NO: 11), 3E1O-VH-CDR1 D31N (SEQ ID NO: 15), 3E10-VH- CDR2 (SEQ ID NO:4), and 3E10-VH-CDR3 (SEQ ID NO:5).
  • CDRs complementarity determining regions
  • an AOC comprising a humanized 3E10 antibody or antigen- binding fragment thereof described herein includes a set of complementarity determining regions (CDRs) collectively having no more than seven amino acid substitutions, relative to the set of CDRs having the amino acid sequences of 3E10-VL-CDR1 (SEQ ID NO:9), 3E10-VL-CDR2 (SEQ ID NO: 10), 3E10-VL-CDR3 (SEQ ID NO:11), 3E10-VH-CDR1 D31N (SEQ ID NO:15), 3E10-VH-CDR2 (SEQ ID NO:4), and 3E10-VH-CDR3 (SEQ ID NO:5).
  • CDRs complementarity determining regions
  • an AOC comprising a humanized 3E10 antibody or antigen- binding fragment thereof described herein includes a set of complementarity determining regions (CDRs) collectively having no more than six amino acid substitutions, relative to the set of CDRs having the amino acid sequences of 3E10-VL-CDR1 (SEQ ID NO:9), 3E10-VL-CDR2 (SEQ ID NO: 10), 3E10-VL-CDR3 (SEQ ID NO: 11), 3E1O-VH-CDR1 D31N (SEQ ID NO: 15), 3E10-VH- CDR2 (SEQ ID NO:4), and 3E10-VH-CDR3 (SEQ ID NO:5).
  • CDRs complementarity determining regions
  • an AOC comprising a humanized 3E10 antibody or antigen- binding fragment thereof described herein includes a set of complementarity determining regions (CDRs) collectively having no more than five amino acid substitutions, relative to the set of CDRs having the amino acid sequences of 3E10-VL-CDR1 (SEQ ID NO:9), 3E10-VL-CDR2 (SEQ ID NO: 10), 3E10-VL-CDR3 (SEQ ID NO: 11), 3E1O-VH-CDR1 D31N (SEQ ID NO: 15), 3E10-VH- CDR2 (SEQ ID NO:4), and 3E10-VH-CDR3 (SEQ ID NO:5).
  • CDRs complementarity determining regions
  • an AOC comprising a humanized 3E10 antibody or antigen- binding fragment thereof described herein includes a set of complementarity determining regions (CDRs) collectively having no more than four amino acid substitutions, relative to the set of CDRs having the amino acid sequences of 3E10-VL-CDR1 (SEQ ID NO:9), 3E10-VL-CDR2 (SEQ ID NO:10), 3E10-VL-CDR3 (SEQ ID NO: 11), 3E1O-VH-CDR1 D31N (SEQ ID NO: 15), 3E10-VH- CDR2 (SEQ ID NO:4), and 3E10-VH-CDR3 (SEQ ID NO:5).
  • CDRs complementarity determining regions
  • an AOC comprising a humanized 3E10 antibody or antigen- binding fragment thereof described herein includes a set of complementarity determining regions (CDRs) collectively having no more than three amino acid substitutions, relative to the set of CDRs having the amino acid sequences of 3E10-VL-CDR1 (SEQ ID NO:9), 3E10-VL-CDR2 (SEQ ID NO: 10), 3E10-VL-CDR3 (SEQ ID NO: 11), 3E1O-VH-CDR1 D31N (SEQ ID NO: 15), 3E10-VH- CDR2 (SEQ ID NO:4), and 3E10-VH-CDR3 (SEQ ID NO:5).
  • CDRs complementarity determining regions
  • an AOC comprising a humanized 3E10 antibody or antigen- binding fragment thereof described herein includes a set of complementarity determining regions (CDRs) collectively having no more than two amino acid substitutions, relative to the set of CDRs having the amino acid sequences of 3E10-VL-CDR1 (SEQ ID NO:9), 3E10-VL-CDR2 (SEQ ID NO: 10), 3E10-VL-CDR3 (SEQ ID NO: 11), 3E1O-VH-CDR1 D31N (SEQ ID NO: 15), 3E10-VH- CDR2 (SEQ ID NO:4), and 3E10-VH-CDR3 (SEQ ID NO:5).
  • CDRs complementarity determining regions
  • an AOC comprising a humanized 3E10 antibody or antigen- binding fragment thereof described herein includes a set of complementarity determining regions (CDRs) collectively having no more than one amino acid substitution, relative to the set of CDRs having the amino acid sequences of 3E10-VL-CDR1 (SEQ ID NO:9), 3E10-VL-CDR2 (SEQ ID NO: 10), 3E10-VL-CDR3 (SEQ ID NO: 11), 3E1O-VH-CDR1 D31N (SEQ ID NO: 15), 3E10-VH- CDR2 (SEQ ID NO:4), and 3E10-VH-CDR3 (SEQ ID NO:5).
  • CDRs complementarity determining regions
  • an AOC described herein can comprise a humanized 3E10 antibody or antigen-binding fragment thereof includes a light chain variable domain (VL) complementarity determining region (CDR) 1 comprising the amino acid sequence of 3E10-VL- CDR1 (SEQ ID NO: 9), a VL CDR2 comprising the amino acid sequence of 3E10-VL-CDR2 (SEQ ID NO: 10), a VL CDR3 comprising the amino acid sequence of 3E10-VL-CDR3 (SEQ ID NO: 11), a heavy chain variable domain (VH) CDR1 comprising the amino acid sequence of 3E10- VH-CDR1 D31N (SEQ ID NO: 15), a VH CDR2 comprising the amino acid sequence of 3E10- VH-CDR2 (SEQ ID NO: 4), and a VH CDR3 comprising the amino acid sequence of 3E10-VH- CDR3 (SEQ ID NO: 5).
  • VL light chain variable domain
  • CDR complement
  • an AOC comprising a humanized 3E10 antibody or antigen- binding fragment thereof described herein includes a set of complementarity determining regions (CDRs) collectively having no more than 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid substitutions, relative to the CDR sequences of 3E10-D31N variant (SEQ ID NOs: 15-18 and 22- 24), selected from, but not limited to, a G to S substitution at position 5 of VH CDR2, a T to S substitution at position 14 of VH CDR2, an S to T substitution at position 5 of VL CDR1, an M to L substitution at position 14 of VL CDR1, an H to A substitution at position 15 of VL CDR1, and an E to Q substitution at position 6 of VL CDR2.
  • CDRs complementarity determining regions
  • an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof includes VH CDR2 comprising the amino acid sequence of 3E10-VH-CDR2.1 (SEQ ID NO: 26) or 3E10-VH-CDR2.2 (SEQ ID NO: 27).
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3 (SEQ ID NOs:9-l 1), and VH CDRs 1 and 3 (SEQ ID NOs:3 and 5) according to the parent 3E10 antibody.
  • the 3E 10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3 (SEQ ID NOs:22-24), and VH CDRs 1 and 3 (SEQ ID NOs: 15 and 18) according to the 3E10- D31N variant.
  • an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof includes VL CDR1 comprising the amino acid sequence of 3E10-VL-CDR1.1 (SEQ ID NO: 28) or 3E10-VL-CDR1.2 (SEQ ID NO: 29).
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 2 and 3 (SEQ ID NOs: 10 and 11), and VH CDRs 1-3 (SEQ ID NOs:3-5) according to the parent 3E10 antibody.
  • the humanized 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 2 and 3 (SEQ ID NOs:23 and 24), and VH CRDs 1-3 (SEQ ID NOs: 15, 17 and 18) according to the 3E10- D31N variant.
  • an AOC comprising a humanized 3E10 antibody or antigen -binding fragment thereof includes VL CDR2 comprising the amino acid sequence of 3E10-VL-CDR2 1 (SEQ ID NO: 30).
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 3 (SEQ ID NOs:9 and 11), and VH CDRs 1-3 (SEQ ID NOs: 3-5) according to the parent 3E10 antibody.
  • the humanized 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 3 (SEQ ID NOs:22 and 24), and VH CDRs 1-3 (SEQ ID NOs: 15, 17 and 18)according to the 3E10-D3 IN variant.
  • an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof includes VH CDR2 comprising the amino acid sequence of 3E10-VH-CDR2.3 (SEQ ID NO: 31).
  • the humanized 3E10 antibody or antigen- binding fragment thereof further includes VL CDRs 1-3 (SEQ ID NOs:9-l 1), and VH CDRs 1 and 3 (SEQ ID NOs:3 and 5) according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3 (SEQ ID NOs:22- 24), and VH CDRs 1 and 3 (SEQ ID NOs:15 and 18) according to the 3E10- D3 IN.
  • an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof includes VL CDR1 comprising the amino acid sequence of 3E10-VL-CDR1.3 (SEQ ID NO: 32).
  • the humanized 3E10 antibody or antigen- binding fragment thereof further includes VL CDRs 2 and 3 (SEQ ID NOs:10 and 11), and VH CDRs 1-3 (SEQ ID NOs: 15, 17 and 18) according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 2 and 3 (SEQ ID NOs:23 and 24), and VH CDRs 1-3 (SEQ ID NOs: 15, 17 and 18) according to the 3E10- D3 IN variant.
  • an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof includes VL CDR2 comprising the amino acid sequence of 3E10-VL-CDR2.2 (SEQ ID NO: 33).
  • the humanized 3E10 antibody or antigen- binding fragment thereof further includes VL CDRs 1 and 3 (SEQ ID NOs:9 and 11), and VH CDRs 1-3 (SEQ ID NOs:3-5) according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 3 (SEQ ID NOs:22 and 24), and VH CDRs 1-3 (SEQ ID NOs: 15, 17 and 18) according to the 3E10- D3 IN variant.
  • an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof includes VH CDR1 comprising the amino acid sequence of 3E10-VH-CDR1.C1 (SEQ ID NO: 34), 3E10-VH-CDR1 c2 (SEQ ID NO: 35), 3E10-VH-CDRl .c3 (SEQ ID NO: 36), 3E10-VH-CDRl.c4 (SEQ ID NO: 37), or 3E10-VH-CDRl.c5 (SEQ ID NO: 38).
  • the humanized 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3 (SEQ ID NOs:9-l l), and VH CDRs 2 and 3 (SEQ ID NOs:4 and 5) according to the parent 3E10 antibody.
  • an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof includes VH CDR2 comprising the amino acid sequence of 3E10-VH-CDR2.C1 (SEQ ID NO: 39), 3E10-VH-CDR2.c2 (SEQ ID NO: 40), or 3E10-VH- CDR2.c3 (SEQ ID NO: 41).
  • the humanized 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3 (SEQ ID NOs:9-l 1), and VH CDRs 1 and 3 (SEQ ID NOs:3 and 5) according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3 (SEQ ID NOs:22-24), and VH CDRs 1 and 3 (SEQ ID NOs:15 and 18) according to the 3E10-D3 IN variant.
  • an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof includes VH CDR3 comprising the amino acid sequence of 3E10-VH-CDR3.C1 (SEQ ID NO: 42), 3E10-VH-CDR3.c2 (SEQ ID NO: 43), or 3E10-VH- CDR3.c3 (SEQ ID NO: 44).
  • the humanized 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3 (SEQ ID NOs:9-l 1), and VH CDRs 1 and 2 (SEQ ID NOs:3 and 4) according to the parent 3E10 antibody.
  • the 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3 (SEQ ID NOs:22-24), and VH CDRs 1 and 2 (SEQ ID NOs: 15 and 17) according to the 3E10-D3 IN variant.
  • an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof includes VL CDR1 comprising the amino acid sequence of 3E10-VL-CDR1.C1 (SEQ ID NO: 45), 3E10-VL-CDRl.c2 (SEQ ID NO: 46), 3E10-VL-CDRl.c3 (SEQ ID NO: 47), 3E10-VL-CDRl .c4 (SEQ ID NO: 48), 3E10-VL-CDRl .c5 (SEQ ID NO: 49), or 3E10-VL-CDRl.c6 (SEQ ID NO: 50).
  • the humanized 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 2 and 3 (SEQ ID NOs: 10 and 11), and VH CDRs 1-3 (SEQ ID NOs:3-5) according to the parent 3E10 antibody.
  • the humanized 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 2 and 3 (SEQ ID NOs:23 and 24), and VH CRDs 1-3 (SEQ ID NOs: 15, 17, 18) according to the 3E10- D3 IN variant.
  • an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof includes VL CDR2 comprising the amino acid sequence of 3E10-VL-CDR2.cl (SEQ ID NO: 51).
  • the humanized 3E10 antibody or antigen- binding fragment thereof further includes VL CDRs 1 and 3 (SEQ ID NOs:9 and 11), and VH CDRs 1-3 (SEQ ID NOs:3-5) according to the parent 3E10 antibody.
  • the humanized 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 3 (SEQ ID NOs:22 and 24), and VH CDRs 1-3 (SEQ ID NOs: 15, 17 and 18) according to the 3E10- D3 IN variant.
  • an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof includes VL CDR3 comprising the amino acid sequence of 3E10-VL-CDR3.C1 (SEQ ID NO: 52), 3E10-VL-CDR3.c2 (SEQ ID NO: 53), 3E10-VL-CDR3.c3 (SEQ ID NO: 54), 3E10-VL-CDR3.c4 (SEQ ID NO: 55), 3E10-VL-CDR3.c5 (SEQ ID NO: 56), or 3E10-VL-CDR3.c6 (SEQ ID NO: 57).
  • VL CDR3 comprising the amino acid sequence of 3E10-VL-CDR3.C1 (SEQ ID NO: 52), 3E10-VL-CDR3.c2 (SEQ ID NO: 53), 3E10-VL-CDR3.c3 (SEQ ID NO: 54), 3E10-VL-CDR3.c4 (SEQ ID NO: 55), 3E10-
  • the humanized 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 2 (SEQ ID NOs:9 and 10), and VH CDRs 1-3 (SEQ ID NOs:3-5) according to the parent 3E10 antibody.
  • the humanized 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 2 (SEQ ID NOs:22 and 23), and VH CDRs 1-3 (SEQ ID NOs: 15, 17 and 18) according to the 3E10- D31N variant.
  • an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof, as described herein, includes no more than 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 CDR amino acid substitutions of the CDR amino acid substitutions described above. Further examples of 3E10 variant CDR sequences are described herein (SEQ ID NOs:58-63).
  • an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof includes VH CDR1 comprising the amino acid sequence of 3E10-VH-CDRlm (SEQ ID NO: 58).
  • the humanized 3E10 antibody or antigen- binding fragment thereof further includes VL CDRs 1-3 (SEQ ID NOs:9-l 1), and VH CDRs 2 and 3 (SEQ ID NOs:4 and 5) according to the parent 3E10 antibody.
  • an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof includes VH CDR2 comprising the amino acid sequence of 3E10-VH-CDR2m (SEQ ID NO: 59).
  • the humanized 3E10 antibody or antigen- binding fragment thereof further includes VL CDRs 1-3 (SEQ ID N0s:9-l 1), and VH CDRs 1 and 3 (SEQ ID NOs: 3 and 5) according to the parent 3E10 antibody.
  • the humanized 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3 (SEQ ID NOs:22-24), and VH CDRs 1 and 3 (SEQ IDN0s: 15 and 18) according to the 3E10-D3 IN variant.
  • an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof includes VH CDR3 comprising the amino acid sequence of 3E10-VH-CDR3m (SEQ ID NO: 60).
  • the humanized 3E10 antibody or antigen- binding fragment thereof further includes VL CDRs 1-3 (SEQ ID NOs:9-l 1), and VH CDRs 1 and 2 (SEQ ID NOs:3 and 4) according to the parent 3E10 antibody.
  • the humanized 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1-3 (SEQ ID NOs:22-24), and VH CDRs 1 and 2 (SEQ ID NOs: 15 and 17) according to the 3E10-D3 IN variant.
  • an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof includes VL CDR1 comprising the amino acid sequence of 3E10-VL-CDRlm (SEQ ID NO: 61).
  • the humanized 3E10 antibody or antigen- binding fragment thereof further includes VL CDRs 2 and 3 (SEQ ID NOs: 10 and 11), and VH CDRs 1-3 (SEQ ID NOs:3-5) according to the parent 3E10 antibody.
  • the humanized 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 2 and 3 (SEQ ID NOs:23 and 24), and VH CDRs 1-3 (SEQ ID NOs: 15,17, and 18) according to the 3E10- D31N variant.
  • an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof includes VL CDR2 comprising the amino acid sequence of 3E10-VL-CDR2m (SEQ ID NO: 62).
  • the humanized 3E10 antibody or antigen- binding fragment thereof further includes VL CDRs 1 and 3 (SEQ ID NOs:9 and 11), and VH CDRs 1-3 (SEQ ID NOs:3-5) according to the parent 3E10 antibody.
  • the humanized 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 3 (SEQ ID NOs:22 and 24), and VH CDRs 1-3 (SEQ ID NOs: 15, 17 and 18) according to the 3E10- D3 IN variant.
  • an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof includes VL CDR3 comprising the amino acid sequence of 3E10-VL-CDR3m (SEQ ID NO: 63).
  • the humanized 3E10 antibody or antigen- binding fragment thereof further includes VL CDRs 1 and 2 (SEQ ID N0s:9 and 10), and VH CDRs 1-3 (SEQ ID NOs:3-5) according to the parent 3E10 antibody.
  • the humanized 3E10 antibody or antigen-binding fragment thereof further includes VL CDRs 1 and 2 (SEQ ID NOs:9 and 10), and VH CDRs 1-3 (SEQ ID NOs: 15, 17 and 18) according to the 3E10- D3 IN variant.
  • an AOC comprising a humanized 3E10 antibody or antigen- binding fragment thereof described herein includes a light chain variable domain (3E10-VL) comprising an amino acid sequence that is at least about 90% identical to an amino acid sequence selected from the group consisting of 3E10-VL-hl (SEQ ID NO:85), 3E10-VL-h2 (SEQ ID NO:86), 3E10-VL-h3 (SEQ ID NO:87), 3E10-VL-h4 (SEQ ID NO:88), 3E10-VL-h5 (SEQ ID NO:89), and 3E10-VL-h6 (SEQ ID NO:90), where the light chain variable domain (3E10-VL) further comprises one or more amino acid residues selected from proline (Pro) at position 15, threonine (Thr) at position 22, tyrosine (Tyr) at position 49, Thr at position 74, asparagine (Asn) at position 76, alanine
  • an AOC comprising the humanized 3E10 antibody or antigen- binding fragment thereof includes a set of 3E10-VL CDRs comprising no more than 5 amino acid substitutions relative to the set of CDRs having the amino acid sequences of 3E10-VL-CDR1 (SEQ ID N0:9), 3E10-VL-CDR2 (SEQ ID NO: 10), 3E10-VL-CDR3 (SEQ ID NO: 11).
  • an AOC comprising the humanized 3E10 antibody or antigen- binding fragment thereof includes a set of 3E10-VL CDRs comprising no more than 4 amino acid substitutions relative to the set of CDRs having the amino acid sequences of 3E10-VL-CDR1 (SEQ ID N0:9), 3E10-VL-CDR2 (SEQ ID NO: 10), 3E10-VL-CDR3 (SEQ ID NO: 11).
  • an AOC comprising the humanized 3E10 antibody or antigen- binding fragment thereof includes a set of 3E10-VL CDRs comprising no more than 3 amino acid substitutions relative to the set of CDRs having the amino acid sequences of 3E10-VL-CDR1 (SEQ ID N0:9), 3E10-VL-CDR2 (SEQ ID NO: 10), 3E10-VL-CDR3 (SEQ ID NO: 11).
  • an AOC comprising the humanized 3E10 antibody or antigen- binding fragment thereof includes a set of 3E10-VL CDRs comprising no more than 2 amino acid substitutions relative to the set of CDRs having the amino acid sequences of 3E10-VL-CDR1 (SEQ ID NO:9), 3E10-VL-CDR2 (SEQ ID NO: 10), 3E10-VL-CDR3 (SEQ ID NO: 11).
  • an AOC comprising the humanized 3E10 antibody or antigen- binding fragment thereof includes a set of 3E10-VL CDRs comprising no more than 1 amino acid substitution relative to the set of CDRs having the amino acid sequences of 3E10-VL-CDR1 (SEQ ID NO:9), 3E10-VL-CDR2 (SEQ ID NO: 10), 3E10-VL-CDR3 (SEQ ID NO: 11).
  • an AOC comprising the humanized 3E10 antibody or antigen- binding fragment thereof includes a set of 3E10-VL CDRs comprising a set of CDRs having the amino acid sequences of 3E10-VL-CDR1 (SEQ ID NO:9), 3E10-VL-CDR2 (SEQ ID NO:10), 3E10-VL-CDR3 (SEQ ID NO: 11).
  • the present disclosure provides an AOC comprising a humanized antibody or antigen-binding fragment thereof with a lysine (Lys) residue at position 49 of the 3E10-VL according to Kabat numbering.
  • the present disclosure provides an AOC comprising a humanized antibody or antigen-binding fragment thereof with a glutamic acid (Glu) residue at position 81 of the 3E10-VL according to Kabat numbering.
  • Glu glutamic acid
  • the present disclosure provides an AOC comprising a humanized antibody or antigen-binding fragment thereof with a proline (Pro) residue at position 15 of the 3E10-VL according to Kabat numbering.
  • an AOC comprising a humanized antibody or antigen-binding fragment thereof with a valine (Vai) residue at position 104, of the 3E10-VL according to Kabat numbering.
  • an AOC comprising a humanized 3E10 antibody or antigen- binding fragment thereof described herein includes a heavy chain variable domain (3E10-VH) comprising an amino acid sequence that is at least about 90% identical to an amino acid sequence selected from the group consisting of 3E10-VH-hl (SEQ ID NO:64), 3E10-VH-h2 (SEQ ID NO:65), 3E10-VH-h3 (SEQ ID NO:66), 3E10-VH-h4 (SEQ ID NO:67), 3E10-VH-h5 (SEQ ID NO:68), 3E10-VH-h6 (SEQ ID NO:69), and 3E10-VH-h7 (SEQ ID NO:70), where the heavy chain
  • an AOC comprising the humanized 3E10 antibody or antigen- binding fragment thereof includes a set of 3E10-VH CDRs comprising no more than 5 amino acid substitutions relative to the set of CDRs having the amino acid sequences of 3E10-VH- CDR1 D31N (SEQ ID NO:15), 3E10-VH-CDR2 (SEQ ID N0:4), and 3E10-VH-CDR3 (SEQ ID NO:5).
  • an AOC comprising the humanized 3E10 antibody or antigen- binding fragment thereof includes a set of 3E10-VH CDRs comprising no more than 4 amino acid substitutions relative to the set of CDRs having the amino acid sequences of 3E10-VH- CDR1 D3 IN (SEQ ID NO: 15), 3E10-VH-CDR2 (SEQ ID NO:4), and 3E10-VH-CDR3 (SEQ ID NO:5).
  • an AOC comprising the humanized 3E10 antibody or antigen- binding fragment thereof includes a set of 3E10-VH CDRs comprising no more than 3 amino acid substitutions relative to the set of CDRs having the amino acid sequences of 3E10-VH- CDR1 D31N (SEQ ID NO:15), 3E10-VH-CDR2 (SEQ ID N0:4), and 3E10-VH-CDR3 (SEQ ID NO:5).
  • an AOC comprising the humanized 3E10 antibody or antigen- binding fragment thereof includes set of 3E10-VH CDRs comprising no more than 2 amino acid substitutions relative to the a set of CDRs having the amino acid sequences of 3E10-VH- CDR1 D31N (SEQ ID NO:15), 3E10-VH-CDR2 (SEQ ID N0:4), and 3E10-VH-CDR3 (SEQ ID NO:5).
  • an AOC comprising the humanized 3E10 antibody or antigen- binding fragment thereof includes a set of 3E10-VH CDRs comprising no more than 1 amino acid substitution relative to the set of CDRs having the amino acid sequences of 3E10-VH- CDR1 D31N (SEQ ID NO: 15), 3E10-VH-CDR2 (SEQ ID N0:4), and 3E10-VH-CDR3 (SEQ ID NO:5).
  • an AOC comprising the humanized 3E10 antibody or antigen- binding fragment thereof includes a set of 3E10-VH CDRs comprising no more than 5, 4, 3, 2, or 1 amino acid substitutions relative to the set of CDRs having the amino acid sequences of 3E10- VH-CDR1 D31N (SEQ ID NO:15), 3E10-VH-CDR2 (SEQ ID NO:4), and 3E1O-VH-CDR3 (SEQ ID NO:5).
  • the present disclosure provides an AOC comprising a humanized antibody or antigen-binding fragment thereof with an arginine (Arg) residue at position 18 of the 3E10-VH according to Kabat numbering.
  • the present disclosure provides an AOC comprising a humanized antibody or antigen-binding fragment thereof with a (Lys) residue at position 19 of the 3E10-VH according to Kabat numbering.
  • the present disclosure provides an AOC comprising a humanized antibody or antigen-binding fragment thereof with an alanine (Ala) residue at position 49 of the 3E10-VH according to Kabat numbering.
  • the present disclosure provides an AOC comprising a humanized antibody or antigen-binding fragment thereof with a glutamine (Gin) residue at position 13, of the 3E10-VH according to Kabat numbering.
  • the present disclosure provides an AOC comprising a humanized antibody or antigen-binding fragment thereof with a leucine (Leu) residue at position 108, of the 3E10-VH according to the Kabat numbering.
  • the present disclosure provides an AOC comprising a humanized antibody or antigen-binding fragment thereof with a valine (Vai) residue at position 109, of the 3E10-VH according to Kabat numbering.
  • the present disclosure provides an AOC comprising a humanized antibody or antigen-binding fragment thereof with a serine (Ser) residue at position 113, of the 3E10-VH according to Kabat numbering.
  • the present disclosure provides an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof with a fragment crystallizable (Fc) region.
  • the present disclosure provides an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof with an Fc region selected from a human IgGl Fc, a human IgG2a Fc, a human IgG2b Fc, a human IgG3 Fc, and a human IgG4 Fc.
  • the present disclosure provides an AOC comprising humanized 3E10 antibodies or variants thereof, or antigen-binding fragments thereof comprising a heavy chain constant domain (CH).
  • AOC comprising humanized 3E10 antibodies or variants thereof, or antigen-binding fragments thereof comprising a heavy chain constant domain (CH).
  • an AOC comprising the humanized 3E10 antibody or antigen- binding fragment thereof comprises an Fc region selected from a human yl CHI, a human y2 CHI, a human y3 CHI, and a human y4 CHI.
  • the present disclosure provides an AOC comprising a humanized 3E10 antibody or antigen-binding fragment thereof comprising a light chain constant domain (CL).
  • the present disclosure provides an AOC comprising a humanized 3E10 antibody or variant comprising an Fc region selected from the group consisting of a human X CL and a human K CL.
  • an AOC comprising the humanized 3E10 antibody or antigen- binding fragment thereof comprising a combination of a light chain variable domain (VL) and a heavy chain variable domain (VH) selected from 3E10-VL-hl (SEQ ID NO:85) and 3E10-VH-hl (SEQ ID NO:64), 3E10-VL-hl (SEQ ID NO:85) and 3E10-VH-h2 (SEQ ID NO:65), 3E10-VL- hl (SEQ ID NO:85) and 3E10-VH-h3 (SEQ ID NO:66), 3E10-VL-hl (SEQ ID NO:85) and 3E10- VH-h4 (SEQ ID NO: 67), 3E10-VL-h2 (SEQ ID NO: 86) and 3E10-VH-hl (SEQ ID NO: 64), 3E10- VL-h2 (SEQ ID NO:86) and 3E10-VH-hl (
  • an AOC comprising the humanized 3E10 antibody or antigen- binding fragment thereof comprises a combination of a light chain variable domain (VL) of 3E10- VL-h6 (SEQ ID NO: 90) and a heavy chain variable domain (VH) of 3E10-VH-h6 (SEQ ID NO:69).
  • VL light chain variable domain
  • VH heavy chain variable domain
  • Antibodies useful in the compositions, conjugates, and methods described herein include whole immunoglobulin (i.e., an intact antibody) of any class, fragments thereof, and synthetic proteins containing at least the antigen-binding variable domain of an antibody.
  • the variable domains differ in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not usually evenly distributed through the variable domains of antibodies. It is typically concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of the variable domains are called the framework (FR).
  • CDRs complementarity determining regions
  • FR framework
  • variable domains of native heavy and light chains each comprise four FR regions, largely adopting a beta-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the beta-sheet structure.
  • the CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies. Therefore, the antibodies typically contain at least the CDRs necessary to maintain DNA binding.
  • the 3E10 antibody is typically a monoclonal 3E10, or a variant, derivative, fragment, fusion, or humanized form thereof that binds the same or different epitope(s) as 3E10.
  • a deposit according to the terms of the Budapest Treaty of a hybridoma cell line producing monoclonal antibody 3E10 was received on September 6, 2000, and accepted by, American Type Culture Collection (ATCC), 10801 University Boulevard., Manassas, VA 20110-2209, USA, and given Patent Deposit Number PTA-2439.
  • ATCC American Type Culture Collection
  • the antibody can have the same or different epitope specificity as monoclonal antibody 3E10 produced by ATCC No. PTA 2439 hybridoma.
  • the antibody can have the paratope of monoclonal antibody 3E10.
  • the antibody can be a single chain variable fragment of 3E10, or a variant, e.g., a conservative variant thereof.
  • the antibody can be a single chain variable fragment of 3E10 (3E10 Fv), or a variant thereof.
  • the heavy chain complementarity determining regions can be defined according to the IMGT system.
  • the complementarity determining regions (CDRs) as identified by the IMGT system include CDR Hl.3 (original sequence): GFTFSDYG (SEQ ID NO: 191); CDR Hl.4 (with D31N mutation): GFTFSNYG (SEQ ID NO: 192); CDR H2.2: ISSGSSTI (SEQ ID NO: 193) and variant ISSSSSTI (SEQ ID NO: 194); CDR H3.2: ARRGLLLDY (SEQ ID NO: 195).
  • the light chain complementarity determining regions can be defined according to the IMGT system.
  • the complementarity determining regions (CDRs) as identified by the IMGT system include CDR LI.2 KSVSTSSYSY (SEQ ID NO: 196) and variant KTVSTSSYSY (SEQ ID NO: 197); CDR L2 2: YAS; CDR L3.2: QHSREFPWT (SEQ ID NO: 198).
  • compositions, conjugates, and methods typically utilize antibodies that maintain the ability to penetrate cells, and optionally nuclei.
  • the mechanisms of cellular internalization by autoantibodies are diverse. Some are taken into cells through electrostatic interactions or FcR-mediated endocytosis, while others utilize mechanisms based on association with cell surface myosin or calreticulin, followed by endocytosis (Ying-Chyi et al., Eur J Immunol 38, 3178-3190 (2008), Yanase et al., J Clin Invest 100, 25-31 (1997)).
  • the 3E10 antibodies and antigen-binding fragments thereof can transit cellular membranes via an equilibrative nucleoside (ENT) transporter.
  • 3E10 transits cellular membranes via an ENT1, ENT2, ENT3 or ENT4 transporter (See, e.g., WO 2015/106290 Al and WO 2016/033324 Al, each of which is incorporated by reference herein, in its entirety).
  • 3E10 penetrates cells in an Fc- independent mechanism (as evidenced by the ability of 3E10 fragments lacking an Fc to penetrate cells) but involves presence of the nucleoside transporter ENT2 (Weisbart et al., Sci Rep 5: 12022. doi: 10.1038/srepl2022.
  • the antibodies utilized in the disclosed compositions, conjugates, and methods are ones that penetrates cells in an Fc- independent mechanism and involve the presence of the nucleoside transporter ENT2.
  • the antibody -oligonucleotide conjugates (AOC) provided herein comprises a linker.
  • the linker (L) described herein links the 3E10 antibody or antigen-binding fragment thereof to an oligonucleotide, e.g., an siRNA or antisense oligonucleotide.
  • the term “linker” as used herein includes, without limitation, any known linker for use in antibody- oligonucleotide-conjugates known in the art.
  • the AOC comprises, one, two, three, four, or more linkers.
  • one or more amino acids suitable conjugation of a 3E10 antibody or antigen-binding fragment thereof provided herein are selected from lysine, cysteine, histidine, arginine, aspartic acid, glutamine, serine, threonine and tyrosine.
  • one or more amino acids suitable for conjugation are introduced by substitution of one or more amino acids in the 3E10 antibody or antigen-binding fragment thereof.
  • the one or more conjugated amino acids are lysine or arginine, and conjugation is conducted via amine conjugation.
  • one or more conjugated amino acids are glutamine (Gin) and conjugation is conducted via transglutaminase (TGase) mediated enzymatic conjugation.
  • one or more conjugated amino acids are cysteine (Cys) and conjugation is conducted via thiol conjugation.
  • NHS-PEG reagent can be used to modify primary amines in a 3E10 antibody antigen-binding fragment thereof provided herein.
  • a method of site-specific conjugation is by means of transglutaminase.
  • Transglutaminases which also include bacterial transglutaminase (BTG) are a family of enzymes which catalyse the formation of a covalent bond between the y-carbonyl-amide group of glutamines and the primary amine group of lysines.
  • a peptide or antibody can be a substrate for transglutaminase according to the methods of the present disclosure.
  • peptide or antibody contains a Gin or a Lys residue, and in particular a Gin residue.
  • the peptide or antibody is not a transglutaminase substrate, so one or more Gin or Lys residues, and in particular Gin residues, are inserted into the peptide or antibody sequence to make the peptide a substrate for transglutaminase.
  • a Gin or Lys residue may be inserted at any position in the peptide or antibody sequence, however, it is preferably inserted at a position where the physiological properties, such as the therapeutic activity of the peptide is not affected to a degree where the peptide is not useful anymore, e.g., in a therapeutic intervention. Insertions of amino acid residues in peptides can be brought about by standard techniques known to persons skilled in the art, such as post-translational chemical modification or transgenic techniques, as described in US Patent No. 11.123,439 and US/2017/0355859, the contents of which are hereby incorporated by reference.
  • transglutaminases also accept substrates other than lysine as amine donor, they are used to modify proteins including antibodies at suitable acceptor glutamines (Josten et al., J. Immunol. Methods 240, 47-54 (2000); Mindt et al., Bioconjugate Chem. 19, 271- 278 (2008); Dennler et al., in Antibody Drug Conjugates (Ducry, L., Ed.), pp 205-215, Humana Press. (2013), the contents of which are incorporated herein by reference).
  • Transglutaminases have been used for the conjugation of drugs to antibodies containing artificial glutamine tags which are acceptor glutamine residues which have been introduced into the antibody by genetic engineering (Strop et al., Chem. Biol. 20, 161-167 (2013)). Furthermore, the conserved glutamine residue Q295 (Kabat EU numbering) of the constant region of the heavy chain of antibodies is the only y- carbonyl-amide donor for the bacterial transglutaminase (EC 2.3.2.13) in the backbone of aglycosylated IgGl molecules, and is thus an acceptor glutamine, whereas no acceptor glutamine is present in the backbone of IgGl when the antibody has been glycosylated at position N297 (Kabat EU numbering) of the heavy chain.
  • bacterial transglutaminase can be used for the conjugation of an amine-donor substrate, for example a drug-linker construct, at an acceptor glutamine residue of an antibody.
  • acceptor glutamines can be introduced by engineering of the antibody by mutations or by the generation of aglycosylated antibodies.
  • aglycosylated antibodies can be introduced by deglycosylation using N-glycosidase F (PNGase F) or by mutation of N297 of the glycosylation site of the heavy chain (Kabat EU numbering) to any other amino acid except N.
  • PNGase F N-glycosidase F
  • Kabat EU numbering mutation of N297 of the glycosylation site of the heavy chain
  • the chemical modification strategy utilized to create AOCs described herein is lysine conjugation.
  • Lysine residues in proteins, e.g., antibodies possess a primary amine group (-NH2) in their side chains, making them suitable targets for chemical modification.
  • This primary amine group can react with various chemical reagents, including small molecules or polymers (e.g., cleavable and non-cleavable linkers).
  • lysine conjugation can be either site-specific or random.
  • site-specific conjugation specific lysine residues within a protein, e.g., antibody, can be targeted ensuring precise control over the modification.
  • random conjugation involves modifying lysine residues without selectivity.
  • Example 27 shows greater uptake of 3E10-D31N monoclonal antibody (V66) oligonucleotide conjugates utilizing transglutaminase-mediated enzymatic conjugation in A427 cells, and in Example 28, which utilize hindered disulfide linker (SPDMV) conjugate (transglutaminase-SPDMV), and imparted the highest exon-skipping (-15%), representing a greater than 10X improvement over lysine-PEG8 AOC.
  • SPDMV hindered disulfide linker
  • the conjugation strategy is selected from one of the following: a. Lysine Attachment
  • the linker moiety is conjugated to the antibody or antigen binding fragment therein through an amine linkage at one or more surface-exposed lysine residues on the antibody or antigen binding fragment thereof.
  • lysine conjugation is a random process, with respect to which lysines are conjugated to the liker- payload.
  • some preference for conjugation at certain lysines can occur due to the context of the primary, secondary, ternary, and/or quaternary structure surrounding a particular lysine residue.
  • Many different chemistries are known in the art for attaching payloads to proteins at lysine groups.
  • activated esters on the drug-linker complexes can react with the antibody lysine residues and achieve conjugation via amide bonds, or stable amidine bonds can be generated on an antibody by the reaction of imido ester compounds, such as Traut’s reagent, with antibody lysine residues.
  • O-succinimide reagents such as N-hydroxysuccinimidyl (NHS) or sulfo-NHS esters
  • the present disclosure provides pharmaceutical compositions comprising an antibody-oligonucleotide conjugate (AOC) having the formula A-(L- Pr) q , where: A is a 3E10 antibody or antigen-binding fragment thereof as described herein, L is a linker as described herein, P is an oligonucleotide moiety as described herein, r is an integer from 1 to 4, and q is an integer from 1 to 16, in which L is conjugated to A through lysine moieties.
  • AOC antibody-oligonucleotide conjugate
  • a composition comprising an AOC where lysine attachment is used to conjugate the drug to the antibody or antigen binding fragment thereof as described herein will have an average DAR of at least 4 (an average of at least four drug moieties attached to each antibody).
  • such a composition will have an average DAR of at least 6.
  • such a composition will have an average DAR of at least 8.
  • such a composition will have an average DAR of at least 10.
  • such a composition will have an average DAR of at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, or more.
  • a composition comprising an AOC where lysine attachment is used to conjugate the drug to the antibody or antigen binding fragment thereof as described herein, r is 1 and q is at least 4. In some embodiments, r is 1 and q is at least 6. In some embodiments, r is 1 and q is at least 8. In some embodiments, r is 1 and q is at least 10. In some embodiments, r is 1 and q is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, or more.
  • a composition comprising an AOC where lysine attachment is used to conjugate the drug to the antibody or antigen binding fragment thereof as described herein, r is 2 (e.g., the linker is a branched linker) and q is at least 2. In some embodiments, r is 2 and q is at least 3. In some embodiments, r is 2 and q is at least 4. In some embodiments, r is 2 and q is at least 5. In some embodiments, r is 2 and q is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, or more.
  • a composition comprising an AOC where lysine attachment is used to conjugate the drug to the antibody or antigen binding fragment thereof as described herein, the linker is highly branched, e.g., r is at least 3. In some embodiments, r is at least 4. In some embodiments, r is at least 5, 6, 7, 8, or more.
  • lysine conjugation can be either site-specific or random.
  • site-specific conjugation specific lysine residues within a protein, e.g., antibody, can be targeted ensuring precise control over the modification.
  • random conjugation involves modifying lysine residues without selectivity.
  • Example 6 shows greater uptake of 3E10-D31N monoclonal antibody (V66) oligonucleotide conjugates utilizing transglutaminase-mediated enzymatic conjugation in A427 cells, and in Example 7, which utilize hindered disulfide linker (SPDMV) conjugate (transglutaminase- SPDMV), and imparted the highest exon-skipping (-15%), representing a greater than 10X improvement over lysine-PEG8 AOC.
  • SPDMV hindered disulfide linker
  • the linker moiety is conjugated to the antibody or antigen binding fragment therein through a sulfide linkage at one or more surface-exposed cysteine residues on the antibody or antigen binding fragment thereof. In some embodiments of AOCs described herein, the linker moiety is conjugated to the antibody or antigen binding fragment therein through a thiol side chain of one or more cysteine residues on the antibody or antigen binding fragment thereof.
  • antibodies do not possess free thiols, and all cysteine residues form disulfide bonds.
  • human IgGl which is commonly used in modem ADCs, there are 4 interchain and 12 intrachain disulfide bonds.
  • the 4 interchain disulfides which are generally not critical for structural stability of IgGl, can be selectively reduced under mild conditions to give 2, 4, 6, or 8 free thiols while keeping the 12 intrachain disulfides intact. Due to the limited number of conjugation sites and the distinct reactivity of the thiol group, cysteine-based conjugation allows for controlled DAR and heterogeneity. Engineered Cys residues can also be used for site specific conjugation without the partial reduction of the endogenous disulfide bonds using, e.g., EnCys-mAb technology. Many different chemistries are known in the art for attaching payloads to proteins at cystine groups.
  • 8 nucleophilic cysteine residues can first be liberated from the reduced inter-chain disulfide bonds via reducing agents and later conjugated with drug-linker complexes.
  • This approach generates ADCs with heterogeneous conjugation sites and a different number of drugs attached, resulting in a drug to antibody ratio (DAR) ranging from 0 ⁇ 8.
  • DAR drug to antibody ratio
  • DTT dithiothreitol
  • TCEP tri s(2-carboxy ethyl) phosphine
  • DTNB 5,5 ’ -dithiobis (2-nitrobenzoic acid)
  • the present disclosure provides pharmaceutical compositions comprising an antibody-oligonucleotide conjugate (AOC) having the formula A-(L- Pr)q, where: A is a 3E10 antibody or antigen-binding fragment thereof as described herein, L is a linker as described herein, P is an oligonucleotide moiety as described herein, r is an integer from 1 to 4, and q is an integer from 1 to 16, in which L is conjugated to A through cysteine moi eties.
  • AOC antibody-oligonucleotide conjugate
  • AOC antibody-oligonucleotide conjugate having the formula A-(L- Pr)q, where: A is a 3E10 antibody or antigen-binding fragment thereof as described herein, L is a linker as described herein, P is an oligonucleotide moiety as described herein, r is an integer from 1 to 4, and q is an integer from 1 to 16, in which L is conjugated to A through cysteine moi eties
  • a composition comprising an AOC where cysteine attachment is used to conjugate the drug to the antibody or antigen binding fragment thereof as described herein will have an average DAR of at least 2.
  • such a composition will have an average DAR of at least 3.
  • such a composition will have an average DAR of at least 4.
  • such a composition will have an average DAR of at least 5.
  • such a composition will have an average DAR of at least 6.
  • such a composition will have an average DAR of at least 7.
  • such a composition will have an average DAR of about 8.
  • such a composition will have an average DAR of at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or about 8.
  • a composition comprising an AOC where cysteine attachment is used to conjugate the drug to the antibody or antigen binding fragment thereof as described herein, r is 1 and q is at least 2. In some embodiments, r is 1 and q is at least 3. In some embodiments, r is 1 and q is at least 4. In some embodiments, r is 1 and q is at least 5. In some embodiments, r is 1 and q is at least 6. In some embodiments, r is 1 and q is at least 7. In some embodiments, r is 1 and q is about 8. In some embodiments, r is 1 and q is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or 8.
  • a composition comprising an AOC where cysteine attachment is used to conjugate the drug to the antibody or antigen binding fragment thereof as described herein, r is 2 (e.g., the linker is a branched linker) and q is at least 2. In some embodiments, r is 2 and q is at least 3. In some embodiments, r is 2 and q is at least 4. In some embodiments, r is 2 and q is at least 5. In some embodiments, r is 2 and q is at least 6. In some embodiments, r is 2 and q is at least 7. In some embodiments, r is 2 and q is about 8.
  • r is 2 and q is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or about 8.
  • a composition comprising an AOC where cysteine attachment is used to conjugate the drug to the antibody or antigen binding fragment thereof as described herein, the linker is highly branched, e.g., r is at least 3.
  • r is at least 4.
  • r is at least 5, 6, 7, 8, or more.
  • the linker moiety is conjugated to the antibody or antigen binding fragment therein through the primary amide side chain of one or more glutamine residues on the antibody or antigen binding fragment thereof.
  • transglutaminase derived from Streptomyces mobaraensis catalyzes transpeptidation where a primary amine-containing linker is covalently attached to the primary amide side chain of a specific glutamine (Q295) within deglycosylated antibodies, resulting in ADCs with a defined DAR of 2 (one conjugation site per heavy chain)
  • ADCs with a defined DAR of 2 (one conjugation site per heavy chain)
  • the present disclosure provides pharmaceutical compositions comprising an antibody-oligonucleotide conjugate (AOC) having the formula A-(L- P r)q, where: A is a 3E 10 antibody or antigen-binding fragment thereof as described herein, L is a linker as described herein, P is a payload moiety as described herein, r is an integer from 1 to 4, and q is an integer from 1 to 16, in which L is conjugated to A through glutamine moieties.
  • AOC antibody-oligonucleotide conjugate
  • a composition comprising an AOC where glutamine attachment is used to conjugate the drug to the antibody or antigen binding fragment thereof as described herein will have an average Drug Antibody Ratio (DAR) of about 2.
  • DAR Drug Antibody Ratio
  • such a composition will have an average DAR of at least 2.
  • such a composition will have an average DAR of at least 3.
  • such a composition will have an average DAR of about 4.
  • such a composition will have an average DAR of about 2, at least 2, at least 3, or about 4.
  • a composition comprising an AOC where glutamine attachment is used to conjugate the drug to the antibody or antigen binding fragment thereof as described herein r is 1 and q is about 2. In some embodiments, r is 1 and q is at least 2. In some embodiments, r is 1 and q is at least 3. In some embodiments, r is 1 and q is about 4. In some embodiments, r is 1 and q is about 2, at least 2, at least 3, or about 4. In some embodiments, a composition comprising an AOC where glutamine attachment is used to conjugate the drug to the antibody or antigen binding fragment thereof as described herein, r is 2 (e.g., the linker is a branched linker) and q is about 2.
  • r is 2 and q is at least 2. In some embodiments, r is 2 and q is at least 3. In some embodiments, r is 2 and q is about 4. In some embodiments, r is 2 and q is about 2, at least 2, at least 3, or about 4. In yet other embodiments, a composition comprising an AOC where cysteine attachment is used to conjugate the drug to the antibody or antigen binding fragment thereof as described herein, the linker is highly branched, e.g., r is at least 3. In some embodiments, r is at least 4. In some embodiments, r is at least 5, 6, 7, 8, or more.
  • the linker is a cleavable linker.
  • cleavable linker refers to a linker which can connect two or more molecules and then be cleaved once exposed to an agent.
  • Cleavable linkers can include chemically or enzymatically unstable or degradable linkages.
  • Cleavable linkers generally rely on processes inside the cell to liberate the drug, such as reduction in the cytoplasm, exposure to acidic conditions in the lysosome, or cleavage by specific proteases or other enzymes within the cell.
  • Cleavable linkers generally incorporate one or more chemical bonds that are either chemically or enzymatically cleavable while the remainder of the linker is non-cleavable.
  • the cleavable linker is an acid-labile linker, a phosphatase linker, glucuronidase linker, a cathepsin-B cleavable linker, a cathepsin-L cleavable linker, a protease-sensitive linker, a photo-labile linker, or a disulfide (SPDMV) transglutaminase- containing linker.
  • SPDMV disulfide
  • the cleavable linker is selected from the group consisting of succinyl, O-succinyl, 4-succinimidyl-oxycarbonyl-a-(2-pyridyldithio)toluene, sulfosuccinimidyl 6-(3’-(2-pyridyldithio)propionamido)hexanoate, N-succinimidyl-3-(-2-pyridyldithio)- proprionate, succinimidyl 6-(3(2-pyridyldithio)propionamido)hexanoate, 3-(2-pyridyldithio)- propionyl hydrazide, S-(2-thiopyridyl)-L-cysteine, N-succinimidyl 4-(2-pyridyldithio)butanoate (SPDB) (CAS: 115088-06-7), N-
  • the cleavable linker is a homo-bi-functional linker, optionally comprising an alkyl or polyethylene glycol (PEG) chain.
  • the linker length of the polyethylene glycol (PEG) chain is 4 PEG molecules, i.e., PEG4.
  • the PEG chain is PEG8.
  • the PEG chain is PEG12.
  • the cleavable homo-bi-functional linker is selected from the group consisting of DSP (Lomant’s Reagent) (CAS: 57757-57-0) and Acid-PEG4-S-S-PEG4- Acid (CAS: 2055015-40-0).
  • linkers which contain cleavable disulfide bonds include, but are not limited to “DPDPB”, l,4-di-[3’-(2’-pyridyldithio) propionamido]butane; “SADP”, (N- succinimidyl (4-azidophenyl) l,3’-dithio propionate); “Sulfo-SADP” (Sulfosuccinimidyl (4-azi- dophenyldithio) propionate; “DSP”-Dithio bis (succinimidylproprionate); “DTSSP”-3,3’-Dithio bis (sulfosuccinimidylpropionate); “DTBP” -dimethyl 3,3dithiobispropionimidate-2HCI.
  • linkers cleavable by oxidation include “DST’-disuccinimidyl tartarate; and “S-S-(S-
  • the linker L is selected from:
  • the linker L is selected from:
  • the linker moiety is conjugated to the antibody or antigen binding fragment therein through a cathepsin-cleavable linker.
  • AOCs can enter cells via receptor-mediated endocytosis, during intracellular transit or trafficking, and thus they may ultimately encounter the acidic degradative environment of the lysosome which contains multiple proteases and other catalytic enzymes for breakdown of internalized biologic substances.
  • cleavable linkers therefore leverage an attribute of the lysosome for payload release such as lability to low pH environment, disulfide reducing environment, or cleavage by a lysosomal protease such as cathepsin B.
  • Protease cleavable linkers or (peptide linkers) typically contain a dipeptide sequence based on deduced canonical cleavage specificity for a given protease. Common dipeptide sequences are Valine-Citrulline or Valine- Alanine. These linkers have been used frequently for conjugation of both ADCs and AOCs.
  • the payloads Upon release via linker cleavage, the payloads then require escape from the endosome to traffic to the specific subcellular region in order to mediate an effect.
  • 3E10 and its derivatives are anti-DNA antibodies with the unique property of direct cell entry and subsequent trafficking to the nucleus of cells. This occurs via interaction of antibody UNA complexes with the cell surface transporter ENT2 (equilibrative nucleoside transporter-2) and so does not require the classical endocytic mechanism employing clathrin or dynamin mediated internalization. Further, upon internalization, the antibody does not encounter early or late endosomes and, importantly, does not encounter the harsh environment of the lysosome. As a result, trafficking occurs directly to the nucleus.
  • an AOC described herein comprises a cleavable linker for which the catalytic agent is present within the within the nucleus for selective release within that organelle.
  • cysteine protease Cathepsin L can also be present within the nucleus of cells. See, e.g., Goulet et al., “Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation,” Mol Cancer Res. 2007 Sep;5(9):899-907, incorporated herein by reference in its entirety.
  • This ubiquitous protease has previously been shown to be present primarily in lysosomes as well as in secreted form.
  • Translation initiation within the cathepsin L mRNA for both mouse and human cells has been shown to take place at alternative internal start sites resulting in a polypeptide lacking an NH2-terminal signal peptide.
  • Other cathepsins typically identified in lysosomes have also been identified in the nucleus, including cathepsin D, cathepsin V, and cathepsin B.
  • a nuclear form of the cysteine protease cathepsin-L is found in mouse tumor cells (and also in human tumor cells) (Goulet et al., “Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation,” Mol Cancer Res. 2007 Sep;5(9):899-907; and Soond et al., “Lost or Forgotten: The nuclear cathepsin protein isoforms in cancer,” Cancer Lett. 2019 Oct 10;462:43-50, each incorporated herein by reference in their entireties. Indeed there have been identified several proteases identified that localize to the nucleus but cathepsin-L is most prominent. Further, in cancer cells cathepsin-L appears to play a significant role in cell cycle progression and importantly tumor progression and metastasis.
  • AOCs disclosed herein comprise dipeptides that are substrates for proteolytic cleavage by nuclear localized cathepsins, optionally cathepsin L, cathepsin S, cathepsin D, cathepsin V, and/or cathepsin B.
  • the present disclosure provides an antibody-oligonucleotide conjugate (AOC) having the formula A-(L-P r ) q , where: A is a 3E 10 antibody or antigen-binding fragment thereof as described herein (e g., as described in the section titled 3E10 Antibodies and Antigen-Binding Fragments), L is a cathepsin-cleavable linker, P is a payload moiety, r is an integer from 1 to 4 and q is an integer from 1 to 16. In some embodiments, L is a cathepsin L- cleavable linker. In some embodiments, L is a cathepsin S-cleavable linker.
  • AOC antibody-oligonucleotide conjugate
  • L is a cathepsin D-cleavable linker. In some embodiments, L is a cathepsin B-cleavable linker. In some embodiments, L is a cathepsin V-cleavable linker.
  • L comprises a dipeptide selected from Phe-Gln, Val-Gln, Leu- Gln, Tyr-Met, Phe-Arg, Phe-Gly, Trp-Thr, Tyr-Gly, Phe-Thr, Val-Gly, Val-Cit, Val-Arg, Thr-Thr, and Val-Thr.
  • L further comprises one or more PEG molecules.
  • the linker is a non-cleavable linker.
  • “non-cleavable linker” refers to linkers where the release of the biologically active molecule does not depend on, for example, the differential properties between the plasma and some cytoplasmic compartments, or whether the linker has a physical property that permits enzymatic cleavage or chemical cleavage.
  • Non-cleavable linkers can be alkylene chains, or can be polymeric in nature, such as, for example, those based upon polyalkylene glycol polymers, amide polymers, or can include segments of alkylene chains, polyalkylene glycols and/or amide polymers.
  • the non-cleavable linker is selected from DBCO-C6-NHS ester (CAS: 1384870-47-6) and DBCO- PEG8-NHS ester.
  • the non-cleavable linker is a homo-bi-functional linker, optionally comprising an alkyl or polyethylene glycol (PEG) chain.
  • the non- cleavable homo-bi-functional linker is selected from DSS (CAS: 68528-80-3) and Bis-PEG8-NHS ester.
  • non-cleavable linkers can include N-succinimidyl (4-iodoacetyl)- aminobenzoate, sulfosuccinimidyl(4-iodoacetyl)-aminobenzoate, dichlorotriazinic acid, N- succinimidyl-[(N-maleimidopropionamido)-tetraethyleneglycol] ester (NHS-PEG4-maleimide), N-succinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (SMCC), or N-sulfosuccinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (sulfoSMCC).
  • NHS-PEG4-maleimide N-succinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate
  • sulfoSMCC N-sulfosuccinimid
  • non-cleavable linkers are “Sulfo-LC-SMPT”- (sulfosuccinimidyl 6-[alphamethyl-alpha-(2-pyridylthio) toluamido ⁇ hexanoate; “SMPT” - 4- succinimidyloxycarbonyl-alpha-methyl-a(2-pyridyldithio)toluene; “ABH”-Azidobenzoyl hydrazide; “NHS-ASA”-N-Hydroxysuccinimidyl-4-azi dosalicyclic acid; “SASD”- Sulfosuccinimidyl 2-(pazidosali- cylamido)ethyl-l,3-dithiopropionate; “APDP”-N- ⁇ 4-(p-azi dosalicylamido) buthy ⁇ -3’ (2’-pyidyldithio)propion
  • Bifunctional chemical linkers include 4-succinimidyl-oxycarbonyl-C-(2- pyridyldithio) toluene; sulfosuccinimidyl-6-O-methyl-O-(pyridyldithiol)-toluamidohe-xanoate; N-succinimidyl-3(2-pyridyldithio)-propri onate; succinimidyl-6-3(-(-2-pyridyldithio)- proprionamidohexanoate; sulfosuccinimidyl-6-3 (-(-2-pyridyldithio)-propionamido hexanoate; 3- (2-pyridyldithio)-propionyl hydrazide, Ellman’s reagent, dichlorotriazinic acid, S-(2-thiopyridyl)- Lcysteine,
  • cross-linking agents there are a large number of chemical cross-linking agents that are known to those skilled in the art and useful for cross-linking portions of a conjugate.
  • the cross-linking agents are heterobifunctional cross-linkers, which can be used to link molecules in a stepwise manner.
  • Heterobifunctional crosslinkers provide the ability to design more specific coupling methods for conjugating, thereby reducing the occurrences of unwanted side reactions such as homo-protein polymers.
  • a wide variety of heterobifunctional cross-linkers are known in the art, including succinimidyl 4-(N-maleimidomethyl) cyclohexane- 1 -carboxylate (SMCC), m-Maleimidobenzoyl N-hydroxysuccinimide ester (MBS); N- succinimidyl (4-iodoacetyl) aminobenzoate (SIAB); succinimidyl 4-(p-ma-30 leimidophenyl) butyrate (SMPB); l-ethyl-3-(3- dimethylaminopropyl) carbodiimide hydrochloride (EDC); 4-succinimidyloxycarbonyl-a-methyl-a-(2-pyridyldithio)- tolune (SMPT); N-succinimidyl 3-(2-pyridyldithio) propi onate (SPDP); succinimidyl 6-[3-(2- pyridyl
  • cross-linking agents having N- hydroxysuccinimide moieties can be obtained as the N-hydroxysulfosuccinimide analogs, which generally have greater water solubility.
  • those cross-linking agents having disulfide bridges within the linking chain can be synthesized instead as the alkyl derivatives so as to reduce the amount of linker cleavage /// vivo.
  • heterobifunctional cross-linkers there exists a number of other cross-linking agents including homobifunctional and photoreactive cross- linkers.
  • DSS Di succinimidyl subcrate
  • BMH bismaleimidohexane
  • DMP dimethylpimelimidate 2 HC1
  • BASED bis-[B-(4- azidosalicylamido)ethyl]disul fide
  • BASED bis-[B-(4- azidosalicylamido)ethyl]disul fide
  • SANPAH N-succinimidyl-6(4’-azido-2’-nitrophe nylamino)hexanoate
  • One class of heterobifunctional cross-linkers contain the primary amine reactive group, N-hydroxysuccinimide (NHS), or its water soluble analog N- hydroxysulfosuccinimide (sulfa-NHS).
  • NHS N-hydroxysuccinimide
  • sulfa-NHS water soluble analog N- hydroxysulfosuccinimide
  • Primary amines lysine epsilon groups
  • alkaline pH is unprotonated and react by nucleophilic attack on NHS or sulfa-NHS esters. This reaction results in the formation of an amide bond, and release of NHS or sulfa-NHS as a byproduct.
  • Another reactive group useful as part of a hetero bifunctional cross-linker is a thiol reactive group.
  • Common thiol reactive groups include maleimides, halogens, and pyridyl disulfides.
  • Maleimides react specifically with free sulfhydryls (cysteine residues) in minutes, under slightly acidic to neutral (pH 6.5-7.5) conditions.
  • Halogens iodo acetyl functions
  • the universal antibody-oligonucleotide conjugate (AOC) provided herein comprises a linker attachment schema selected from the group consisting of: conjugation to exposed lysines, cysteine conjugation following modest reduction of 3E10, engineering free cysteines (e.g., at the C-terminus), site-specific transglutaminase linkage, wherein the linkage can further comprise click chemistry, and any combination thereof.
  • an AOC provided herein further comprises a linker attachment schema comprising engineering free cysteines (e.g., at the C-terminus).
  • an AOC provided herein comprises an antibody that is cysteine-engineered at the site of linker attachment.
  • an AOC provided herein comprises a cleavable linker comprising a cleavable disulfide bond.
  • an AOC provided herein comprises a linker wherein the linker is a hindered linker, wherein the linker comprises a carbon atom bearing a sulfur capable of forming a disulfide bond, and wherein the carbon atom is substituted with at least one substituent other than H.
  • the substituent comprises a hydrocarbyl or a substituted hydrocarbyl moiety.
  • the linker L is selected from: [0398] In some embodiments, the linker L is selected from:
  • the present disclosure provides an antibody-oligonucleotide conjugate (AOC) having the formula A-(L-P r )q, wherein: A is a 3E10 antibody or antigen-binding fragment thereof, L is a linker, P is an oligonucleotide moiety described herein, r is an integer from 1 to 4, and q is an integer from 1 to 16.
  • AOC antibody-oligonucleotide conjugate
  • the term “therapeutic oligonucleotide” refers to an oligonucleotide that has a biological, a cytotoxic, or a therapeutic effect in a cell.
  • the therapeutic oligonucleotide is a functional nucleic acid, such as an oligonucleotide or a polynucleotide.
  • a 3E10 antibody or antigen-binding fragment thereof described herein is used to deliver a gene-regulating polynucleotide that inhibits, reduces or silences expression a gene product that promotes cancer growth and/or progression, e.g., by targeting the gene or a transcript thereof.
  • gene-regulating polynucleotides include siRNAs and antisense oligonucleotides.
  • compositions described herein comprise a conjugate, comprising a 3E10 antibody or antigen-binding fragment thereof conjugated through a cleavable linker to an siRNA molecule that targets cMyc mRNA.
  • compositions described herein comprise a conjugate, comprising a 3E10 antibody or antigen-binding fragment thereof conjugated through a non-cleavable linker to an siRNA molecule that targets cMyc mRNA.
  • the Small interfering RNA also known as short interfering RNA or silencing RNA, is a class of double-stranded non-coding RNA molecules, typically from about 20 to about 27 nucleotides in length, from about 8 to about 50 nucleotides in length or from about 10 to about 30 nucleotides in length, and is processed within the RNA interference (RNAi) pathway.
  • RNAi RNA interference
  • an siRNA molecule comprises at least one 2' modified nucleotide, at least one modified internucleotide linkage, at least one inverted abasic moiety, or any combination thereof.
  • nucleic acid drugs such as siRNA can regulate post- transcriptional gene expression, and silence target genes, such as those involved in signaling pathways associated with cancer progression. See, for example, Zhou et al., Delivery of nucleic acid therapeutics for cancer immunotherapy, Medicine in Drug Discovery, March 24, 2020; and Dahlman et al., In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight, Nature Nanotechnol. 2014;9(8):648-55, the disclosures of which are incorporated herein by reference in their entireties for all purposes.
  • siRNAs may be used for modulating the expression of immune checkpoint molecules, such as those described herein, by regulating the post-translational gene expression and/or silencing corresponding genes.
  • siRNAs can be used for indirectly regulating the activity of immune checkpoint molecules by modulating the expression of agonists or inhibitors of immune checkpoint molecules.
  • compositions for treatment of cancer described herein include a conjugate, comprising a 3E10 antibody or antigen-binding fragment thereof conjugated through a cleavable linker to an siRNA molecule that targets cMyc mRNA.
  • compositions for treatment of cancer described herein includes a conjugate, comprising a 3E10 antibody or antigen-binding fragment thereof conjugated through a non-cleavable linker to an siRNA molecule that targets cMyc mRNA.
  • siRNAs can similarly be used for silencing genes regulating tumor growth or angiogenesis.
  • siRNAs have been used to target vascular endothelial growth factor (VEGF) and kinesin spindle protein (KSP) (for solid tumors, e.g., liver metastasis from colon cancer).
  • VEGF vascular endothelial growth factor
  • KSP kinesin spindle protein
  • siRNAs include, but are not limited to, genes encoding protein kinase N3 (PKN3) (e.g., for metastatic pancreatic cancer), M2 subunit of ribonucleotide reductase (RRM2) (e.g., for solid tumors), Myc oncoprotein (e.g., for hepatocellular carcinoma), ephrin type-A receptor 2 (EphA2) (e.g., for advanced cancers), and KRAS G12D mutation (e.g., for advanced pancreatic cancers).
  • PDN3 protein kinase N3
  • Myc oncoprotein e.g., for hepatocellular carcinoma
  • EphA2 ephrin type-A receptor 2
  • KRAS G12D mutation e.g., for advanced pancreatic cancers.
  • siRNA and associated cancer types are provided in Table 1A below. See, for example, Xiong H. et al., Int. J. Mol. Sci., 22(7):3295 (2021), the disclosure of which is incorporated herein by reference in its entirety for all purposes.
  • Table 1A Example siRNA and associated cancer types
  • Table IB Non-limiting example sequences of siRNA oligonucleotide molecules for use in treating various disorders are provided in Table IB below.
  • Table IB Example siRNA oligonucleotide sequences and associated disorders
  • compositions described herein comprise a conjugate, comprising a 3E10 antibody or an antigen-binding fragment thereof conjugated through a cleavable linker to an antisense oligonucleotide.
  • compositions described herein comprise a conjugate, comprising a 3E10 antibody or an antigen-binding fragment thereof conjugated through a non-cleavable linker to an antisense oligonucleotide.
  • ASOs Antisense oligonucleotides
  • an ASO is a single-stranded sequence complementary to the sequence of the target gene’s transcribed messenger RNA (mRNA) within a cell.
  • mRNA messenger RNA
  • An ASO targets the corresponding mRNA to degrade the targeted complex by mechanisms such as endogenous cellular RNase H.
  • ASO being used for cancer therapy
  • an ASO targeting CD39 mRNA resulting in an increase in CD8+ T cell proliferation, thereby improving antitumor immune responses. See, for example, Zhou, et al. Delivery of nucleic acid therapeutics for cancer immunotherapy. Medicine in Drug Discovery, 6 (2020) 100023, the disclosure of which is incorporated herein by reference in its entirety for all purposes.
  • the binding (e.g., hybridization) of the oligonucleotide, e.g., siRNA or ASO of an antibody-oligonucleotide conjugate, to target mRNA leads to degradation of the target mRNA or blocks translation of the target mRNA.
  • the binding of the oligonucleotide to the target mRNA creates a duplex nucleic acid molecule, which then recruits an endogenous nuclease for degradation of the mRNA.
  • the oligonucleotide has a stretch of DNA nucleotides sufficient to recruit RNaseH, and thereby trigger degradation of the target mRNA.
  • the oligonucleotide may have a stretch (e.g., a central stretch) of at least 6 or at least 8 DNA nucleotides, and which is optionally a stretch of 9 or 10 DNA nucleotides.
  • one or more DNA and/or RNA nucleotides comprise a 2’ chemical modification independently selected from 2’-Fluoro, 2’-Methyl, and 2’-Ethyl.
  • a siRNA or an ASO may have a design.
  • the antisense oligonucleotide may be a gapmer (i.e., have a gapmer design) having a 5’ and a 3’ segment, each of the 5’ and 3’ segments independently being from 2 to 6 nucleotides or from 2 to 4 nucleotides, and where the 5’ and 3’ segments do not contain DNA nucleotides.
  • the gapmer is a 3-8-3 gapmer, having a central block of DNA nucleotides and 5' and 3 ' segments of 3 RNA nucleotides each.
  • the gapmer is a 2-10-2 gapmer, having a central block of 10 DNA nucleotides and a 5' and 3' segments of 2 RNA nucleotides each. Additional non-limiting examples of gapmer designs are described in U.S. Patent Appl. Publ. No. 2012/0322851.
  • one or more nucleotides of the 5’ segment and the 3’ segment comprise 2’-0 substituents, optionally where all of the nucleotides of the 5’ segment and the 3’ segment comprise 2’-0 substituents.
  • Exemplary 2’-0 substituents are independently selected from 2’-0 methyl, 2’-0 ethyl, 2’-0 methoxyethyl (MOE), and a bridged nucleotide (e.g., a locked or bi-cyclic nucleotide) having a 2’ to 4’ bridge.
  • the bridged nucleotide has a methylene bridge (LNA) or a constrained ethyl bridge (cEt).
  • LNA methylene bridge
  • cEt constrained ethyl bridge
  • 2' modified nucleosides please see e.g. Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429- 4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3(2), 293-213, and Deleavey and Damha, Chemistry and Biology 2012, 19, 937.
  • the term “gapmer” refers to an oligonucleotide having a central block of deoxynucleotides (also referred to herein as “DNA nucleotides”) with 5' and 3' segments (of at least 2 nucleotides) of RNA nucleotides.
  • DNA nucleotide refers to a nucleotide that is not an RNA nucleotide.
  • DNA nucleotides typically have a 2’ H, but may alternatively have various 2’ chemical modifications, including 2’-halo and 2’-lower alkyl (e.g., Cl -4).
  • the 2’ chemical modifications of DNA nucleotides are independently selected from 2’-Fluoro, 2’-Methyl, and 2’-Ethyl.
  • the oligonucleotide has a modified backbone or modified internucleotide linkages.
  • internucleotide linkage refers to the linkage between two adjacent nucleosides in a polynucleotide molecule.
  • the internucleotide linkage is a phosphodiester bond that forms between two oxygen atoms of the phosphate group and an oxygen atom of the sugar (either at 3’ or 5’ position) to form two ester bonds bridging between the two adjacent nucleosides.
  • Modification of the intemucleotide linkage may provide different characteristics, including but not limited to enhanced stability.
  • phosphorothioate or phosphorodithioate linkages increase the resistance of the internucleotide linkage to nucleases.
  • PACE phosphoacetate linkage
  • Internucleotide linkages and oligonucleotide backbone modifications which may be employed in the oligonucleotides of the present description include, but are not limited to, phosphodiester, phosphorothioate, phosphorodithioate, methylphosphonate, alkylphosphonate, alkylphosphonothioate, phosphotriester, phosphoramidate, phosphoramidite, phosphorodiamidate, siloxane, carbonate, carboalkoxy, acetamidate, carbamate, morpholino, peptide nucleic acid, borano, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphorothioate, and sulfone intemucleoside linkages.
  • the oligonucleotide comprises one or more phosphorothioate or phosphorodithioate nucleotides. [0424] In some embodiments, the oligonucleotide comprises one or more phosphorothioate or phosphorodithioate internucleotide linkages. In some embodiments, phosphorothioate or phosphorodithioate bonds can be introduced between the last three to five nucleotides at the 5’- and/or 3 ’-end of the oligonucleotide to reduce exonuclease degradation.
  • the oligonucleotide has a combination of phosphodiester and phosphorothioate/phosphorodithioate linkages. In some embodiments, the oligonucleotide contains at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten phosphorothioate or phosphorodithioate internucleotide linkages. In some embodiments, the oligonucleotide comprises substantially alternating phosphodiester and phosphorothioate internucleotide linkages. In some embodiments, the oligonucleotide is fully phosphorothioate/phosphorodithioate linked (i.e., all bonds are either phosphorothioate or phosphorodithioate).
  • the oligonucleotide may contain one or more modified bases.
  • cytosine is replaced with 5-methylcytosine, which may enhance base pairing.
  • Other modified bases can be employed to reduce immunogenicity, where needed.
  • Other modified bases are described in US Patent No. 10,064,959, which is hereby incorporated by reference.
  • cytidine nucleobases in the oligonucleotide are 5-methyl cytidine.
  • C cytidine nucleobase
  • U includes pseudouridine and N1 -methylpseudouridine.
  • the present disclosure provides an antibody-oligonucleotide conjugate (AOC) having the formula A-(L-P r )q, wherein: A is a 3E10 antibody or antigen-binding fragment thereof, L is a linker, P is an ASO described herein, r is an integer from 1 to 4, and q is an integer from 1 to 16.
  • AOC antibody-oligonucleotide conjugate
  • Table 7 Example sequences of oligos for use in treating various disorders.
  • Table 8 Example single stranded oligonucleotide sequences capable of inducing exon skipping for use in treating DMD.
  • the ASO comprises a sequence selected from Tables 6-8. In some embodiments, the ASO comprises a sequence selected from SEQ ID NOs: 201-1031. In some embodiments, any of the nucleic acids of Table 6-8 can be linked to any 3E10 antibody or antigen-binding fragment thereof described herein via any linker described herein. In some embodiments, any of the nucleic acids of Table 6-8 is linked to any 3E10 antibody or antigen- binding fragment thereof described herein via a cathepsin L cleavable linker.
  • any of the nucleic acids of Table 6-8 is linked to any 3E10 antibody or antigen- binding fragment thereof described herein via a cleavable linker comprising a -Phe-Gln- dipeptide. In some embodiments, any of the nucleic acids of Table 6-8 is linked to any 3E10 antibody or antigen-binding fragment thereof described herein via a cleavable linker comprising a -Val-Gln- dipeptide. In some embodiments, any of the nucleic acids of Table 6-8 is linked to any 3E10 antibody or antigen-binding fragment thereof described herein via a cleavable linker comprising a -Leu-Gin- dipeptide.
  • the present disclosure provides an antibody-oligonucleotide conjugate (AOC) having the formula A-(L-P r ) q , wherein: A is a 3E10 antibody or antigen-binding fragment thereof, L is a linker, P is an oligonucleotide moiety described herein, r is an integer from 1 to 4, and q is an integer from 1 to 16.
  • AOC antibody-oligonucleotide conjugate
  • L is a cathepsin-L cleavable linker
  • A is an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60.
  • the cathepsin-L cleavable linker comprises a -Phe-Gln- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Val-Gln- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Leu-Gin- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Tyr-Met- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Phe-Arg- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Phe-Gly- dipeptide. In some embodiments, the cathepsin-L comprises cleavable linker comprises a -Trp-Thr- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Tyr-Gly- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Phe-Thr- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Val-Gly- dipeptide. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a heavy chain variable region (VH) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO:90.
  • VH heavy chain variable region
  • VL light chain variable region
  • the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:69 and a VL with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:90. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 69 and a VL with an amino acid sequence having at least 99% sequence identity to SEQ ID NO:90. In some embodiments, the cathepsin-L cleavable linker is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the cathepsin-L cleavable linker is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cathepsin-L cleavable linker is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the cathepsin-L cleavable linker is an un- branched linker.
  • the cathepsin-L cleavable linker is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms.
  • the branched linker has four arms.
  • the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cathepsin-L cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cathepsin-L cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the cancer cells express the ENT2 transporter protein. In some embodiments, the cancer cells express functional ENT2, wherein the ENT2 nucleoside salvage pathway is not disrupted such that nucleic acid molecules and the 3E10 antibody or antigen-binding fragment thereof with nucleic acid molecules can enter the cells via the ENT2 transporter.
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl-dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cathepsin-L cleavable linker
  • A is an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5.
  • the cathepsin-L cleavable linker comprises a -Phe-Gln- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Val-Gln- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Leu-Gin- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Tyr-Met- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Phe-Arg- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Phe-Gly- dipeptide. In some embodiments, the cathepsin-L comprises cleavable linker comprises a -Trp-Thr- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Tyr-Gly- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Phe-Thr- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Val-Gly- dipeptide. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a heavy chain variable region (VH) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 69 and a light chain variable region (VL) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO:90.
  • VH heavy chain variable region
  • VL light chain variable region
  • the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 69 and a VL with an amino acid sequence having at least 98% sequence identity to SEQ ID NOVO. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 69 and a VL with an amino acid sequence having at least 99% sequence identity to SEQ ID NOVO. In some embodiments, the cathepsin-L cleavable linker is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the cathepsin-L cleavable linker is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cathepsin-L cleavable linker is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the cathepsin-L cleavable linker is an un-branched linker.
  • the cathepsin-L cleavable linker is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms.
  • the branched linker has four arms.
  • the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms. [0436] In some embodiments, compositions of an AOC with a cathepsin-L cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2. In some such compositions, the average DAR for AOC in the composition is at least 4. In some such compositions, the average DAR for AOC in the composition is at least 6. In some such compositions, the average DAR for AOC in the composition is at least 8. In some such compositions, the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cathepsin-L cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl-dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cathepsin-L cleavable linker
  • A is an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5.
  • the cathepsin-L cleavable linker comprises a -Phe-Gln- dipeptide.
  • the cathepsin-L cleavable linker comprises a -VaLGln- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Leu-Gin- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Tyr-Met- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Phe-Arg- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Phe-Gly- dipeptide. In some embodiments, the cathepsin-L comprises cleavable linker comprises a -Trp-Thr- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Tyr-Gly- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Phe-Thr- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Val-Gly- dipeptide. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a heavy chain variable region (VH) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 127 and a light chain variable region (VL) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 126.
  • VH heavy chain variable region
  • VL light chain variable region
  • the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 127 and a VL with an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 126. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 127 and a VL with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 126. In some embodiments, the cathepsin-L cleavable linker is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the cathepsin-L cleavable linker is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cathepsin-L cleavable linker is attached to the antibody or antigen-binding fragment thereof at a glutamine residue. [0439] In some embodiments of an AOC with a cathepsin-L cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5, the cathepsin-L cleavable linker is an un- branched linker.
  • the cathepsin-L cleavable linker is a branched linker.
  • the branched linker has two arms. In some embodiments, the branched linker has three arms. In some embodiments, the branched linker has four arms. In some embodiments, the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cathepsin-L cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cathepsin-L cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl-dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cathepsin-L cleavable linker
  • A is an antibody or antigen-binding fragment thereof that comprises heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:90.
  • the cathepsin-L cleavable linker comprises a -Phe-Gln- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Val- Gln- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Leu-Gln- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Tyr-Met- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Phe-Arg- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Phe-Gly- dipeptide. In some embodiments, the cathepsin-L comprises cleavable linker comprises a -Trp- Thr- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Tyr-Gly- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Phe-Thr- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -VaLGly- dipeptide. In some embodiments, the cathepsin-L cleavable linker is attached to the antibody or antigen-binding fragment thereof at a lysine residue. In some embodiments, the cathepsin-L cleavable linker is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cathepsin-L cleavable linker is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the cathepsin-L cleavable linker is an un-branched linker.
  • the cathepsin-L cleavable linker is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms.
  • the branched linker has four arms.
  • the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cathepsin-L cleavable linker and an antibody or antigen-binding fragment thereof that comprises heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:90 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cathepsin-L cleavable linker and an antibody or antigen-binding fragment thereof that comprises heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:90, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cathepsin-L cleavable linker
  • A is an antibody or antigen-binding fragment thereof that comprises heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO: 117.
  • the cathepsin-L cleavable linker comprises a -Phe-Gln- dipeptide.
  • the cathepsin-L cleavable linker comprises a -VaL Gln- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Leu-Gln- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Tyr-Met- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Phe-Arg- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Phe-Gly- dipeptide. In some embodiments, the cathepsin-L comprises cleavable linker comprises a -Trp- Thr- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Tyr-Gly- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Phe-Thr- dipeptide. In some embodiments, the cathepsin-L cleavable linker comprises a -Val-Gly- dipeptide. In some embodiments, the cathepsin-L cleavable linker is attached to the antibody or antigen-binding fragment thereof at a lysine residue. In some embodiments, the cathepsin-L cleavable linker is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cathepsin-L cleavable linker is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the cathepsin-L cleavable linker is an un-branched linker.
  • the cathepsin-L cleavable linker is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms.
  • the branched linker has four arms.
  • the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cathepsin-L cleavable linker and an antibody or antigen-binding fragment thereof that comprises heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO: 117 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cathepsin-L cleavable linker and an antibody or antigen-binding fragment thereof that comprises Heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO: 117, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cleavable linker comprising a -Phe-Gln- dipeptide
  • A is an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60.
  • the antibody or antigen-binding fragment thereof further comprises a heavy chain variable region (VH) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO:90.
  • the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:69 and a VL with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:90. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 99% sequence identity to SEQ ID NO:69 and a VL with an amino acid sequence having at least 99% sequence identity to SEQ ID NO:90. In some embodiments, the cleavable linker comprising a -Phe-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the cleavable linker comprising a -Phe-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cleavable linker comprising a -Phe-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the cleavable linker comprising a -Phe-Gln- dipeptide is an un-branched linker.
  • the cleavable linker comprising a -Phe-Gln- dipeptide is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms. In some embodiments, the branched linker has four arms. In some embodiments, the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cleavable linker comprising a -Phe-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cleavable linker comprising a -Phe-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer. In some embodiments, the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastom
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cleavable linker comprising a -Phe-Gln- dipeptide
  • A is an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5.
  • the antibody or antigen-binding fragment thereof further comprises a heavy chain variable region (VH) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO:90.
  • the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:69 and a VL with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:90. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 99% sequence identity to SEQ ID NO:69 and a VL with an amino acid sequence having at least 99% sequence identity to SEQ ID NO:90. In some embodiments, the cleavable linker comprising a -Phe-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the cleavable linker comprising a -Phe-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cleavable linker comprising a -Phe-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • an AOC with a cleavable linker comprising a -Phe-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 1 1 and VH CDRs of SEQ ID NOs: 15, 4, and 5 the cleavable linker comprising a -Phe-Gln- dipeptide is an un-branched linker.
  • the cleavable linker comprising a -Phe-Gln- dipeptide is a branched linker.
  • the branched linker has two arms. In some embodiments, the branched linker has three arms.
  • the branched linker has four arms. In some embodiments, the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cleavable linker comprising a -Phe-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cleavable linker comprising a -Phe-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cleavable linker comprising a -Phe-Gln- dipeptide
  • A is an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5.
  • the antibody or antigen-binding fragment thereof further comprises a heavy chain variable region (VH) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 117.
  • the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 105 and a VL with an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 117. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 105 and a VL with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 117. In some embodiments, the cleavable linker comprising a -Phe-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the cleavable linker comprising a -Phe-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cleavable linker comprising a -Phe-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • an AOC with a cleavable linker comprising a -Phe-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5 the cleavable linker comprising a -Phe-Gln- dipeptide is an un-branched linker.
  • the cleavable linker comprising a -Phe-Gln- dipeptide is a branched linker.
  • the branched linker has two arms. In some embodiments, the branched linker has three arms.
  • the branched linker has four arms. In some embodiments, the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cleavable linker comprising a -Phe-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cleavable linker comprising a -Phe-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cleavable linker comprising a -Phe-Gln- dipeptide
  • A is an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:90.
  • the cleavable linker comprising a -Phe-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the cleavable linker comprising a -Phe-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cleavable linker comprising a -Phe-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the cleavable linker comprising a - Phe-Gln- dipeptide is an un-branched linker.
  • the cleavable linker comprising a -Phe-Gln- dipeptide is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms. In some embodiments, the branched linker has four arms. In some embodiments, the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cleavable linker comprising a -Phe-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:90 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cleavable linker comprising a -Phe-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:90, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer. In some embodiments, the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastom
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl-dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cleavable linker comprising a -Phe-Gln- dipeptide
  • A is an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO: 117.
  • the cleavable linker comprising a -Phe-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the cleavable linker comprising a -Phe-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cleavable linker comprising a -Phe-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the cleavable linker comprising a - Phe-Gln- dipeptide is an un-branched linker.
  • the cleavable linker comprising a -Phe-Gln- dipeptide is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms. In some embodiments, the branched linker has four arms. In some embodiments, the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cleavable linker comprising a -Phe-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:117 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cleavable linker comprising a -Phe-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO: 117, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer. In some embodiments, the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastom
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cleavable linker comprising a -Val-Gln- dipeptide
  • A is an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60.
  • the antibody or antigen-binding fragment thereof further comprises a heavy chain variable region (VH) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO:90.
  • the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:69 and a VL with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:90. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 99% sequence identity to SEQ ID NO:69 and a VL with an amino acid sequence having at least 99% sequence identity to SEQ ID NO:90. In some embodiments, the cleavable linker comprising a -Val-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the cleavable linker comprising a -Val-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cleavable linker comprising a -Val-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the cleavable linker comprising a -Val-Gln- dipeptide is an un-branched linker.
  • the cleavable linker comprising a -Val-Gln- dipeptide is a branched linker.
  • the branched linker has two arms. In some embodiments, the branched linker has three arms.
  • the branched linker has four arms. In some embodiments, the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cleavable linker comprising a -Val-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cleavable linker comprising a -Val-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer. In some embodiments, the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastom
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cleavable linker comprising a -Val-Gln- dipeptide
  • A is an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5.
  • the antibody or antigen-binding fragment thereof further comprises a heavy chain variable region (VH) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 69 and a light chain variable region (VL) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO:90.
  • the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:69 and a VL with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:90. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 69 and a VL with an amino acid sequence having at least 99% sequence identity to SEQ ID NO:90. In some embodiments, the cleavable linker comprising a -Val-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the cleavable linker comprising a -Val-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cleavable linker comprising a -Val-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • an AOC with a cleavable linker comprising a -Val-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5 the cleavable linker comprising a -Val-Gln- dipeptide is an un-branched linker.
  • the cleavable linker comprising a -Val-Gln- dipeptide is a branched linker.
  • the branched linker has two arms. In some embodiments, the branched linker has three arms.
  • the branched linker has four arms. In some embodiments, the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cleavable linker comprising a -Val-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cleavable linker comprising a -Val-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl-dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cleavable linker comprising a -Val-Gln- dipeptide
  • A is an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5.
  • the antibody or antigen-binding fragment thereof further comprises a heavy chain variable region (VH) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 117.
  • the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 105 and a VL with an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 117. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 105 and a VL with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 117. In some embodiments, the cleavable linker comprising a -Val-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the cleavable linker comprising a -Val-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cleavable linker comprising a -Val-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • an AOC with a cleavable linker comprising a -Val-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5 the cleavable linker comprising a -Val-Gln- dipeptide is an un-branched linker.
  • the cleavable linker comprising a -Val-Gln- dipeptide is a branched linker.
  • the branched linker has two arms. In some embodiments, the branched linker has three arms.
  • the branched linker has four arms. In some embodiments, the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cleavable linker comprising a -Val-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cleavable linker comprising a -Val-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cleavable linker comprising a -Val-Gln- dipeptide
  • A is an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:90.
  • the cleavable linker comprising a -Val-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the cleavable linker comprising a -Val-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cleavable linker comprising a -Val-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the cleavable linker comprising a - Val-Gln- dipeptide is an un-branched linker.
  • the cleavable linker comprising a -Val-Gln- dipeptide is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms. In some embodiments, the branched linker has four arms. In some embodiments, the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cleavable linker comprising a -Val-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NOVO are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cleavable linker comprising a -Val-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NOVO, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer. In some embodiments, the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastom
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl-dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cleavable linker comprising a -Val-Gln- dipeptide
  • A is an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO: 117.
  • the cleavable linker comprising a -Val-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the cleavable linker comprising a -Val-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cleavable linker comprising a -Val-Gln- dipeptide is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the cleavable linker comprising a - Val-Gln- dipeptide is an un-branched linker.
  • the cleavable linker comprising a -Val-Gln- dipeptide is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms. In some embodiments, the branched linker has four arms. In some embodiments, the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cleavable linker comprising a -Val-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:117 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cleavable linker comprising a -Val-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO: 117, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer. In some embodiments, the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastom
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cleavable linker comprising a -Leu-Gin- dipeptide
  • A is an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60.
  • the antibody or antigen-binding fragment thereof further comprises a heavy chain variable region (VH) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence having at least 95% sequence identity to SEQ ID NOVO.
  • the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:69 and a VL with an amino acid sequence having at least 98% sequence identity to SEQ ID NOVO. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 69 and a VL with an amino acid sequence having at least 99% sequence identity to SEQ ID NOVO. In some embodiments, the cleavable linker comprising a -Leu-Gin- dipeptide is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the cleavable linker comprising a -Leu-Gin- dipeptide is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cleavable linker comprising a -Leu-Gin- dipeptide is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the cleavable linker comprising a -Leu-Gln- dipeptide is an un-branched linker.
  • the cleavable linker comprising a -Leu-Gin- dipeptide is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms. In some embodiments, the branched linker has four arms. In some embodiments, the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cleavable linker comprising a -Leu-Gin- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cleavable linker comprising a -Leu-Gin- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer. In some embodiments, the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastom
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cleavable linker comprising a -Leu-Gin- dipeptide
  • A is an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5.
  • the antibody or antigen-binding fragment thereof further comprises a heavy chain variable region (VH) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 69 and a light chain variable region (VL) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO:90.
  • the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:69 and a VL with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:90. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 69 and a VL with an amino acid sequence having at least 99% sequence identity to SEQ ID NO:90. In some embodiments, the cleavable linker comprising a -Leu-Gin- dipeptide is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the cleavable linker comprising a -Leu-Gin- dipeptide is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cleavable linker comprising a -Leu-Gin- dipeptide is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • an AOC with a cleavable linker comprising a -Leu-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5 the cleavable linker comprising a -Leu-Gin- dipeptide is an un-branched linker.
  • the cleavable linker comprising a -Leu-Gin- dipeptide is a branched linker.
  • the branched linker has two arms. In some embodiments, the branched linker has three arms.
  • the branched linker has four arms. In some embodiments, the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cleavable linker comprising a -Leu-Gin- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cleavable linker comprising a -Leu-Gin- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cleavable linker comprising a -Leu-Gin- dipeptide
  • A is an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5.
  • the antibody or antigen-binding fragment thereof further comprises a heavy chain variable region (VH) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 117.
  • the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 105 and a VL with an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 117. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 105 and a VL with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 117. In some embodiments, the cleavable linker comprising a -Leu-Gin- dipeptide is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the cleavable linker comprising a -Leu-Gin- dipeptide is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cleavable linker comprising a -Leu-Gin- dipeptide is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • an AOC with a cleavable linker comprising a -Leu-Gln- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 1 1 and VH CDRs of SEQ ID NOs: 15, 26, and 5 the cleavable linker comprising a -Leu-Gin- dipeptide is an un-branched linker.
  • the cleavable linker comprising a -Leu-Gin- dipeptide is a branched linker.
  • the branched linker has two arms. In some embodiments, the branched linker has three arms.
  • the branched linker has four arms. In some embodiments, the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cleavable linker comprising a -Leu-Gin- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cleavable linker comprising a -Leu-Gin- dipeptide and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cleavable linker comprising a -Leu-Gin- dipeptide
  • A is an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:90.
  • the cleavable linker comprising a -Leu-Gin- dipeptide is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the cleavable linker comprising a -Leu-Gin- dipeptide is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cleavable linker comprising a -Leu-Gin- dipeptide is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the cleavable linker comprising a - Leu-Gin- dipeptide is an un-branched linker.
  • the cleavable linker comprising a -Leu-Gin- dipeptide is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms. In some embodiments, the branched linker has four arms. In some embodiments, the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cleavable linker comprising a -Leu-Gin- dipeptide and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:90 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cleavable linker comprising a -Leu-Gin- dipeptide and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:90, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer. In some embodiments, the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastom
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cleavable linker comprising a -Leu-Gin- dipeptide
  • A is an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO: 117.
  • the cleavable linker comprising a -Leu-Gin- dipeptide is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the cleavable linker comprising a -Leu-Gin- dipeptide is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the cleavable linker comprising a -Leu-Gin- dipeptide is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the cleavable linker comprising a - Leu-Gin- dipeptide is an un-branched linker.
  • the cleavable linker comprising a -Leu-Gin- dipeptide is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms. In some embodiments, the branched linker has four arms. In some embodiments, the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cleavable linker comprising a -Leu-Gin- dipeptide and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:117 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cleavable linker comprising a -Leu-Gin- dipeptide and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO: 117, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer. In some embodiments, the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastom
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl-dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a disulfide cleavable linker
  • A is an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60.
  • the antibody or antigen-binding fragment thereof further comprises a heavy chain variable region (VH) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO:90.
  • the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:69 and a VL with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:90. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 69 and a VL with an amino acid sequence having at least 99% sequence identity to SEQ ID NO:90. In some embodiments, the disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the disulfide cleavable linker is an un-branched linker.
  • the disulfide cleavable linker is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms.
  • the branched linker has four arms.
  • the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms. [0512] In some embodiments, compositions of an AOC with a disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2. In some such compositions, the average DAR for AOC in the composition is at least 4. In some such compositions, the average DAR for AOC in the composition is at least 6. In some such compositions, the average DAR for AOC in the composition is at least 8. In some such compositions, the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl-dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a disulfide cleavable linker
  • A is an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5.
  • the antibody or antigen-binding fragment thereof further comprises a heavy chain variable region (VH) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO:90.
  • the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:69 and a VL with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:90. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 69 and a VL with an amino acid sequence having at least 99% sequence identity to SEQ ID NO:90. In some embodiments, the disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the disulfide cleavable linker is an un-branched linker.
  • the disulfide cleavable linker is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms.
  • the branched linker has four arms.
  • the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms. [0516] In some embodiments, compositions of an AOC with a disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2. In some such compositions, the average DAR for AOC in the composition is at least 4. In some such compositions, the average DAR for AOC in the composition is at least 6. In some such compositions, the average DAR for AOC in the composition is at least 8. In some such compositions, the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl-dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a disulfide cleavable linker
  • A is an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5.
  • the antibody or antigen-binding fragment thereof further comprises a heavy chain variable region (VH) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 1 17.
  • the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 105 and a VL with an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 117. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 105 and a VL with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 117. In some embodiments, the disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the disulfide cleavable linker is an un-branched linker.
  • the disulfide cleavable linker is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms.
  • the branched linker has four arms.
  • the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms. [0520] In some embodiments, compositions of an AOC with a disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2. In some such compositions, the average DAR for AOC in the composition is at least 4. In some such compositions, the average DAR for AOC in the composition is at least 6. In some such compositions, the average DAR for AOC in the composition is at least 8. In some such compositions, the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl-dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a disulfide cleavable linker
  • A is an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:90.
  • the disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a cysteine residue.
  • the disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the disulfide cleavable linker is an un-branched linker.
  • the disulfide cleavable linker is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms.
  • the branched linker has four arms.
  • the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:90 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:90, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a disulfide cleavable linker
  • A is an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO: 117.
  • the disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a cysteine residue.
  • the disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the disulfide cleavable linker is an un-branched linker.
  • the disulfide cleavable linker is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms.
  • the branched linker has four arms.
  • the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO: 117 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO: 117, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a hindered disulfide cleavable linker
  • A is an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60.
  • the antibody or antigen-binding fragment thereof further comprises a heavy chain variable region (VH) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence having at least 95% sequence identity to SEQ ID NOVO.
  • the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:69 and a VL with an amino acid sequence having at least 98% sequence identity to SEQ ID NOVO. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 99% sequence identity to SEQ ID NO:69 and a VL with an amino acid sequence having at least 99% sequence identity to SEQ ID NO:90. In some embodiments, the hindered disulfide cleavable linker is attached to the antibody or antigen- binding fragment thereof at a lysine residue.
  • the hindered disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the hindered disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the hindered disulfide cleavable linker is an un-branched linker.
  • the hindered disulfide cleavable linker is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms.
  • the branched linker has four arms.
  • the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a hindered disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a hindered disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a hindered disulfide cleavable linker
  • A is an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5.
  • the antibody or antigen- binding fragment thereof further comprises a heavy chain variable region (VH) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence having at least 95% sequence identity to SEQ ID NOVO.
  • the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 98% sequence identity to SEQ ID NO:69 and a VL with an amino acid sequence having at least 98% sequence identity to SEQ ID NOVO. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 99% sequence identity to SEQ ID NO:69 and a VL with an amino acid sequence having at least 99% sequence identity to SEQ ID NO:90. In some embodiments, the hindered disulfide cleavable linker is attached to the antibody or antigen- binding fragment thereof at a lysine residue.
  • the hindered disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the hindered disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the hindered disulfide cleavable linker is an un-branched linker.
  • the hindered disulfide cleavable linker is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms.
  • the branched linker has four arms.
  • the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a hindered disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a hindered disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a hindered disulfide cleavable linker
  • A is an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5.
  • the antibody or antigen-binding fragment thereof further comprises a heavy chain variable region (VH) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 117.
  • the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 105 and a VL with an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 117. In some embodiments, the antibody or antigen-binding fragment thereof further comprises a VH with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 105 and a VL with an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 117. In some embodiments, the hindered disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the hindered disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a cysteine residue. In some embodiments, the hindered disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the hindered disulfide cleavable linker is an un-branched linker.
  • the hindered disulfide cleavable linker is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms.
  • the branched linker has four arms.
  • the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a hindered disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5 are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a hindered disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a hindered disulfide cleavable linker
  • A is an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:90.
  • the hindered disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the hindered disulfide cleavable linker is attached to the antibody or antigen- binding fragment thereof at a cysteine residue.
  • the hindered disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the hindered disulfide cleavable linker is an un-branched linker. In some embodiments, the hindered disulfide cleavable linker is a branched linker.
  • the branched linker has two arms. In some embodiments, the branched linker has three arms. In some embodiments, the branched linker has four arms. In some embodiments, the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a hindered disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NOVO are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a hindered disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NOVO, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a hindered disulfide cleavable linker
  • A is an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO: 117.
  • the hindered disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a lysine residue.
  • the hindered disulfide cleavable linker is attached to the antibody or antigen- binding fragment thereof at a cysteine residue.
  • the hindered disulfide cleavable linker is attached to the antibody or antigen-binding fragment thereof at a glutamine residue.
  • the hindered disulfide cleavable linker is an un-branched linker.
  • the hindered disulfide cleavable linker is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms.
  • the branched linker has four arms.
  • the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more. In some embodiments, the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a hindered disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region comprising a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater. In some such compositions, the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a hindered disulfide cleavable linker and an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO: 117, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer. In some embodiments, the cancer is a biliary tract cancer. In some embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is a cervical cancer. In yet other some embodiments, the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastom
  • DIPG
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl-dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • the present disclosure provides an antibody-oligonucleotide conjugate (AOC) having the formula A-(L-P r ) q , wherein: A is a 3E10 antibody or antigen-binding fragment thereof, L is a linker, P is an oligonucleotide moiety described herein, r is an integer from 1 to 4, and q is an integer from 1 to 16.
  • AOC antibody-oligonucleotide conjugate
  • L is a cathepsin-L cleavable linker attached to the 3E10 antibody or antigen-binding fragment thereof at a lysine residue.
  • the cathepsin-L cleavable linker comprises a -Phe-Gln- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Val-Gln- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Leu-Gin- dipeptide.
  • the cathepsin-L comprises cleavable linker comprises a -Tyr-Met- dipeptide.
  • the cathepsin-L comprises cleavable linker comprises a -Phe-Arg- dipeptide. In embodiments, the cathepsin-L comprises cleavable linker comprises a -Phe-Gly- dipeptide. In embodiments, the cathepsin-L comprises cleavable linker comprises a -Trp-Thr- dipeptide. In embodiments, the cathepsin-L comprises cleavable linker comprises a -Tyr-Gly- dipeptide. In embodiments, the cathepsin-L comprises cleavable linker comprises a -Phe-Thr- dipeptide.
  • the cathepsin-L comprises cleavable linker comprises a -Val-Gly- dipeptide.
  • the antibody or antigen-binding fragment thereof comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60.
  • the antibody or antigen-binding fragment thereof comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5.
  • the antibody or antigen-binding fragment thereof comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5.
  • the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:90. In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO:105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:117.
  • the cathepsin-L cleavable linker is an un-branched linker.
  • the cathepsin-L cleavable linker is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms.
  • the branched linker has four arms.
  • the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more.
  • the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cathepsin-L cleavable linker attached to the 3E10 antibody or antigen-binding fragment thereof at a lysine residue are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater.
  • the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cathepsin-L cleavable linker attached to the 3E10 antibody or antigen-binding fragment thereof at a lysine residue, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer.
  • the cancer is a gastric cancer.
  • the cancer is a cervical cancer.
  • the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord tumor, endocrine cancer, esophageal cancer, gastric cancer, hepatobiliary cancer, myel
  • DIPG diffuse intrinsic pontine
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • L is a cathepsin-L cleavable linker attached to the 3E10 antibody or antigen-binding fragment thereof at a cysteine residue.
  • the cathepsin-L cleavable linker comprises a -Phe-Gln- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Val-Gln- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Leu-Gin- dipeptide.
  • the cathepsin-L comprises cleavable linker comprises a -Tyr-Met- dipeptide.
  • the cathepsin-L comprises cleavable linker comprises a -Phe-Arg- dipeptide. In embodiments, the cathepsin-L comprises cleavable linker comprises a -Phe-Gly- dipeptide. In embodiments, the cathepsin-L comprises cleavable linker comprises a -Trp-Thr- dipeptide. In embodiments, the cathepsin-L comprises cleavable linker comprises a -Tyr-Gly- dipeptide. In embodiments, the cathepsin-L comprises cleavable linker comprises a -Phe-Thr- dipeptide.
  • the cathepsin-L comprises cleavable linker comprises a -Val-Gly- dipeptide.
  • the antibody or antigen-binding fragment thereof comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60.
  • the antibody or antigen-binding fragment thereof comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5.
  • the antibody or antigen-binding fragment thereof comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5.
  • the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:90. In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:117.
  • the cathepsin-L cleavable linker is an un-branched linker.
  • the cathepsin-L cleavable linker is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms.
  • the branched linker has four arms.
  • the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more.
  • the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cathepsin-L cleavable linker attached to the 3E10 antibody or antigen-binding fragment thereof at a cysteine residue are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater.
  • the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cathepsin-L cleavable linker attached to the 3E10 antibody or antigen-binding fragment thereof at a cysteine residue, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer.
  • the cancer is a gastric cancer.
  • the cancer is a cervical cancer.
  • the cancer is colorectal cancer, pancreatic cancer, lung cancer, ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, glioma, brain stem glioma, head and neck cancer, lymphomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, leukemia, neuroblastoma, Wilms tumor, bone cancer, brain stem tumor, childhood diffuse intrinsic pontine glioma (DIPG), retinoblastoma, rhabdoid tumor, sarcoma, spinal cord tumor, endocrine cancer, esophageal cancer, gastric cancer, hepatobiliary cancer, myel
  • DIPG diffuse intrinsic pontine
  • the oligonucleotide (P) is an siRNA. In some embodiments, the oligonucleotide (P) is an antisense oligonucleotide (ASO). In some embodiments, the ASO is an RNase Hl -dependent antisense oligonucleotide. In some embodiments, the ASO mediates exon skipping.
  • the present disclosure provides pharmaceutical compositions comprising an antibody-oligonucleotide conjugate (AOC) having the formula A-(L- P r) q , where: A is a 3E10 antibody or antigen-binding fragment thereof as described herein (e.g., as described in the section titled 3E10 Antibodies and Antigen-Binding Fragments), L is a linker, P is a payload moiety as described herein, r is an integer from 1 to 4 and q is an integer from 1 to 16.
  • AOC antibody-oligonucleotide conjugate
  • L is a cathepsin-L cleavable linker attached to the 3E10 antibody or antigen-binding fragment thereof at a glutamine residue.
  • the cathepsin- L cleavable linker comprises a -Phe-Gln- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Val-Gln- dipeptide.
  • the cathepsin-L cleavable linker comprises a -Leu-Gin- dipeptide.
  • the cathepsin-L comprises cleavable linker comprises a -Tyr-Met- dipeptide.
  • the cathepsin-L comprises cleavable linker comprises a -Phe-Arg- dipeptide. In embodiments, the cathepsin-L comprises cleavable linker comprises a -Phe-Gly- dipeptide. In embodiments, the cathepsin-L comprises cleavable linker comprises a -Trp-Thr- dipeptide. In embodiments, the cathepsin-L comprises cleavable linker comprises a -Tyr-Gly- dipeptide. In embodiments, the cathepsin-L comprises cleavable linker comprises a -Phe-Thr- dipeptide.
  • the cathepsin-L comprises cleavable linker comprises a -Val-Gly- dipeptide.
  • the antibody or antigen-binding fragment thereof comprises VL CDRs of SEQ ID NOs: 61, 62, and 63 and VH CDRs of SEQ ID NOs: 58, 59, and 60.
  • the antibody or antigen-binding fragment thereof comprises VL CDRs of SEQ ID NOs: 9, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 4, and 5.
  • the antibody or antigen-binding fragment thereof comprises VL CDRs of SEQ ID NOs: 29, 10, and 11 and VH CDRs of SEQ ID NOs: 15, 26, and 5.
  • the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO:69 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:90. In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) with an amino acid sequence of SEQ ID NO:105 and a light chain variable region (VL) with an amino acid sequence of SEQ ID NO:117.
  • the cathepsin-L cleavable linker is an un-branched linker.
  • the cathepsin-L cleavable linker is a branched linker.
  • the branched linker has two arms.
  • the branched linker has three arms.
  • the branched linker has four arms.
  • the branched linker has at least 2 arms, at least 3 arms, at least 4 arms, or more.
  • the branched linker has from 2 to 6 arms, from 2 to 5 arms, from 2 to 4 arms, from 2 to 3 arms, from 3 to 6 arms, from 3 to 5 arms, from 3 to 4 arms, from 4 to 6 arms, or from 5 to 6 arms.
  • compositions of an AOC with a cathepsin-L cleavable linker attached to the 3E10 antibody or antigen-binding fragment thereof at a glutamine residue are provided.
  • the average drug to antibody ratio (DAR) for AOC in the composition at least 2.
  • the average DAR for AOC in the composition is at least 4.
  • the average DAR for AOC in the composition is at least 6.
  • the average DAR for AOC in the composition is at least 8.
  • the average DAR for AOC in the composition is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or greater.
  • the average DAR for AOC in the composition is at least 6.
  • methods are provided for treating cancer by administering, to a subject in need thereof, a therapeutically effective amount of an AOC with a cathepsin-L cleavable linker attached to the 3E10 antibody or antigen-binding fragment thereof at a glutamine residue, as described above.
  • the cancer is a colorectal cancer.
  • the cancer is an ovarian cancer.
  • the cancer is a breast cancer.
  • the cancer is a pancreatic cancer.
  • the cancer is a non-small cell lung cancer.
  • the cancer is a biliary tract cancer.
  • the cancer is a gastric cancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des conjugués anticorps-oligonucléotide (AOC) ayant un anticorps, un fragment de liaison à l'antigène de celui-ci, ou un fragment de liaison à l'antigène de celui-ci, conjugué par l'intermédiaire d'un lieur à une fraction oligonucléotidique (par exemple, une molécule d'ARNsi ou une molécule ASO antisens). <i />. L'invention concerne également des compositions comprenant les AOC et des méthodes d'utilisation des AOC.
EP24709225.7A 2023-01-23 2024-01-23 Conjugués anticorps-oligonucléotide Pending EP4655007A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202363481132P 2023-01-23 2023-01-23
US202363487850P 2023-03-01 2023-03-01
US202363580971P 2023-09-06 2023-09-06
US202363585831P 2023-09-27 2023-09-27
PCT/US2024/012633 WO2024158824A1 (fr) 2023-01-23 2024-01-23 Conjugués anticorps-oligonucléotide

Publications (1)

Publication Number Publication Date
EP4655007A1 true EP4655007A1 (fr) 2025-12-03

Family

ID=90361186

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24709225.7A Pending EP4655007A1 (fr) 2023-01-23 2024-01-23 Conjugués anticorps-oligonucléotide

Country Status (2)

Country Link
EP (1) EP4655007A1 (fr)
WO (1) WO2024158824A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025213130A1 (fr) * 2024-04-04 2025-10-09 Yale University Conjugués anticorps-médicament
WO2026039779A1 (fr) * 2024-08-15 2026-02-19 Yale University Anticorps 3e10 humanisés et fragments de liaison à l'antigène optimisés pour la liaison rad51

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4812397A (en) 1987-02-10 1989-03-14 The Regents Of The University Of California MAB-anti-DNA related to nephritis
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US4952394A (en) 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
WO1991004753A1 (fr) * 1989-10-02 1991-04-18 Cetus Corporation Conjugues d'oligonucleotides non codants et leurs emplois therapeutiques
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5137877B1 (en) 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5618528A (en) 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1997032602A1 (fr) 1996-03-08 1997-09-12 The Regents Of The University Of California Systeme de liberation utilisant mab 3e10 et ses mutants et/ou ses fragments fonctionnels
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20010035606A1 (en) 2000-03-28 2001-11-01 Schoen Alan H. Set of blocks for packing a cube
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP3263596A1 (fr) 2002-12-16 2018-01-03 Genentech, Inc. Variantes de l'immunoglobuline et leurs utilisations
CA2548817A1 (fr) 2003-12-04 2005-06-23 Xencor, Inc. Procedes pour produire des proteines variantes presentant une plus grande concentration en chaine hote et compositions de celles-ci
US20070105770A1 (en) 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2490699A1 (fr) 2009-10-20 2012-08-29 Santaris Pharma A/S Administration orale d'oligonucléotides de lna thérapeutiquement efficaces
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
US9764038B2 (en) 2011-12-23 2017-09-19 Innate Pharma Enzymatic conjugation of antibodies
US9283272B2 (en) 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
US9562228B2 (en) * 2012-09-14 2017-02-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of MYC by double-stranded RNA
EP3094646B1 (fr) * 2014-01-13 2020-04-15 Valerion Therapeutics, LLC Fragment d'internalisation
CA2995673A1 (fr) 2014-08-27 2016-03-03 Valerion Therapeutics, Llc Fractions d'internalisation utilisables en vue du traitement du cancer
RU2751512C2 (ru) 2015-06-22 2021-07-14 Байер Фарма Акциенгезельшафт Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы
EP3655432A4 (fr) 2017-07-17 2021-04-14 Nucleus Therapeutics Pty Ltd Protéines de liaison 1
AU2020336992A1 (en) * 2019-08-30 2022-04-14 Yale University Compositions and methods for delivery of nucleic acids to cells
EP4346907A4 (fr) * 2021-05-25 2025-06-25 Transmab Pty Ltd Immunoglobuline i améliorée
WO2022246511A1 (fr) * 2021-05-25 2022-12-01 Transmab Pty Ltd Immunoglobuline ii améliorée
WO2023168352A1 (fr) 2022-03-03 2023-09-07 Yale University Anticorps 3e10 humanisés, variants et fragments de liaison à l'antigène de ceux-ci

Also Published As

Publication number Publication date
WO2024158824A1 (fr) 2024-08-02

Similar Documents

Publication Publication Date Title
JP7654757B2 (ja) 抗トランスフェリン受容体抗体およびその使用
TWI904804B (zh) 抗體-藥物結合物之用途
JP2023527638A (ja) 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法
JP2023537798A (ja) 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法
EP4655007A1 (fr) Conjugués anticorps-oligonucléotide
EP4642488A1 (fr) Conjugués anticorps-médicament
US20240229033A1 (en) Compositions for Inhibiting Growth of Targeted Cells
WO2024197302A1 (fr) Compositions et méthodes d&#39;administration de conjugués d&#39;oligonucléotides et d&#39;anticorps pour le saut d&#39;exon
WO2026011073A1 (fr) Conjugués anticorps-médicament
WO2025213130A1 (fr) Conjugués anticorps-médicament
HK40056619A (en) Anti-transferrin receptor antibodies and uses thereof
BR112019027448A2 (pt) imunoconjugados de anticorpo de ror1
HK40004013A (en) Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250819

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR